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Summary 
Reactive oxygen species (ROS) have been reported to be locally produced after 
stimulation of various transmembrane receptors, including those for cytokines, 
growth factors and hormones. Transient ROS generation leads to the reversible 
oxidation of redox-sensitive proteins, which may either result in their transient 
activation or inactivation. Even though the role of ROS as a signal transducer is 
widely accepted, little is known about the identity of redox-sensitive proteins and the 
reduction mechanism by which they are re-generated. Thioredoxin-1 (Trx1) is an 
oxidoreductase known to influence a variety of cellular processes including 
proliferation, apoptosis and gene expression. In higher plants and cyanobacteria 
different proteomic approaches allowed for the identification of various thioredoxin 
target proteins. However, no comprehensive study of Trx1 interactions in the cytosol 
of mammalian cells has been performed so far. In this thesis, mechanism-based 
kinetic trapping was applied to identify proteins forming mixed disulfide intermediates 
with Trx1 in the cytosol of a human T cell leukemia line. Most previously established 
target proteins of Trx1 could be identified, including ribonucleotide reductase, 
peroxiredoxins and annexin-2, thus confirming the validity of the approach. 
Interestingly, a substantial number of newly identified proteins currently lacks 
functional annotation, suggesting that several thioredoxin-regulated pathways still 
await initial characterization. Of those newly identified proteins with known function, a 
significant portion is associated with cell cycle control and regulation of apoptosis, 
while others participate in various signal transduction pathways, cytoskeleton and 
membrane dynamics, metabolism and transcriptional control. These results strongly 
support the long-held belief that Trx1 not only plays a role in ROS scavenging and 
reductive metabolism but is also extensively involved in interactions with key 
regulatory proteins associated with cellular behavior and fate. While Trx1-interactions 
are clearly pleiotropic in that they affect a variety of processes simultaneously, we 
have found strong evidence that they are nevertheless highly target specific. The 
newly identified Trx1 target proteins cdk6 and caspase-2 were selected for further 
study. For cdk6 the thioredoxin-interacting cysteine residue was identified and for 
caspase-2 redox regulation of activity by Trx1 could be demonstrated in vitro, lending 
further support to the biological relevance of Trx-based regulation. 
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Zusammenfassung 
Reaktive Sauerstoffspezies (ROS) werden lokal nach Stimulation verschiedener 
Transmembranrezeptoren produziert. Die transiente Bildung von ROS bewirkt eine 
Oxidation redox-sensitiver Proteine, was zu deren Aktivierung oder Inaktivierung 
führen kann. Trotz der allgemein akzeptierten Rolle von ROS als Botenstoff ist 
bislang wenig über die Identität und Regeneration oxidations-sensitiver Proteine 
bekannt. Thioredoxin-1 (Trx1) ist eine reduzierende Thiol-abhängige Oxidoreduktase, 
die mit zahlreichen zellulären Prozessen, wie z.B. Proliferation, Apoptose und 
Genexpression in Verbindung steht. In höheren Pflanzen und Cyanobakterien 
wurden verschiedene Proteom-Analysen zur Identifizierung von Thioredoxin-
Zielproteinen erfolgreich angewandt. Entsprechende Studien an Säugerzellen 
wurden jedoch bislang nicht durchgeführt. Zur Identifizierung von Proteinen die mit 
Trx1 ein gemischtes Disulfid-Intermediat ausbilden, wurde die sogenannte 
mechanism-based kinetic trapping Technik auf die humane Jurkat T-Zelllinie 
angewandt. Dabei konnten bereits bekannte Trx1 Zielproteine wie Ribonukleotid-
Reduktase, Peroxiredoxine und Annexin-2 identifiziert werden. Ein nicht 
unerheblicher Anteil der neu identifizierten Proteine ist bislang ohne funktionelle 
Zuordnung was auf die Existenz noch nicht charakterisierter redox-sensitiver 
Signalwege hindeutet. Interessanterweise ist ein signifikanter Anteil der mit Trx1 
interagierenden Proteine mit der Regulation von Zellzyklus und Apoptose assoziiert, 
während andere redox-sensitive Proteine an Signaltransduktion, Zytoskelett- und 
Membrandynamik, Metabolismus und Transkriptionskontrolle beteiligt sind. Diese 
Daten unterstützen die lange gehegte Auffassung, dass Trx1 nicht nur eine Rolle bei 
der Neutralisierung von ROS und im Metabolismus spielt, sondern darüber hinaus 
intensiv an der Regulation von Signaltransduktion, Zellzyklus und Zelltod beteiligt ist. 
Die in dieser Arbeit beschriebenen Trx1-Interaktionen sind pleiotrop, in dem Sinne, 
dass sie eine Vielzahl an zellulären Prozessen betreffen, jedoch zugleich sehr 
spezifisch für bestimmte Zielproteine. Zur Identifizierung der Cysteine die von Trx1 
reduziert werden wurden Mutagenese-Studien am neu gefundenen Trx1 Zielprotein 
cdk6 durchgeführt. Darüber hinaus konnte eine Regulation der Aktivität von 
Caspase-2 durch Trx1 in vitro nachgewiesen werden. 
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1 Introduction 
1.1 Oxygen and its reactive species 
Oxygen is the third most abundant element by mass in the universe after hydrogen 
and helium (Suess & Urey, 1956) constituting 20.9% of the volume of air. Its 
molecular form (O2) is essential for the survival of all aerobic organisms which use 
oxidative phosphorylation to generate ATP, the main energy source of the cell. A flux 
of electrons through the mitochondrial electron-transport chain (ETC) is used to build 
a proton gradient across the inner mitochondrial membrane. Four major protein 
complexes have been identified to form the ETC, NADH dehydrogenase (complex I), 
succinate dehydrogenase (complex II), cytochrome bc1 (complex III) and cytochrome 
c oxidase (complex IV). The proton gradient generated by complex I, III and IV is 
used by ATP synthase (complex V) to drive synthesis of ATP from ADP. Complex IV 
catalyzes the complete reduction of O2 to H2O without the formation of oxygen 
radicals. However, some electrons escape the ETC especially from complex I and III, 
which can react with O2 to form superoxide anion (O2• –) (Balaban et al, 2005). It has 
been estimated that 0.1% to 0.5% of the total cellular O2 reacts to O2• – (Staniek & 
Nohl, 2000; St-Pierre et al, 2002) which is spontaneously or enzymatically converted 
to hydrogen peroxide (H2O2). In the presence of transition metal ions H2O2 can be 
converted to the even more reactive hydroxyl radical (OH•). These and other O2 
metabolites have been termed reactive oxygen species (ROS) due to their higher 
reactivity and oxidizing capacity compared to molecular oxygen (Figure 1). Besides 
the mitochondria, ROS can be generated from other cellular sources including 
NADPH cytochrome P450 reductase, hypoxanthine/xanthine oxidase, NADPH 
oxidase, lipoxygenase or cyclooxygenase (COX) (Kamata & Hirata, 1999). 
Due to their potential to induce DNA adducts and breaks, lipid peroxidation or protein 
Figure 1: The O2 reduction pathway and the family of reactive oxygen species (ROS) 
Overview of O2 reduction to H2O. Redox potential, half life (T1/2) and estimated cellular concentration 
in vivo are listed. Adapted from Giorgio et al (2007) and Forman et al (2002). 
   ROS   
 O2 ? O2• – ? H2O2 ? OH• ? H2O
Redox potential (V):  -0.33  +0.89  +0.38  +2.31  
T1/2 (sec):   10-6  10-5  10-9   
In vivo concentration (M):   10-10  10-7  10-15   
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carbonylation, ROS have long been considered to be toxic metabolic by-products 
(Imlay, 2003). The free-radical or oxidative stress hypothesis first formulated by 
Denham Harman states that oxidizing species are generated during aerobic 
metabolism which results in a pattern of cumulative damage that eventually leads to 
tissue dysfunction followed by the onset of aging and development of diseases 
(Harman, 1956). This hypothesis is in agreement with the fact that the cell normally 
employs a variety of enzymes and small-molecule scavengers to detoxify ROS. 
Superoxide dismutase (SOD) accelerates the dismutation of O2• – to H2O2 by 104 fold 
to a nearly diffusion limited rate that effectively prevents most other reactions of O2• – 
in cells. Catalase converts H2O2 to H2O and O2, but in most cells this enzyme is 
confined to peroxisomes allowing H2O2 to react with other proteins before it comes in 
contact with catalase. The two main enzymatic systems dedicated to H2O2 
elimination use thiols as reducing agents. Glutathione peroxidases (GPx) are 
selenocysteine-containing proteins which reduce H2O2 to water by using reduced 
glutathione as an electron donor. Peroxiredoxins (Prx), formerly known as thioredoxin 
peroxidases, directly reduce H2O2 by oxidation of their active site cysteines to a 
disulfide bond (Forman et al, 2002). In addition to these antioxidant enzymes, ROS 
can be scavenged non-enzymatically by small molecule antioxidants like vitamin A, C 
or E. 
Oxidative stress has been implicated to play a role in a large number of diseases 
including atherosclerosis, diabetes mellitus, neurodegenerative diseases, chronic 
inflammation and cancer (Dröge, 2002). However, ROS are not only produced under 
pathological conditions. In macrophages, neutrophils and other phagocytes the 
enzyme NAPDH oxidase (Nox) catalyzes mitochondria-independent production of 
O2• – and NADP+ from O2 and NAPDH during the so-called respiratory burst to 
efficiently kill bacteria and fungi (Lambeth, 2004). In addition, T cells also express a 
phagocyte-type NADPH oxidase which is required for regulation of T cell receptor 
signaling (Jackson et al, 2004). Furthermore, ROS are generated after stimulation by 
a variety of cytokines and growth factors, including TNF-α, IL-1, IFN-γ, EGF and 
PDGF (Thannickal & Fanburg, 2000). Therefore, it is now well established that ROS 
play an important regulatory role also under physiological conditions. 
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1.2 Redox regulation: Control of protein activity by thiol modifications 
The sulphydryl group (−SH) of cysteine residues can react with ROS to different 
oxidation products. Oxidation of cysteine leads to the formation of sulphenic acid 
(−SOH) which is highly reactive and likely to react with a second cysteine to form a 
disulfide bond (−S−S−). If sulphenic acid is further oxidized, sulphinic acid (−SO2H) is 
generated which can no longer form disulfide bonds. Sulphinic acid in the active site 
of certain peroxiredoxins can be reduced by the enzyme sulfiredoxin (Srx) (Biteau et 
al, 2003; Chang et al, 2004). Eventually, oxidation of sulphinic acid leads to the 
formation of sulphonic acid (−SO3H), and this oxidation step is believed to be 
irreversible. S-Nitrosothiols (−S−NO) are generated by oxidation of cysteine residues 
by nitric oxide (NO), a reaction called S-nitrosylation. Alternatively, cysteines can 
form of a disulfide bond with glutathione, a modification known as S-glutathionylation 
(−S−SG) (Figure 2). 
 
Oxidative modification of cysteines in redox-sensitive proteins represents a 
mechanism through which redox signals can be transmitted within the cell. In this 
way the redox state of protein thiols serves as a “molecular switch” to reversibly 
Figure 2: Oxidative modifications of cysteine residues
Oxidation of protein cysteine residues (−SH) to various oxidation products. See text for details. 
RNS = reactive nitrogen species. Adapted from Paget & Buttner (2003) and Berndt et al (2007). 
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activate or inactivate protein function. As this process resembles the well-established 
phosphorylative regulation of protein function by kinases and phosphatases, the term 
“redox regulation” was coined. Remarkably, kinases and phosphatases as key 
enzymes in phosphorylative signal transduction are also subject to redox regulation, 
thereby generating cross-talk between these two chemically distinct regulatory 
mechanisms. 
1.2.1 Redox regulation of protein tyrosine phosphatases 
Phosphorylation of protein tyrosine residues is one of the most important regulatory 
mechanisms of signal transduction controlling a vast number of cellular processes. 
Cellular phosphotyrosine levels are regulated by the antagonistic activities of protein 
tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Due to their 
central role in the regulation of proliferation, a number of these enzymes function as 
oncoproteins and tumor suppressors, respectively. Based on the early observation 
that treatment of cells with H2O2 leads to increased phosphorylation of the insulin 
receptor (Koshio et al, 1988) it was later shown that PTPs are transiently inactivated 
by oxidation of their active site cysteines thereby inhibiting counter-regulation of PTK 
activity (Knebel et al, 1996). PTPs hydrolyze phospho-ester bonds via an invariant 
cysteine residue which has a low pKa of 5.0 - 6.7 due to the unique environment of 
the PTP active site. Therefore, the catalytic cysteine is present as thiolate anion at 
physiological pH allowing it to act as a nucleophile during catalysis but also rendering 
it susceptible to oxidation (Salmeen & Barford, 2005; Tonks, 2006). Protein tyrosine 
phosphatase 1B (PTP1B) has been shown to become inactivated after stimulation of 
cells with EGF and insulin (Lee et al, 1998; Mahadev et al, 2001; Meng et al, 2004). It 
could be demonstrated that the SH2 domain-containing protein tyrosine 
phosphatase-2 (SHP2) is transiently oxidized in response to PDGF stimulation (Meng 
et al, 2002) which was later also confirmed for T cell receptor stimulation (Kwon et al, 
2005a). In addition, phosphatase and tensin homolog (PTEN), a lipid and protein 
phosphatase (Myers et al, 1997; Maehama & Dixon, 1998) has been shown to be 
reversibly inactivated in macrophages after stimulation with lipopolysaccharide (LPS) 
(Leslie et al, 2003). It is essential for the reversible regulation of PTPs that the active 
site cysteine is not over-oxidized to sulphinic or sulphonic acid, as this would 
irreversibly inactivate the enzyme (Figure 3A). 
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Based on the crystal structure of PTP1B a novel mechanism was identified that 
allows for reversible redox-regulation of the phosphatase and at the same time 
prevents over-oxidation. Oxidation of the catalytic cysteine to sulphenic acid is 
followed by its conversion to a cyclic sulphenylamide species though S-N bonding 
with the amide nitrogen of the adjacent serine (Figure 3B+C), which induces a 
conformational change in the active site that disrupts the interaction with its substrate 
and exposes the oxidized cysteine (Salmeen et al, 2003; van Montfort et al, 2003). 
Thereby, irreversible inactivation is prevented and re-activation of the phosphatase 
by reduction is facilitated. 
Figure 3: Oxidative inactivation of PTPs
(A) Oxidative inactivation and reactivation of PTPs .Adapted from (den Hertog et al, 2005), (B) 
reduced PTP1B (C) cyclic sulphenylamide in oxidized PTP1B. (B) and (C) taken from van Montfort et 
al (2003). 
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In contrast to classical PTPs like PTP1B, dual specific phosphatases, e.g. PTEN, 
cdc25 and low molecular weight protein tyrosine phosphatase (LMW-PTP) contain a 
second cysteine in their active sites which can form a disulfide bond with the adjacent 
cysteine thereby protecting the protein from over-oxidation. This disulfide bond can 
be readily reduced allowing tight control of protein activity by redox-regulation 
(Salmeen & Barford, 2005). 
1.2.2 Redox regulation of protein kinases 
The best characterized redox-regulated kinase is apoptosis signal-regulating 
kinase 1 (ASK1) which activates both the c-Jun N-terminal kinase (JNK) and p38 
mitogen-activated protein kinase (MAPK) cascade by direct phosphorylation of their 
upstream kinases MKK4/MKK7 and MKK3/MMK6, respectively. ASK1 is activated by 
oxidative stress (Ichijo et al, 1997), tumor necrosis factor (TNF) receptor stimulation 
(Nishitoh et al, 1998) or Toll-like receptor 4 (TLR4) activation (Matsuzawa et al, 
2005). In addition, it has been demonstrated that ASK1 induces apoptosis by 
triggering a mitochondria-dependent pathway including cleavage of pro-apoptotic 
Bcl-2 family members, Bax mitochondrial translocation, cytochrome c release and 
subsequent activation of caspase-9 and caspase-3 (Hatai et al, 2000). In non-
stressed cells, reduced thioredoxin-1 (Trx1) tightly binds the N-terminal domain of 
ASK1, thus inhibiting its multimerization and activation. Upon oxidative stress, Trx1 is 
oxidized and dissociates from ASK1, thereby promoting kinase activation (Saitoh et 
al, 1998; Liu et al, 2000). Furthermore, glutaredoxin-1 has been shown to inhibit 
ASK1 at its C-terminus and dissociate from ASK1 upon induction of oxidative stress 
by glucose deprivation (Song et al, 2002). In contrast to the described Trx1 oxidation 
model, a novel mechanism was proposed according to which oxidation not only 
induces phosphorylation of ASK1 but also formation of disulfide-linked ASK1 
multimers required for JNK activation. In this model, Trx1 only transiently interacts 
with ASK1 to negatively regulate its activity by multimer reduction (Nadeau et al, 
2007). Even though disulfide-linked ASK1 multimers may play a role for its activation 
the classical Trx1-oxidation model has not been disproven and more work needs to 
be done to elaborate the physiological function of these conjugates. 
 
Other kinases have been suggested to be regulated by direct redox modifications. 
The proto-oncogenic kinase c-Src forms high molecular weight complexes upon 
treatment with NO donors, leading to phosphorylation-independent activation 
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(Akhand et al, 1999). The opposite effect was observed for Janus kinase-2 (JAK2) 
which is inactivated by NO treatment, thus inhibiting activation of quiescent BaF3 
cells (Duhé et al, 1998). Very recently, disulfide-mediated regulation of different 
kinases has been reported. The Src homology 2 (SH2) domain of C-terminal Src 
kinase (Csk) contains a unique disulfide bond that is not present in other SH2 
domains. Reduction of this disulfide in vitro increases Csk kinase activity by an order 
of magnitude compared to the oxidized protein (Mills et al, 2007). Even though the in 
vivo relevance of this regulatory disulfide still needs to be demonstrated, these data 
suggest that Csk may be redox-regulated in a way similar to non-classical PTPs like 
PTEN and LMW-PTP. Similarly, cyclic AMP-dependent protein kinase (PKA), a key 
regulator of lipolysis, is inhibited by H2O2 and re-activated by dithiothreitol (DTT) or 
the thioredoxin system (see chapter 1.3.2). Phylogenetic analysis suggests that a 
regulatory disulfide bond is formed between the regulatory and catalytic subunit of 
PKA (de Piña et al, 2008). 
Oxidation does not always lead to inhibition of protein function as has been 
demonstrated for protein kinase C (PKC) which was found to be activated by 
oxidants (Gopalakrishna et al, 2008). Moreover, cGMP-dependent protein kinase 
isoform α (PKGIα) forms an intermolecular disulfide bond between its subunits 
leading to direct activation of the kinase and increased affinity for substrates 
(Burgoyne et al, 2007). Interestingly, inter-subunit crosslinking changed kinase 
activity of PKGIα and PKA in opposite directions (de Piña et al, 2008) showing that 
disulfide bond formation can have different consequences in closely related proteins. 
 
In comparison to phosphorylation-based regulation of signal transduction where 
kinases and phosphatases counter-regulate protein activity, redox-regulation by 
protein oxidation is antagonized by thiol-disulfide oxidoreductases that reduce 
disulfide-bonds and thereby ensure reversible modulation of protein function. 
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1.3 Thiol-disulfide oxidoreductases 
In addition to those enzymes directly involved in ROS scavenging, like catalase, 
superoxide dismutase or peroxiredoxins (see chapter 1.1), the cell also utilizes 
disulfide reductases to maintain cellular thiol redox homeostasis. Thioredoxin and 
glutaredoxin comprise the family of thioredoxin thiol-disulfide oxidoreductases which 
is characterized by the thioredoxin fold with a common CxxC active site motif (Martin, 
1995). These proteins contribute to a reduced intracellular redox state by reduction of 
protein thiols and thereby play an important role in the oxidative stress response 
(Holmgren, 2000). Importantly, thioredoxin and glutaredoxin also contribute to redox-
regulation by modulating the activity of kinases, phosphatases, transcription factors 
and other mediators of signal transduction (Ghezzi, 2005). 
1.3.1 The glutathione/glutaredoxin system 
Glutathione (γ-glutamyl-cysteinyl-glycine) is the most abundant low-molecular-weight 
thiol in mammalian cells and exist as either reduced (GSH) or oxidized form 
(glutathione disulfide; GSSG). Under physiological conditions cytosolic glutathione is 
Figure 4: The glutathione/glutaredoxin system
(A) De-glutathionylation of substrate proteins by the mono-thiol mechanism. (B) Disulfide bond 
reduction by the di-thiol mechanism. GR: glutathione reductase 
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maintained almost exclusively in the reduced state and serves as intracellular redox 
buffer (Filomeni et al, 2002). 
 
GSH can function as substrate for glutathione peroxidases which catalyze its reaction 
with peroxides to GSSG and H2O. However, the increase in GSSG during oxidative 
stress is generally transient due to its rapid reduction by glutathione reductase. In 
addition to its role in the detoxification of electrophilic xenobiotics by glutathione S-
transferases (GSTs) (Townsend & Tew, 2003), GSH can form a mixed disulfide bond 
(GS−S−R) with cysteine residues. Protein S-Glutathionylation represents another 
mechanism besides intra- or intermolecular protein-protein disulfide bond formation 
and generation of cyclic sulphenylamides to prevent over-oxidation of proteins. De-
glutathionylation is catalyzed by the oxidoreductase glutaredoxin (Grx), also known 
as thioltransferase. During the so-called mono-thiol reaction GSH is transferred from 
a target protein to the active site cysteine of Grx (Figure 4A). Glutathionylated Grx 
can then be reduced by another GSH molecule, leading to the formation of GSSG 
(Holmgren, 2000). In addition to the mono-thiol mechanism, Grx has been shown to 
act as a protein disulfide reductase for bacterial ribonucleotide reductase using a di-
thiol mechanism (Holmgren, 1989) comparable to thioredoxin (Figure 4B). However, 
whether this reaction mechanism has any relevance for other proteins or in other 
organisms is still a matter of dispute. 
 
Like disulfide-bond formation, glutathionylation often inhibits protein activity as 
reported for GAPDH (Lind et al, 1998; Mohr et al, 1999), PTB1B (Barrett et al, 1999) 
or nuclear factor κB (NFκB) (Pineda-Molina et al, 2001), but it may also increase 
protein activity as shown for HIV-1 protease (Davis et al, 1997) or matrix 
metalloproteinases (Okamoto et al, 2001). 
1.3.2 The thioredoxin system 
The thioredoxin system consists of the enzymes thioredoxin (Trx) and thioredoxin 
reductase (TrxR) as well as nicotinamide adenine dinucleotide phosphate (NADPH). 
Thioredoxins are ubiquitously expressed proteins with thiol-dependent 
oxidoreductase activity that reduce protein disulfides using their two active site 
cysteines. Upon reduction of target proteins Trx is itself oxidized in its active site. Trx 
is regenerated by TrxR, a homodimeric flavoenzyme that contains a redox active 
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disulfide and one tightly bound flavin adenine dinucleotide (FAD) per subunit. The 
active site of TrxR with the unique sequence Gly-Cys-SeCys-Gly contains a 
selenocysteine (SeCys) (Gladyshev et al, 1996). The highly reactive selenolate and 
the accessibility of the active site are the reasons why mammalian TrxR possesses 
wide substrate specificity and can reduce thioredoxins of other species, a variety of 
physiological substrates as well as several small compounds (Mustacich & Powis, 
2000). 
1.3.3 Forms and localization of thioredoxins 
Thioredoxin was first identified in E.coli as an electron donor for ribonucleotide 
reductase (Laurent et al, 1964) before it was described in mammals (Moore, 1967) 
and later purified from rat hepatoma cells (Herrmann & Moore, 1973). In mammalian 
cells two Trx isoforms encoded by two different genes are expressed. 
 
The TXN1 gene coding for human Trx1 is organized in five exons separated by four 
introns and maps to position 9q31 on chromosome 9 (Kaghad et al, 1994; Heppell-
Parton et al, 1995). Human Trx1 is a ubiquitous cytosolic 105-amino acid protein with 
a molecular weight of 12 kDa, which can translocate to the nucleus (Hirota et al, 
1999; Kabe et al, 2005) or gets secreted to the extracellular space by various cell 
types (Rubartelli et al, 1992). Apart from the two active site cysteines (Cys32 and 
Cys35), human Trx1 contains three additional non-catalytic cysteines (Cys62, Cys69 
and Cys73). Trx1 was independently described as IL-1-like autocrine growth factor 
from a Epstein-Bar virus (EBV) transformed B cell line (Wakasugi et al, 1987), ATL-
derived factor (ADF) from HTLV-I transformed T cells (Teshigawara et al, 1985; 
Tagaya et al, 1989) and early pregnancy factor isolated from ovine placental extracts 
Figure 5: The Trx system 
Disulfide bond reduction by Trx. During the catalytic cycle Trx becomes oxidized. It is subsequently 
reduced by the selenoprotein TrxR under the consumption of NADPH. 
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(Clarke et al, 1991), which all share the same amino acid sequence with human Trx1 
(Deiss & Kimchi, 1991; Gasdaska et al, 1994). 
 
Trx2 encoded by the TXN2 gene on 22q13.1 contains an N-terminal mitochondrial 
localization sequence. It is a 116-amino acid protein with a molecular mass of 18 kDa 
and a conserved thioredoxin active site but no other non-catalytical cysteines 
(Spyrou et al, 1997). In addition to Trx1 and Trx2 a third variant of human Trx, called 
Sptrx, is highly expressed in spermatozoa (Miranda-Vizuete et al, 2001). 
 
A truncated form a Trx1 (Trx80) comprising the 80 N-terminal amino acids is 
generated by proteolytic cleavage. Trx80 has been found to be secreted by various 
cell lines (Sahaf et al, 1997) and seems to be identical to eosinophil cytotoxicity 
enhancing factor (ECEF) secreted by phorbol ester (PMA)-stimulated U937 cells 
(Silberstein et al, 1993). Trx80 has no catalytic activity but functions as a mitogenic 
cytokine for resting human peripheral blood mononuclear cells (Pekkari et al, 2000). 
Furthermore, Trx80 induces activation and IL-12 secretion of monocytes (Pekkari et 
al, 2001). 
 
Plants possess two thioredoxin systems that can be distinguished by the electron 
donor and the enzyme that catalyzes thioredoxin reduction. The chloroplastic 
FRT/Trx system is composed of ferredoxin, ferredoxin-thioredoxin reductase (FRT), 
thioredoxin m and f. In the light, electrons are transferred from photosystem I to the 
iron-sulfur protein FRT via ferredoxin. In turn, FRT reduces thioredoxin m and f which 
reduce their targets involved in carbon assimilation, photorespiration and 
metabolism, thereby conferring a strict, light-sensitive control of both the assimilatory 
and dissimilatory pathway. In contrast, the NAPDH-thioredoxin reductase (NTR) 
system uses NAPDH for the reduction of cytosolic thioredoxin h which plays a role in 
seed germination and oxidative protection (Baumann & Juttner, 2002). Unlike in 
bacteria and animals, a large number of genes encode for thioredoxins in plants. In 
the genome of Arabidopsis thaliana 19 different thioredoxins have been identified 
and evidence suggest that individual tissues express characteristic members of the 
thioredoxin family (Buchanan & Balmer, 2004). 
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1.3.4 Structure of Trx1 
Oxidized E.coli Trx was the first thioredoxin to be structurally solved (Holmgren et al, 
1975), subsequently refined to 1.68 Å resolution (Katti et al, 1990). Later, also 
reduced E.coli Trx (Jeng et al, 1994) as well as human thioredoxin were crystallized 
(Qin et al, 1994; Weichsel et al, 1996) showing that Trx is a compact globular protein 
with a five-stranded β-sheet surrounded by four α-helices. Its active site disulfide is 
located at a C-terminal end of a β-strand (β2) and the beginning of the α2-helix 
(Figure 6). It turned out that thioredoxins from archaebacteria to humans show large 
variations in the amino acid sequence (27-69% sequence identity to E.coli 
thioredoxin) but still have similar three-dimensional structures (Eklund et al, 1991). 
This so-called thioredoxin fold is also present in other proteins like protein disulfide-
isomerase (PDI) (Eklund et al, 1991). Structures of oxidized and reduced Trx are 
very similar with only slight differences in the active site and hydrogen bonding 
pattern (Jeng et al, 1994; Holmgren, 1995). 
Recombinant human Trx1 forms covalent disulfide-linked homodimers via Cys73, in 
the presence of oxidants or when stored at high concentrations (Ren et al, 1993; 
Weichsel et al, 1996). As the active site is buried in the dimer interface, Trx1 
homodimers are catalytically inactive. It remains unknown if Trx dimer formation 
occurs in intact cells under physiological conditions. 
Figure 6: Crystal structure of reduced human Trx1
X-ray structure of human Trx1 generated from the Protein Data Bank (PDB) entry 1ERT (Weichsel et 
al, 1996) using Swiss-PbdViewer 4.0 
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1.3.5 Catalytic mechanism of Trx1 
All thioredoxins, including human Trx1, Trx2 and Sptrx, contain a conserved Cys-Gly-
Pro-Cys motive in the their active site (Holmgren, 1989). Upon binding of oxidized 
substrates to the hydrophobic surface of Trx1, the thiolate anion of the N-terminal 
Cys32 acts as a nucleophile and attacks the target disulfide bond, leading to the 
formation of a covalent mixed-disulfide bond between Trx1 and its target protein 
(Kallis & Holmgren, 1980). In a second step, the mixed disulfide is resolved by a 
nucleophilic attack of the second active site cysteine (Cys35), thus generating a 
reduced substrate and an oxidized Trx1 (Figure 7). The standard redox potential of 
Trx1 is −230 mV (Watson et al, 2003) and it has been shown that Trx1 is 95% 
reduced in the cytoplasm (Nkabyo et al, 2002) and in the nucleus (Watson & Jones, 
2003) under basal conditions. 
In addition to its established function as a reductase, it has been proposed that Trx1 
may also catalyze the reverse reaction under oxidative conditions (Watson et al, 
2004). However, so far there is no direct evidence that Trx1 acts as a protein oxidase 
in mammalian cells. 
1.3.6 Regulation of Trx1 expression and activity 
Thioredoxin-1 activity is regulated at the transcriptional level, by post-translational 
modifications and by protein-protein interactions. The Trx1 promoter contains binding 
sites for different transcription factors including AP-1, NFκB and Oct-1 (Kaghad et al, 
Figure 7: Reaction mechanism of Trx1
Disulfide bond reduction by Trx1 is initiated by a nucleophilic attack of Trx1 Cys32 leading to formation 
of a mixed disulfide which is resolved by Trx1 Cys35.
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1994) as well as an oxidative stress response element (Masutani et al, 1996; 
Taniguchi et al, 1996). Trx1 expression is induced by a variety of stress stimuli 
including hypoxia (Berggren et al, 1996), O2 (Das et al, 1999), H2O2 (Sachi et al, 
1995; Higashikubo et al, 1999), UV irradiation (Hoshi et al, 1997) or LPS (Ejima et al, 
1999). On the protein level, Trx1 activity may be regulated by redox-modifications of 
its cysteines. Glutathionylation of Trx1 at Cys73 after oxidative stress was reported to 
inhibit its enzymatic activity (Casagrande et al, 2002) and may represent a crosstalk 
between the glutathione and the thioredoxin system. Besides the disulfide bond 
between Cys32 and Cys35, formed during the catalytic cycle of Trx1, a second 
intramolecular disulfide between Cys62 and Cys69 was identified after treatment with 
diamide (Figure 8A). Interestingly, this second disulfide inhibited reduction of the 
active site disulfide by TrxR (Watson et al, 2003), suggesting that the interaction with 
TrxR is influenced by the α3-helix within which these two cysteines are located. This 
possibility is supported by the finding that homo-dimerisation of recombinant Trx1 via 
Cys73 made the active site inaccessible for reduction (Gasdaska et al, 1996). 
However, whether disulfides involving non-catalytic cysteines are also formed in vivo 
under physiological conditions remains to be proven. Recently, in vitro disulfide bond 
formation between Cys62 and Cys69 was investigated by another group of 
researchers (Hashemy & Holmgren, 2008). However, in contrast to the observations 
made by Watson and colleagues, the Cys62-Cys69 disulfide bond could only be 
induced by H2O2 treatment, whereas treatment with diamide led to formation of 
disulfide-linked dimers and multimers. It has been suggested that H2O2 generated by 
NADPH oxidases may transiently inactivate Trx1 (via Cys62-Cys69 disulfide bond 
formation or glutathionylation) to inhibit Trx1-mediated regeneration of 
peroxiredoxins. The resulting increase in H2O2 concentration could then facilitate the 
oxidation of redox-regulated proteins. In the same line, transient inactivation of Trx1 
could lead to prolonged oxidative inactivation of PTPs, thus enhancing 
phosphorylation-driven signaling events (Hashemy & Holmgren, 2008). 
 
In addition to disulfide bond formation and glutathionylation, Trx1 is potentially also 
regulated by S-nitrosylation. In endothelial cells, Trx1 has found to be S-nitrosylated 
at Cys69 which appeared to increase its enzymatic activity (Haendeler et al, 2002), 
whereas another study showed that Trx1 was nitrosylated at Cys73 in vitro (Mitchell 
& Marletta, 2005). In the recent study by Hashemy and Holmgren (2008), 
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recombinant Trx1 was found to be nitrosylated at both Cys69 and Cys73 resulting in 
the inhibition of Trx1 activity (Figure 8B). The conflicting results regarding the site(s) 
of nitrosylation and its influence on Trx1 activity may derive from differences in the 
thiol-disulfide redox status of the Trx1 samples used. 
 
Additionally, Trx1 is regulated by the interaction with vitamin D3 up-regulated protein 
1 (VDUP1), also known as thioredoxin-interacting protein (Txnip) or thioredoxin 
binding protein-2 (TBP-2). VDUP1 was initially discovered as a 46 kDa protein up-
regulated after vitamin D3 treatment in HL-60 cells (Chen & DeLuca, 1994) and later 
found to bind Trx1 in a yeast two-hybrid screen. VDUP1 binds reduced, but not 
oxidized Trx1, nor to a Trx1 mutant in which the two active site cysteines were 
replaced by serine. The interaction inhibits Trx1 activity both in vitro and in vivo. 
Furthermore, over-expression of VDUP1 in HEK or COS-7 cells reduced expression 
levels of endogenous Trx1 (Nishiyama et al, 1999a; Yamanaka et al, 2000). Due to 
its ability to inhibit Trx1 activity and to downregulate Trx1 expression, VDUP1 has 
been proposed to function as mediator of oxidative stress (Junn et al, 2000). 
 
Besides its role as Trx1 inhibitor, VDUP1 has multiple Trx1-indepedent functions in 
diverse cellular responses including proliferation, differentiation or apoptosis and has 
been demonstrated to act as tumor suppressor (Han et al, 2003; Kim et al, 2007). 
Figure 8: Cysteine modifications of Trx1
(A) Disulfide bond formation of Cys32/Cys35, Cys62/Cys69 and disulfide-linkage of Trx1 monomers 
via Cys73. (B) S-Nitrosylation of Cys69 and Cys73. (C) Glutathionylation of Cys73. 
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1.3.7 Biological functions of Trx1 
The importance of Trx1 for embryonic development has been demonstrated with 
mice carrying a targeted disruption of the Trx1 gene. Homozygous animals die 
shortly after implantation whereas heterozygous animals are viable, fertile and 
appear normal (Matsui et al, 1996). Consistent with this phenotype, Trx1 is 
expressed in various different organs during fetal development (Fujii et al, 1991a). 
 
Besides providing electrons for ribonucleotide reductase (Laurent et al, 1964), the 
function first recognized to depend on Trx1, various other functions have since then 
been identified. One of the main functions of Trx1 is its role as an antioxidant, namely 
to maintain the activity of peroxide-scavenging peroxiredoxins (Prx) by reducing their 
oxidized forms. So far, six mammalian Prx isoforms have been described which can 
be classified into 2-Cys, atypical 2-Cys and 1-Cys peroxiredoxins. Upon oxidation, 
the 2-Cys peroxiredoxins, which include Prx1, -2, -3 and -4, form a Trx-reducible 
inter-subunit disulfide bond, whereas the atypical 2-Cys peroxiredoxin Prx5 forms an 
intra-subunit disulfide bond. In contrast, the 1-Cys peroxiredoxin Prx6 does not form 
a disulfide intermediate and is also not a substrate for Trx1. Among the 2-Cys 
peroxiredoxins, only Prx1 and Prx2 are localized in the cytoplasm, while Prx3 is 
confined to the mitochondria and Prx4 is found in the ER as well as in the 
extracellular space (Rhee et al, 2005). During the catalytic cycle of typical 2-Cys 
peroxiredoxins, the conserved H2O2-sensitive peroxidative cysteine is selectively 
oxidized to the sulfenic acid which then reacts with a conserved C-terminal cysteine 
of another Prx subunit to form a disulfide-linked homodimer. The dimer is 
subsequently reduced by Trx1 to its monomeric form (Chae et al, 1994a; Chae et al, 
1994b). Of note, plasma Trx1 has been shown to reduce glutathione peroxidase 3 
(Björnstedt et al, 1994), a process indicating an extracellular antioxidative function of 
Trx1. 
Trx1 was reported to activate a number of transcription factors, including NFκB which 
plays an important role during the immune response, in inflammation and cancer 
(Karin, 2006). Binding of NFκB to DNA can be promoted by Trx1 (Hayashi et al, 
1993) and this effect depends on Cys62 in the p50 subunit of NFκB. Oxidation of 
Cys62 leads to the formation of a disulfide-linked p50 homodimer, which interferes 
with DNA binding and can be reduced by Trx1 (Matthews et al, 1992). Later it has 
been shown that Trx1 has opposing roles in NFκB regulation in the cytosol and the 
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nucleus. In the cytoplasm Trx1 inhibits NFκB activation by blocking degradation of 
the cytosolic inhibitor IκBα. Upon stimulation with TNF-α, UV irradiation or PMA Trx1 
translocates to the nucleus where it reduces and activates NFκB p50 (Hirota et al, 
1999). Trx1 interacts with redox-factor 1 (Ref-1) to activate the transcription factors 
activator protein 1 (AP-1) (Hirota et al, 1997; Wei et al, 2000) and hypoxia-inducible 
factor-1 alpha (HIF-1α) (Ema et al, 1999). Other transcription factors regulated by 
Trx1 include the glucocorticoid receptor (Grippo et al, 1985; Makino et al, 1999) and 
estrogen receptor (Hayashi et al, 1997). Furthermore, Trx1 reduces a disulfide-linked 
complex formed between the heat-shock protein DnaJb5 and class II histone 
deacetylases (HDACs) thereby inhibiting its nuclear import independently of its 
phosphorylation status. This Trx1-mediated modulation of HDAC nucleocytoplasmic 
shuttling has been linked to the regulation of cardiac hypertrophy (Ago et al, 2008). 
The activity of the tumor suppressor p53 is regulated by Ref-1 and it has been shown 
that Trx1 augments DNA binding of p53 in a Ref-1-dependent manner, which leads 
to an enhanced p53-dependent expression of the cell cycle inhibitor p21 (Ueno et al, 
1999). Another tumor suppressor, the lipid and protein phosphatase PTEN, is also 
regulated by Trx1. Upon exposure to H2O2, PTEN is inactivated by the formation of 
an intramolecular disulfide bond involving its catalytic cysteine, which can be reduced 
by Trx1, at least in vitro (Lee et al, 2002). In stark contrast, according to other 
researchers, Trx1 forms a disulfide bond with a cysteine in the C2 domain, thereby 
inhibiting PTEN activity through steric interference (Meuillet et al, 2004). Most 
recently, it was reported that mouse embryonic fibroblasts (MEFs) from VDUP1-
deficient mice show increased oxidation of PTEN and elevated Akt activation, which 
has been explained by reduced Trx1 activity in VDUP-/- MEFs (Hui et al, 2008). 
However, this explanation is in conflict with to the described function of VDUP1 as 
negative regulator of Trx1. Thus, Trx1 seems to regulate PTEN activity by thiol-
disulfide exchange, but the exact mechanism still awaits further clarification. In 
addition to PTEN other PTPs have been shown to serve as substrate for Trx1 
including cdc25 (Sohn & Rudolph, 2003) and PTP1B (Lee et al, 1998). LMW-PTP 
has been shown to be redox regulated by Grx1 (Kanda et al, 2006). However the 
influence of Trx1 on this phosphatase has not been analyzed so far and a possible 
co-regulation of LMW-PTP by both redox systems can not be excluded. 
 
Trx1 is secreted to the extracellular space by a variety of normal and transformed 
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cells including EBV-positive B cells (Wakasugi et al, 1987; Wakasugi et al, 1990), T 
lymphocytes (Ericson et al, 1992) and various cancer cells (Rubartelli et al, 1992). 
Secretory Trx1 can act as growth factor for fibroblasts (Oblong et al, 1994), 
lymphocytes (Wakasugi et al, 1990) and tumor cells (Nakamura et al, 1992). This 
mitogenic effect depends on the active site cysteines of Trx1 and can not be 
mimicked by E.coli thioredoxin (Oblong et al, 1994). Trx1 does not act as a classical 
growth factor via any known growth factor receptor, but instead can sensitize cells to 
autocrine growth factors like IL-2 or bFGF (Gasdaska et al, 1995; Powis et al, 1997). 
Expression of IL-2, IL-6, IL-8 and TNF-α was increased by extracellular Trx1 in 
several cell lines (Schenk et al, 1996). Trx1 was show to mediate reduction of the 
TNFR-family member CD30 on the cell surface of lymphocytes, which affects both 
CD30 ligand binding and effector function of these cells (Schwertassek et al, 2007). 
Apart from its function as growth factor Trx1 is a chemoattractant for neutrophils, 
monocytes and T cells (Bertini et al, 1999; Miller et al, 2000). Secretion of Trx1 is 
enhanced after stimulation with PMA, calcium ionophores, LPS or oxidative stress 
(Sahaf & Rosen, 2000) but the molecular mechanism is still unknown. Neither 
brefeldin A nor dinitrophenol, two inhibitors of the exocytic pathway can block 
secretion of Trx1, showing that Trx1 secretion is not mediated via the classical 
ER/golgi pathway. Furthermore, Trx1 cannot be detected in the membrane-bound 
compartment of secreting cells (Rubartelli et al, 1992) and its secretion does not 
depend on the redox state of the active site cysteines (Tanudji et al, 2003). Very 
recently, caspase-1 has been demonstrated to be required for unconventional 
secretion of Trx1 from UVB irradiated keratinocytes and LPS/ATP stimulated 
macrophages (Keller et al, 2008) thereby providing a novel link between inflammation 
and non-conventional protein secretion. 
 
S-Nitrosylation of Trx1 has been observed repeatedly. However, its influence on Trx1 
activity still remains controversial (Haendeler et al, 2002; Sumbayev, 2003; Hashemy 
et al, 2007). Interestingly, Trx1 regulates caspase-3 activity not by disulfide-reduction 
but instead by trans-nitrosylation involving the active site thiol of the caspase 
(Mitchell et al, 2007). Upon stimulation of the death-receptor CD95, caspase-3 is 
denitrosylated by Trx1 and Trx2, a process required for its activation and initiation of 
apoptosis (Benhar et al, 2008). This finding is consistent with data showing that Trx1 
can promote denitrosylation in vitro after treatment with nitrosylating agents 
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(Stoyanovsky et al, 2005; Sengupta et al, 2007) and reveals a novel role for Trx1 in 
NO-mediated signal transduction besides its well established function as protein-
disulfide reductase. 
1.3.8 Trx1 in human diseases 
As Trx1 influences a broad range of cellular functions including control of the cellular 
redox balance, promotion of cell growth, inhibition of apoptosis and modulation of 
inflammation, it apparently also plays an important role in a broad range of human 
diseases. As a growth-promoting anti-apoptotic protein, Trx1 is frequently linked to 
tumor development. Indeed, Trx1 is over-expressed in various cancers including liver 
(Nakamura et al, 1992; Kawahara et al, 1996), lung (Gasdaska et al, 1994; Kim et al, 
2003), colon (Berggren et al, 1996) and cervix cancer (Fujii et al, 1991b). Trx1 was 
shown to be associated with increased proliferation of tumor cells, inhibition of 
apoptosis, aggressive tumor growth and decreased patient survival (Lincoln et al, 
2003; Raffel et al, 2003). In addition to inhibiting ASK1-mediated apoptosis and 
tumor suppression by PTEN, Trx1 further augments vascularization of the tumor by 
increasing the expression level and activity of HIF-1α which leads to enhanced 
production of vascular endothelial growth factor (VEGF) (Welsh et al, 2002; Kim et al, 
2005b). 
Based on its growth-promoting activity Trx1 has been proposed to be classified as an 
oncogene (Grogan et al, 2000) but this proposal has not received wide acceptance. 
Even though Trx1 is over-expressed in many tumors, elevated expression levels are 
also observed in non-cancerous cells and tissues (Arner & Holmgren, 2006). The 
strongest refutation of the oncogene hypothesis stems from mice over-expressing 
Trx1 under the control of a β-actin promoter. These mice develop normally and show 
no increase in malignancies compared to wild-type mice, instead they have an 
extended life span (Takagi et al, 1999; Mitsui et al, 2002). Thus, high expression 
levels of Trx1 in tumors appears to be a consequence of malignancy, associated with 
metabolic adaptation and a high proliferation rate, rather than being the cause of 
malignant transformation (Lillig & Holmgren, 2007). Nevertheless, Trx1 may play an 
important role for tumor progression due to its anti-apoptotic effects which directly 
influence the efficiency of chemotherapy. Accordingly, reduction of Trx1 expression 
levels has been shown to sensitize human bladder cancer cells to doxorubicin, 
mitomycin C, etopsoside and UV irradiation (Yokomizo et al, 1995). Conversely, 
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over-expression of Trx1 in fibrosarcoma cells results in drug resistance (Sasada et al, 
1996) and high levels of Trx1 are associated with increased resistance to docetaxel 
in primary breast cancer (Kim et al, 2005a). 
 
In addition to its function in neoplastic diseases, Trx1 plays a role in retroviral 
infections. Human T cell leukemia virus type 1 (HTLV-1) infection can induce the 
development of adult T cell leukemia (ATL) which leads to up-regulation of the IL-2 
receptor α chain induced by ATL-derived factor (ADF) (Teshigawara et al, 1985), 
later found to be identical to Trx1 (Tagaya et al, 1989). Moreover, Trx1 is up-
regulated in HTLV-1 positive T cells (Makino et al, 1992), potentially contributing to 
increased proliferation and inhibition of apoptosis in these cells. The increased levels 
of Trx1 may result from transactivation by the viral oncoprotein tax (Masutani et al, 
1996) or down-regulation of VDUP1 (Nishinaka et al, 2004). Epigenetic silencing of 
VDUP1 results in loss of responsiveness to IL-2 in HTLV-1 infected cells which 
Figure 9: Trx1 in cancer and drug resistance
Trx1 regulated pathways influencing tumor development and cancer drug resistance. See text for 
details. Adapted from Kaimul et al (2007).
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further adds to uncontrolled proliferation of these cells (Ahsan et al, 2006). 
Furthermore, it has been proposed that Trx1 suppresses gene expression from the 
HTLV-1 long terminal repeat (LTR) thereby negatively regulating viral gene 
expression (Sasada et al, 2002). 
Infection of cells with human immunodeficiency virus 1 (HIV-1) results in down-
regulation of Trx1 and loss of cells that highly express Trx1 in lymphoid tissue 
(Masutani et al, 1992) whereas Trx1 plasma levels are increased in HIV-1 infected 
patients (Nakamura et al, 1996). The plasma concentration of Trx1 inversely 
correlates with the number of CD4 T cells and the life expectancy of HIV-1 infected 
patients, an observation which may result from the interference of Trx1 with virus-
induced chemotaxis of immune cells (Nakamura et al, 2001a; Nakamura et al, 
2001b). On the host cell, the CD4 co-receptor serves as primary ligand for HIV-1 
gp120 to trigger fusion of the virus with the cell membrane and to mediate entry of 
the virus. The extracellular portion of CD4 consists of four immunoglobin-like 
domains (D1 to D4). The D2 domain contains a disulfide bond which can be reduced 
by Trx1 and locking of CD4 and the Trx1 active site in a reduced state blocked HIV-1 
entry in susceptible cells (Matthias et al, 2002). Reduction of CD4 is enhanced in the 
presence of gp120 and it has been reported that Trx1 can also reduce disulfide 
bonds in gp120 (Ou & Silver, 2006). Even though the exact mechanism of how Trx1 
regulates HIV-1 entry still needs to be clarified, these data provide strong evidence 
for an important role of Trx1 in HIV-1 infection. 
 
Furthermore, Trx1 has been identified as growth factor secreted by an EBV-positive 
B cell line (Wakasugi et al, 1987) and it was shown to prevent EBV-transformed cells 
from entering the lytic phase of virus replication (Sono et al, 1999). In addition, Trx1 
is thought to be involved in various non-viral diseases including reperfusion injury 
(Tao et al, 2004); Alzheimer’s disease (Akterin et al, 2005) or cardiovascular 
disorders (Berndt et al, 2007). 
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1.4 Objective of this work 
Although causing oxidative stress and damage at higher concentrations, ROS fulfill 
positive roles by regulating protein functions through reversible oxidation of 
regulatory cysteine residues. Cysteine-based redox-regulation includes the formation 
of disulfide bonds which are known to modulate the structure and activity of proteins. 
Trx1 catalyzes protein disulfide reduction to counteract oxidation and to influence the 
redox-dependent activity of its target proteins as, for example, transcription factor 
NFκB (Matthews et al, 1992), phosphatase cdc25 (Sohn & Rudolph, 2003) and 
PTP1B (Lee et al, 1998). Proteomic studies led to the identification of candidate 
H2O2-sensitive thiol proteins in mammalian cells (Ghezzi & Bonetto, 2003; Baty et al, 
2005) but so far no proteome-wide identification of cytosolic Trx1 target proteins has 
been performed. The major obstacle for the detection of Trx1 target proteins is the 
short half-life of the thiol-disulfide exchange intermediate. In order to overcome this 
limitation, activity-based kinetic trapping was used to stabilize transient conjugates 
between Trx1 and its target proteins. This method is based on the catalytic reaction 
mechanism of the oxidoreductase in which the two active cysteines are involved. 
Reduction of target disulfide bonds by Trx1 is mediated by the attack of the N-
terminal cysteine in the CXXC active site motive, resulting in the formation of a mixed 
disulfide that covalently links Trx1 and its target protein. In a second reaction step, 
this intermolecular disulfide bond is attacked by the second active site cysteine, 
Cys35. Following the so-called escape reaction, the substrate is reduced. In turn, 
Trx1 itself is oxidized and will be reduced and thereby re-activated by TrxR under the 
consumption of NAPDH (Kallis & Holmgren, 1980) (Figure 10). Because of the 
escape reaction, disulfide-linked Trx1 target complexes are very short-lived and 
difficult to characterize. In order to stabilize these transient complexes, Cys35 was 
replaced by serine, thus prolonging the half-life of the intermediary enzyme-substrate 
conjugate (Qin et al, 1995; Wynn et al, 1995). Thus, the so-called trapping mutant 
Trx1(C35S) remains covalently linked to it substrates and can be isolated by an 
affinity tag attached to it. 
 
Kinetic trapping has been used previously to study individual enzyme:substrate 
interactions of the bacterial periplasmatic oxidoreductase DsbA (Kishigami et al, 
1995), plant thioredoxin f (Brandes et al, 1996), human Trx1 (Hirota et al, 1997) and 
the thiol oxidoreductase ERp57 (Dick et al, 2002; Dick & Cresswell, 2002). Later this 
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approach was used to perform proteomic screens for thioredoxin substrates in yeast 
(Verdoucq et al, 1999), plants (Hisabori et al, 2005) and recently on the surface of 
mammalian cells (Schwertassek et al, 2007). In order to identify cytosolic protein 
targets of Trx1 in mammalian cells, a proteome-wide Trx1 kinetic trapping screen 
was performed on cytosolic preparations of the human Jurkat T cell line. Conjugate 
formation between Trx1 and selected target proteins was analyzed by 
immunoblotting and target cysteine(s) were identified by site-directed mutagenesis. 
 
In addition, novel tools for the analysis of Trx1-medited redox regulation were 
developed. A doxycycline-dependent expression system of the Trx1 trapping mutant 
was generated in Jurkat T cells in order to perform kinetic trapping of Trx1 target 
proteins in intact cells. Moreover, an inducible shRNA-based Trx1 knockdown system 
was established in HeLa cells in order to overcome the lack of specific Trx1 inhibitors 
for the analysis of Trx1-dependent processes. 
 
Figure 10: Principle of kinetic trapping 
Wildt-ype Trx1 WT forms a transient mixed-disulfide with its target protein, which is rapidly resolved by 
the second active site cysteine (Cys35). Trx1:substrate complexes can be stabilized by mutation of 
Cys35 to serine (-OH). Addition of an SBP affinity tag to Trx1(C35S) allows for purification of disulfide-
linked complexes with streptavidin sepharose. 
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2 Materials 
2.1 Chemicals 
Chemicals were from Sigma (Munich), Roth (Karslruhe), AppliChem (Darmstadt), 
Merck (Darmstadt), Serva (Heidelberg) or Perbio (Bonn) if not otherwise stated. 
2.2 Laboratory equipment 
Device Source 
Precision balance (AG287) Mettler 
Analytical balance (PB602-S) Mettler 
freezer -20°C Liebherr 
freezer -80°C Sanyo 
Darkroom film processor (Classic E.O.S) AGFA 
HLPC system (ÄKTA purifier) GE Healthcare 
Centrifuge (5415 R) Eppendorf 
Centrifuge (Heraeus Multifuge 3 S-R) Kendro 
Centrifuge (Heraeus Multifuge 4 KR) Kendro 
Centrifuge (Sorvall Evolution RC) Kendro 
PCR cycler (DNA Engine PTC-200) MJ Research 
Microplate reader (GENios) TECAN 
GelAir Drying System Bio-Rad 
Gel Dryer (Model 583) Bio-Rad 
CO2 incubator (Heraeus BBD 6220) Kendro 
Flow hood (Heraeus Hera Safe) Kendro 
Water bath (Heraeus Julabo TW20) Kendro 
Incubator Shaker (Innova 4200) New Brunswick Scientific 
NuPAGE® Novex 4-12% Bis-Tris Gels (1.0 mm; 9 well) Invitrogen 
NuPAGE® Novex 4-12% Bis-Tris Gels (1.5 mm; 2D well) Invitrogen 
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Electrophoresis Power Supply (EPS 3501XL) GE Healthcare 
Power supply (PowerPac Basic) Bio-Rad 
Power supply (PowerPac 1000) Bio-Rad 
Electrophoresis System (Mini PROTEAN® 3 Cell) Bio-Rad 
Electrophoresis System (SE 400 Sturdier) GE Healthcare 
Thermomixer (compact) Eppendorf 
UV/Vis Photospectrometer (Ultraspec 3100 pro) GE Healthcare 
Electrophoresis System (XCell Sure Lock Mini-Cell) Invitrogen 
Semi-dry blotter (Trans-Blot SD cell) Bio-Rad 
X-ray films (CL-XPosure) Perbio 
 
2.3 Buffers 
Phosphate buffered saline (PBS) 137 mM NaCl 
 2.7 mM KCl 
 10 mM Na2HPO4 
 2 mM KH2PO4 
  
PBS-T 0.1 % (v/v) Tween 20 in PBS 
  
Tris buffered saline (TBS) 10 mM Tris-HCl (pH 7.4) 
 150 mM NaCl 
  
HEPES buffer saline (HBS) 50 mM HEPES (pH 7.0) 
 12 mM Dextrose 
 10 mM KCl 
 280 mM NaCl 
 1.5 mM Na2HPO4 
  
Lysis buffer 1 % (v/v) Triton X-100 in TBS (pH 7.5) 
 Complete protease inhibitor 
(Roche) 
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Streptavidin binding buffer 40 mM Tris-HCl (pH 7.4) 
 300 mM KCl 
 2 mM EDTA (pH 8.0) 
 0.1 % (v/v) Triton X-100 
  
DNA loading buffer (5x) 0.25 % (w/v) bromophenol blue 
 30 % (v/v) glycerol 
 10 mM EDTA 
 10 mM Tris-HCl (pH 7.4) 
  
TAE (50x) 2 M Tris 
 50 mM EDTA (pH 8.0) 
  
His-Tag protein purification:  
Washing buffer 50 mM NaH2PO4 
 300 mM NaCl 
 20 mM Imidazole 
 pH 8.0 
  
Elution buffer 50 mM NaH2PO4 
 300 mM NaCl 
 500 mM Imidazole 
 pH 8.0 
SDS-PAGE:  
Separation gel buffer 1.5 M Tris/HCl pH 8.7 
 0.1 % (w/v) SDS 
  
Stacking gel buffer 0.5 M Tris/HCl pH 6.8 
 0.1 % (w/v) SDS 
  
Running buffer (10x) 250 mM Tris 
 2.5 M Glycine 
 1 % (w/v) SDS 
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SDS sample buffer (10x) 10 % (w/v) SDS 
 500 mM Tris-HCl (pH 7.4) 
 20 % (v/v) Glycerol 
 0.02 % (w/v) bromophenol blue 
  
MES running buffer (20x) 1 M MES 
 1 M Tris 
 0.1 % (w/v) SDS 
 20 mM EDTA 
  
Transfer buffer 25 mM Tris 
 192 mM Glycine 
 20 % (v/v) Methanol 
  
Stripping buffer 62.5 mM Tris pH 6.8 
 2% (w/v) SDS 
 0.7% (v/v) β-mercaptoethanol 
Silver staining:  
Fixing  30 % (v/v) Ethanol 
 10 % (v/v) CH3COOH 
 60 % (v/v) ddH2O 
  
Sensitization 0.02 % (w/v) Na2S2O3•5H2O 
  
Impregnation 0.2 % (w/v) AgNO3 
 0.075% (v/v) formaldehyde 
  
Developer 6 % (w/v) Na2CO3 
 2% (v/v) sensitization solution 
 0.05% (v/v) Formaldehyde 
  
Stop solution  4 % (w/v) Tris 
 2 % (v/v) CH3COOH 
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Colloidal Coomassie solution 10 % (w/v) (NH4)2SO4 
 0.1 % (v/v) H3PO4 
 0.1 % (w/v) Coomassie brilliant blue G250 
 20 % (v/v) methanol (add freshly before use) 
  
Coomassie solution 0.25 % (w/v) Coomassie brilliant blue R250 
 10 % (v/v) CH3COOH 
 45 % (v/v) methanol 
 
Other buffers and solutions are listed in the corresponding sections. 
2.4 Antibodies 
 
Specificity Clone Isotype, species Stock conc. 
Working 
dilution Source Cat. No. 
beta-actin AC-15 IgG1 mouse monoclonal - 1:2.000 Sigma A5441 
Annexin-1 29 IgG1 mouse monoclonal - 1:5.000 
BD 
Biosciences 610066 
Annexin-2 5 IgG1 mouse monoclonal - 1:5.000 
BD 
Biosciences 610068 
Annexin-7 5 IgG1 mouse monoclonal 250 µg/ml 1:1.000 
BD 
Biosciences 610668 
Annexin-11 16 IgG1 mouse monoclonal 250 µg/ml 1:15.000 
BD 
Biosciences 611878 
caspase-2 35 IgG1 mouse monoclonal 250 µg/ml 1:1.000 
BD 
Biosciences 611022 
caspase-3 - rabbit polyclonal - 1:2.000 Cell Signaling 9662 
caspase-8 C15 IgG2B mouse monoclonal - 1:100 P. Krammer - 
caspase-9 F-7 IgG2A mouse monoclonal 0.2 mg/ml 1:1.000 Santa Cruz sc-17784 
cdk1 17 IgG2A mouse monoclonal 0.2 mg/ml 1:1.000 Santa Cruz sc-54 
cdk2 - rabbit polyclonal 0.5 mg/ml 1:1.000 I. Hoffmann - 
cdk4 C-22 rabbit polyclonal 0.2 mg/ml 1:1.000 Santa Cruz sc-260 
cdk6 C-21 rabbit polyclonal 0.2 mg/ml 1:1.000 Santa Cruz  sc-177 
Flag-tag M2 IgG1 monoclonal mouse 1 mg/ml 1:1.000 Sigma F1804 
Peroxiredoxin-1 - rabbit polyclonal - 1:5.000 Upstate 07-609 
p120RasGAP B4F8 mouse monoclonal 1 mg/ml 1:1.000 Upstate 05-178 
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SBP-tag - rabbit polyclonal 1 mg/ml 1:10.000 M. Gutscher - 
Thioredoxin-1 - rabbit polyclonal 1 mg/ml 1:10.000 M. Preuss - 
 
Antibody dilutions were stored in PBS-T / 5% (w/v) BSA / 0.01% (v/v) NaN3 at 4°C. 
 
Secondary HRP-conjugated antibodies 
 
Specificity Clone Isotype, species Stock conc. 
Working 
dilution Source Cat. No. 
mouse - goat polyclonal 0.8 mg/ml 1:10.000 Dianova 115-035-146 
rabbit - goat polyclonal 0.8 mg/ml 1:10.000 Dianova 111-035-144 
 
2.5 Media for eukaryotic cells and bacteria 
 
Media for eukaryotic cells 
 
Dulbecco's modified Eagle medium (DMEM), Gibco 
Iscove's modified Dulbecco's medium (IMDM), Gibco 
Roswell Park Memorial Institute medium (RPMI), Gibco 
Fetal calf serum (FCS) (Gibco), working concentration: 10% (v/v) 
Penicillin, streptomycin (Gibco), working conc. 100 U/ml and 100 µg/ml, respectively 
Neomycin, G418 (Gibco), stock: 500 mg/ml, working concentration: 1 mg/ml 
Puromycin (Gibco), stock: 1 mg/ml, working concentration: 1 µg/ml 
Hygromycin (Invitrogen), stock: 50 mg/ml, working concentration: 250 µg/ml 
Doxycycline (Sigma), stock: 1 mg/ml, working concentration: 1 µg/ml 
 
Media for bacteria 
 
LB broth (Luria/Miller) dry medium containing 1% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 1% (w/v) NaCl, pH7.0 ± 0.2 was obtained from Roth (Karlsruhe). 25 g/l dry 
medium were dissolved in ddH2O and and sterilized by autoclavation. 
 
LB agarose plates were prepared by addition of 1.5% (w/v) agarose prior to 
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sterilization. 
 
For selection medium or plates the following antibiotics were added after 
autoclavation: 
Ampicillin: stock solution 100 mg/ml in ddH2O, working concentration: 100 µg/ml 
Kanamycin: stock solution: 25 mg/ml in ddH2O, working concentration: 25 µg/ml 
2.6 Biological material 
 
E.coli strains 
Strain Characteristics 
E.coli 
M15 [pREP4] 
NaIS StrS RifS Thi– Lac– Ara+ Gal+ Mtl– F– RecA+ Uvr+ Lon+ 
E.coli  
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
E.coli  
DH5-alpha 
F' Phi80dlacZ DeltaM15 Delta(lacZYA-argF)U169 deoR recA1 
endA1 
hsdR17(rK-mK+)phoA supE44 lambda- thi-1 
 
Eukaryotic cell lines 
Line Characteristics Medium Selection 
HeLa T-REx HeLa cells expressing the Tet repressor (TetR) 
(Invitrogen) DMEM - 
HEK 293T human embryonic kidney cell line expressing 
the SV40 large T-antigen DMEM - 
Phoenix-
Ampho 
human embryonic kidney cell line stably 
expressing a amphotrophic viral capsid protein DMEM - 
J16-145 Subclone of the human Jurkat acute 
lymphoblastic leukemia T cell line J16 (Gülow 
et al, 2005) 
IMDM - 
HH T cell line established from the blood of a 61 
year old patient with an aggressive cutaneous 
T-cell leukemia/lymphoma (Starkebaum et al, 
1991) 
RPMI - 
MyLa Sezary T-cell leukemia line obtained from a 
plaque biopsy of a patient with mycosis 
fungoides (Kaltoft et al, 1992) 
RPMI - 
Hut78 T cell lymphoma derived from peripheral blood 
of a 50 year old male patient with Sezary 
syndrome (Gootenberg et al, 1981) 
RPMI - 
Materials 
 
33 
Molt-4 T-cell line derived from the peripheral blood of 
a 19 year old male with acute lymphoblastic 
leukemia in relapse (Minowada et al, 1972) 
RPMI - 
CEM T lymphoblastoid line obtained from the 
peripheral blood of a 4 year old Caucasian 
female with acute lymphoblastoid leukemia 
(Foley et al, 1965) 
RPMI - 
J16-M2.15 J16-145 transduced with the rtTA-M2, clone 15 IMDM Puromycin 
J16-M2 
-Trx1 WT 
-CSCCC 
-CCAAA 
-CSAAA 
J16-M2.15 transduced with pRevTight-Trx1 
WT, CSCCC, CCAAA or CSAAA 
See section 4.5.1 
IMDM Puromycin Hygomycin
HeLa T-REx 
-212 
-252 
-281 
-NCR 
HeLa T-REx transduced with pSR-TRE-NG 
shTrx1 212, 252, 281 or NCR 
See section 4.5.2 
DMEM Neomycin 
 
2.7 Expression vectors 
 
Plasmid Source 
pSUPER-Retro-NeoGFP Oligoengine 
pTER Hans Clevers (van de Wetering et al, 2003) 
pCMV-3Tag-4A Stratagene 
pcDNA3-cdk6-HA Addgene #1868 (van den Heuvel & Harlow, 1993) 
pQE60-hTrx1-SBP-His described earlier (Schwertassek et al, 2007) 
pcDNA3 Invitrogen 
Rc/CMV cyclin D3 Addgene #10912 (Hinds et al, 1992) 
pUHrT 62-1 Herman Bujard (Urlinger et al, 2000) 
pRev-TRE Clontech 
pTRE-Tight Clontech 
pMXs-IN-Puro Adelheid Cerwenka (Tessarz et al, 2007) 
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2.8 Enzymes and kits 
 
Pfu Turbo polymerase Stratagene 
shrimp alkaline phosphatase Promega 
Quick Ligation Kit New England Biolabs 
BCA Protein Assay Kit - Reducing Agent 
Compatible Perbio 
QuickChange Multi Site-Directed Mutagenesis 
Kit Stratagene 
Gel extraction kit NucleoSpin Extract II Macherey-Nagel 
NucleoSpin Plasmid QuickPure Macherey-Nagel 
NucleoBond AX Macherey-Nagel 
Chemiluminescent Substrate SuperSignal West 
Femto Perbio 
Chemiluminescent Substrate SuperSignal West 
Pico Perbio 
1 kb Plus DNA Ladder Invitrogen 
Precision Plus Protein Dual Color Standard Bio-Rad 
 
2.9 Software 
The following computer software was used: Microsoft Office 2003, Adobe Acrobat 
Professional 7.0, Adobe Illustrator CS3, Adobe Photoshop CS2, Textco Gene 
Construction Kit 2.5, Thomson EndNote 6, BD CellQuest Pro, Deep View Swiss-
PdbViewer 4.0, ClustalW. 
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3 Methods 
3.1 Methods in molecular biology 
3.1.1 Small scale isolation of plasmid DNA from E.coli 
For analytical preparation of plasmid DNA the NucleoSpin Plasmid QuickPure kit 
(Macherey-Nagel) was used. An E.coli culture volume of 3 ml was resuspended in 
RNase-containing buffer and plasmid DNA was liberated by SDS/alkaline lysis. After 
neutralization and clarification of the lysate, the plasmid was bound onto a silica 
membrane and washed with ethanol-containing buffer. Finally, pure plasmid DNA 
was eluted in 50 µl H2O. 
3.1.2 Large scale isolation of plasmid DNA from E.coli 
Quantitative preparation of plasmid DNA was performed with the NucleoBond AX kit 
(Macherey-Nagel). Overnight cultures of 250 to 500 ml were lysed in alkaline buffer 
supplemented with RNase, neutralized and plasmid DNA-containing supernatant was 
loaded onto a macroporous silica matrix functionalized with methyl-amino-ethanol 
(MAE). The positively charged MAE group specifically binds the negatively charged 
phosphate backbone of plasmid DNA under acidic pH. After washing, plasmid DNA is 
eluted in a high-salt elution buffer and precipitated with 0.7 volumes of isopropanol. 
NucleoBond Finalizer silica membranes (Macherey-Nagel) were used to concentrate 
and desalt the precipitated plasmid DNA. Finally, elution was done with 0.5 to 1 ml 
ddH2O, depending on the copy number of the plasmid. 
3.1.3 Restriction digest of DNA 
Restriction enzymes were from Promega and New England Biolabs. For cloning 3 µg 
DNA were digested for 1 h at 37°C. 1 U shrimp alkaline phosphatase (Promega) was 
added to preparative vector digestions to avoid re-ligation of the digested plasmid. 
3.1.4 Polymerase chain reaction (PCR) 
Selective amplification of DNA sequences was performed by using the polymerase 
chain reaction (PCR), which is based on cyclic changes in temperature, which 
provides optimal conditions for the different reaction steps. After denaturation of 
template DNA, specific oligonucleotides (primers) hybridize with single stranded DNA 
to form a double stranded starting point for DNA polymerase. In the second 
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elongation step double stranded DNA is synthesized from the single stranded DNA 
template. The newly synthesized DNA double strand is separated in the denaturation 
step and will serve as template for the next amplification cycle. 
Reaction mix for one sample: 
 
2.5 µl 10x Pfu reaction buffer 
1 µl dNTP mix (25 mM each) 
1 µl forward primer (10 pmol/µl) 
1 µl reverse primer (10 pmol/µl) 
1 µl template DNA (200 ng/µl) 
1 µl Pfu Turbo polymerase (2.5 U/µl) 
17.5 µl ddH2O 
 
PCR program: 
Initial denaturation  5 min 95°C 
30 cycles denaturation 
annealing 
elongation 
5 min 95°C 
1 min 50°C* 
5 min** 68°C 
Final elongation  10 min 68°C 
 
* annealing temperature depends on the primers used 
** elongation time depends on the product size (speed of Pfu Turbo: 500 bp/min) 
3.1.5 Site-directed mutagenesis 
The QuikChange site-directed mutagenesis kit (Stratagene) was used to introduce 
point mutations into plasmid DNA. Two primers each complementary to opposite 
strands of the vector and containing the desired mutation were designed and used 
for mutagenesis PCR with PfuTurbo polymerase. This enzyme replicates both 
plasmid strands with high fidelity without displacing the mutated primers which leads 
to the generation of mutated nicked plasmids. Thereafter, DpnI was added to 
specifically digest methylated parental plasmid DNA and select for mutation-
containing DNA. Nicks in the mutated plasmid are repaired in E.coli after 
transformation. 
Methods 
 
37 
3.1.6 Agarose gel electrophoresis 
The agarose powder (standard gel 1% (w/v) agarose) was dissolved in TAE buffer by 
boiling in a microwave. After cooling down to approximately 50°C, 0.5 μg/ml ethidium 
bromide was added to stain the DNA. The DNA sample was mixed with DNA loading 
dye and loaded on the gel. The gel was run 1 h at 100 V using a Power Pack Basic 
power supply (Bio-Rad). Pictures of the gel were taken with a GelDoc 2000 (Bio-
Rad). 
3.1.7 DNA extraction from agarose gels 
The DNA band of interest was visualized with mild UV light and cut out of the gel with 
a scalpel. The DNA was purified with a NucleoSpin Extract II kit (Macherey&Nagel) 
according to the manufacturer’s protocol and eluted in ddH2O. The same kit was 
used to desalt DNA from PCRs. 
3.1.8 Ligation of DNA fragments 
Purified vector and insert DNA were mixed together in a ratio of 1:9 filled up with 
ddH2O to 10 μl. Then 10 μl 2x Quick Ligase buffer and 1 μl T4 Quick Ligase (New 
England Biolabs #M2200L) was added and the mixture was incubated for 10 min at 
RT. 
3.1.9 Cloning of expression vectors 
The expression vector pcDNA3-ckd6-HA was obtained from Addgene (#1868) (van 
den Heuvel & Harlow, 1993). Cysteine-to-serine mutations were introduced with the 
QuikChange site-directed mutagenesis kit (Stratagene) using the following 
oligonucleotides: 
Oligo  Sequence 
C7S_F GAAGGACGGCCTGTCCCGCGCTGACCAG 
C7S_R CTGGTCAGCGCGGGACAGGCCGTCCTTC 
C15S_F GACCAGCAGTACGAATCCGTGGCGGAGATCG 
C15S_R CGATCTCCGCCACGGATTCGTACTGCTGGTC 
C83S_F CAGGTTGTTTGATGTGTCCACAGTGTCACGAACAG 
C83S_R CTGTTCGTGACACTGTGGACACATCAAACAACCTG 
C207S_F CTCTGGAGTGTTGGCTCCATATTTGCAGAAATGTTTCG 
C207S_R CGAAACATTTCTGCAAATATGGAGCCAACACTCCAGAG 
C280S_F GGCAAAGACCTACTTCTGAAGTCTTTGACATTTAACCCAG 
C280S_R CTGGGTTAAATGTCAAAGACTTCAGAAGTAGGTCTTTGCC 
C306S_F CAGGACCTGGAAAGGTCCAAAGAAAACCTGGATTCC 
C306S_R GGAATCCAGGTTTTCTTTGGACCTTTCCAGGTCCTG 
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Cdk6-mutants were cloned into pCMV-3Tag-4A in order to replace the HA tag with a 
3xMyc Tag. The cdk6 coding sequence lacking the stop codon was amplified by PCR 
and inserted into pCMV-3Tag-4A with HindIII and XhoI using the following primers: 
 
HindIII_cdk6_F CCCAAGCTTATGGAGAAGGACGGCC 
cdk6_XhoI_R CCCCTCGAGGGCTGTATTCAGCTC 
 
Eventually, using XhoI and KpnI the 3xMyc tag of pCMV-3Tag-4A-cdk6 was replaced 
by a 3xFlag tag which was generated by annealing the following oligonucleotides: 
 
3xFlag sense TCGAGGATTACAAGGATGACGACGATAAGGACTATAAGGACGATGATGACAAGGACTACAAAGATGATGACGATAAATAAGGGCCCGGTAC 
3xFlag anti-
sense 
CGGGCCCTTATTTATCGTCATCATCTTTGTAGTCCTTGTCATCATCGTCC
TTATAGTCCTTATCGTCGTCATCCTTGTAATCC 
 
3.1.10 Transformation of E.coli 
Competent E.coli DH5α or E.coli XL1-blue were thawn on ice. The ligated DNA was 
added to the bacteria and incubated for 10 min on ice. Heat-shock transformation for 
2 min at 42°C was performed in a Thermomixer compact (Eppendorf). After addition 
of 500 μl fresh LB medium without antibiotics, the bacteria were incubated with 
shaking for 1 h at 37°C to recover. Finally the bacteria were plated on LB-agar plates 
containing 100 μg/ml Ampicillin or 25 µg/ml Kanamycin. 
3.2 Methods in cell biology 
3.2.1 Cultivation of cell lines 
All cells were cultivated at 37°C, 5% CO2. HEK 293T and HeLa T-REx cells were 
cultivated in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FCS / 
100 U/ml penicillin / 100 µg/ml streptomycin. Jurkat J16-145 cells were cultivated in 
Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% FCS / 
100 U/ml penicillin / 100 µg/ml streptomycin. HeLa T-REx cells transfected with pSR-
TRE-NeoGFP shRNA plasmids were cultivated in the presence of 1 mg/ml G418 
(Neomycin). 
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3.2.2 Cryoconservation of cell lines 
For long-term storage, 1 x 106 cells were resuspended in 1 ml FCS / 10% DMSO and 
transferred into cryovials, which were cooled down to -80°C with 1°C/min. After 24-
48 h cells were stored in liquid nitrogen. For thawing, frozen cells were incubated at 
37°C in the water bath and washed twice with 10 ml pre-warmed PBS. After washing 
cells were resuspended in 5 ml cell culture medium and transferred to a 25 cm2 cell 
culture flask. 
3.2.3 Transfection of eukaryotic cell lines 
Exponentially growing HEK 293T cells were harvested 24 h before transfection by 
trypsinization and replated at a density of 1 x 105 to 4 x 105 cells/cm2 in a 175 cm2 
tissue culture flask in 25 ml DMEM / 10% FCS. For the preparation of the calcium 
phosphate-DNA coprecipitate, 50 µg DNA were added to 2.2 ml H2O, combined with 
305 µl 2.5 M CaCl2 and incubated 5 min at room temperature. Meanwhile 25 mM 
chloroquine diphosphate was diluted 1:1,000 directly into the medium. Afterwards 
2.5 ml 2x HEPES buffered saline (HBS) (50 mM HEPES, 12 mM dextrose, 10 mM 
KCl, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.0) were added to the calcium chloride-
DNA solution and air was blown into the mixture for 10 sec. After additional 30 sec 
the calcium phosphate-DNA suspension was transferred into the medium above the 
cell monolayer. The flask was gently rocked to mix the medium which will become 
turbid. After 6-7 hours the medium and DNA precipitate was removed by aspiration 
and fresh pre-warmed DMEM medium was added. The cells were analyzed 48 h 
after transfection. 
3.2.4 Retroviral transduction of eukaryotic cells 
Retrovirus-based transduction was used to stably integrate a gene of interest in the 
genome of eukaryotic target cells. As retrovirus producer cell line the moloney murine 
leukemia virus (MMULV)-based amphotropic cell line phoenix ampho was used. 
Phoenix ampho cells were harvested 24 h before transfection by trypsinization and 
1.5 x 106 cells were replated in a 25 cm2 tissue culture flask in 4 ml 
DMEM / 10% FCS. Before transfection, 25 mM chloroquine diphosphate was diluted 
1:1,000 directly into the medium. The transfection was performed as described above 
using 10 µg DNA, 37 µl 2 M CaCl2 and H2O to a final volume of 300 µl. Formation of 
calcium phosphate precipitates was induced by addition of 300 µl 2x HBS. After the 
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calcium phosphate-DNA suspension was added, the cells were transferred to an 
incubator with biosafety level 2 and medium was changed after 6-7 hours. After 48 h 
the virus-containing supernatant was harvested and filtered through a 0.45 µM filter. 
Infection was performed by addition of 1.5 ml of virus-containing supernatant to 
5 x 105 target cells cultivated in a 24-well plate. To further enhance the infection rate, 
1 µg/µl polyprene (8 mg/ml) was added. Spin-infection was performed with 
suspension cells by centrifugation for 2 h at 1,350 x g. Adherent cells were not 
subjected to spin-infection, but directly placed into an incubator for 24 h. After 
washing with medium, cells were seeded into 25 cm2 cell culture flasks. To select for 
stably transduced target cells, antibiotics were added after 48 h. 
3.2.5 Inducible short-hairpin RNA (shRNA)-mediated knockdown of Trx1 
The administration of small-interfering RNA (siRNA) has been described to efficiently 
suppress gene expression in many eukaryotic cells. Because this reduction in gene 
expression by siRNA is only transient, mammalian expression vectors have been 
developed for the synthesis of short-hairpin RNA (shRNA), which are processed 
intracellularly into short duplex RNAs with siRNA-like properties. Even though cells 
stably transfected with shRNA vectors can maintain long-term suppression of gene 
expression, these cells could undergo adaptation by reducing shRNA expression or 
other compensatory mechanisms. To overcome the problem of adaptation for the 
knockdown of Trx1, a silencing vector for the doxycycline-dependent expression of 
Trx1-specific shRNA was generated. For this purpose the H1 promoter of pSUPER-
retro-NeoGFP (Oligoengine) was replaced with the TetO binding site containing H1 
promoter of pTER (kindly provided by Hans Clevers, Utrecht, Netherlands) using 
EcoRI and HindIII. Trx1-specific target sequences were computed using the 
SiSearch algorithm (Chalk 2004). For each of the four different targeting sequences 
two complementary 63mers were synthesized (see below). 3 µg of each were 
resuspended in annealing buffer (10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA) 
and heated to 90°C for 5 min on a thermocycler. The oligonucleotides were cooled 
down to 4°C with 0.1°C/sec to generate double-stranded DNA, which was then 
cloned into pSR-TER-NeoGFP with BglII and XhoI. HeLa T-REx cells (Invitrogen) 
stably expressing the Tet-repressor were retrovirally transduced with pSR-TRE-
NeoGFP and selected with 1 mg/ml G418/neomycine after 48 h post infection. Trx1 
knockdown was induced by addition of 1 µg/ml doxycycline (Sigma). 
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3.3 Methods in protein biochemistry 
3.3.1 Purification of recombinant proteins from E.coli 
E.coli M15 [pREP4] (Qiagen) were transformed with Trx1 constructs according to 
standard protocol (Sambrook et al., 2001). LB medium supplemented with Ampicillin 
[100 µg/ml] and Kanamycin [25 µg/ml] was inoculated with transformed bacteria and 
incubated over night at 37°C until the OD [600 nm] reached 0.7-0.8. Protein 
expression was induced by addition of 1 mM IPTG and cultures were incubated for 
3 h at 37°C. Bacteria were harvested in 250 ml-centrifugation buckets at 6000 rpm, 
4°C, 15 min (Rotor: SLA 1500; Sorvall Evolution RC). Pellets were solubilized in 
40 ml B-PER Bacterial Protein Extraction Reagent (Pierce) supplemented with 
10 mM Imidazole and incubated for 10 min at RT with end-over-end rotation. Extracts 
were centrifuged at 20,500 rpm, 4°C, 15 min (Rotor: SS34; Sorvall Evolution RC). 
Supernatants were mixed with 2 ml of HIS-Select Nickel Affinity Gel (Sigma-Aldrich) 
equilibrated with extraction reagent, and incubated for 1 h at 4°C with end-over-end 
rotation. Beads were loaded onto 5 ml-Polypropylene columns (Qiagen) and flow-
through was collected for a second incubation with Nickel beads. Columns were 
washed four times with 5 ml washing buffer (for protein purification) and proteins 
were eluted in four steps with 1.5 ml of elution buffer and 5 min incubation after 
addition of the buffer. Beads from the second incubation (flow-through) were treated 
the same. 
Alternatively, extract supernatants were frozen in liquid nitrogen after centrifugation 
and stored at -80°C. After thawing, supernatants were centrifuged again at 
20,500 rpm, 4°C, 15 min (Rotor: SS34; Sorvall Evolution RC) to remove precipitates. 
Protein was purified on an ÄKTA purifier using HisTrap FF columns (1 ml). Washing 
and elution buffer were the same as for manual purification except that 1 M imidazol 
Oligo Sequence 
212 forward GATCCCCCAACGTGATATTCCTTGATTCAAGAGATCAAGGAATATCACGTTGGTTTTTGGAAC 
212 reverse TCGAGTTCCAAAAACCAACGTGATATTCCTTGATCTCTTGAATCAAGGAATATCACGTTGGGG 
252 forward GATCCCGGATGTTGCTTCAGAGTGTTTCAAGAGAACACTCTGAAGCAACATCCTTTTTGGAAC 
252 reverse TCGAGTTCCAAAAAGGATGTTGCTTCAGAGTGTTCTCTTGAAACACTCTGAAGCAACATCCGG 
281 forward GATCCCGCATGCCAACATTCCAGTTTTCAAGAGAAACTGGAATGTTGGCATGCTTTTTGGAAC 
281 reverse TCGAGTTCCAAAAAGCATGCCAACATTCCAGTTTCTCTTGAAAACTGGAATGTTGGCATGCGG 
NCR forward GATCCCCCAGTTGCCATCTGCGTGATTCAAGAGATCACGCAGATGGCAACTGGTTTTTGGAAC 
NCR reverse TCGAGTTCCAAAAACCAGTTGCCATCTGCGTGATCTCTTGAATCACGCAGATGGCAACTGGGG 
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was added to the elution buffer. Proteins were eluted in 1 ml-fractions. Purified 
protein was stored in 1-ml aliquots supplemented with 5 mM DTT and 5 mM EDTA in 
PBS at 4°C. Protein concentration was determined using the BCA Protein Assay Kit -
 Reducing Agent Compatible (Pierce) according to the manufacturer’s protocol. 
3.3.2 Immunoprecipitation of protein complexes 
Proteins were immunoprecipitated from lysate of 1 x 108 cells by addition of 5 µg of 
the corresponding antibody and 30 µl protein G sepharose beads (GE Healthcare). 
After 1 h end-over-end rotation, the beads were washed five times with 1 ml lysis 
buffer, resuspended in 50 µl SDS-sample buffer and boiled for 5 min at 95°C. 
Precipitated proteins were analyzed by immunoblotting. 
3.3.3 Mechanism-based kinetic trapping 
For substrate trapping of intracellular Trx1 target proteins, Jurkat cells (5 x 107) were 
washed twice with PBS and permeabilized with TBS / 0.01% digitonin (pH 7.5) for 
5 min on ice. Streptavidin sepharose beads (Amersham Biosciences) were loaded 
with recombinant oxidoreductase in streptavidin binding buffer (40 mM Tris-HCl 
(pH 7.4), 300 mM KCl, 2 mM EDTA, 0.1% T-X100) with 20 mM DTT and 
subsequently washed to remove the reductant. The beads were added to the 
supernatant of digitonin-permeabilized cells and incubated for 1h at 4°C. The 
reaction was stopped with 20 mM N-ethylmaleimide (NEM) and beads were washed 
two times with TBS / 500 mM NaCl /10 mM NEM /1% T-X100 (pH 7.5), once with 
TBS / 1 mM NEM / 1% T-X100 (pH 7.5), once with TBS / 1 M urea / 1 mM NEM / 
1% T-X100 (pH 7.5) and once with TBS / 0.1% T-X100 (pH 7.5) (300 x g, 4°C, 
3 min). Protein complexes were eluted with 2 mM biotin in PBS for 30 min at 4°C, 
treated with 40 mM NEM and separated by SDS-PAGE under non-reducing or 
reducing conditions. Proteins were visualized by silver staining and analyzed by LC-
MS/MS. 
For re-capturing of denatured Trx1 target complexes, they were separated from 
streptavidin sepharose beads by boiling for five minutes in 10 mM Tris/HCl (pH 7.4), 
150 mM NaCl, 1% SDS, 1 mM iodoacetamide. Before fresh streptavidin sepharose 
beads were added, the SDS concentration was reduced to 0.1% by dilution with 
10 mM Tris/HCl (pH 7.4), 150 mM NaCl. Washing and elution was performed as 
described above. 
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3.3.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using either Mini-PROTEAN 3 Cell (Bio-Rad) for small 
gels or SE 400 Sturdier Vertical Slab Gel Electrophoresis Units (GE Healthcare) for 
large gels: 
 
Stacking gels: 
 4% 6% 
4x Upper Buffer [ml] 6.25 6.25 
30% Acrylamid/N,N’-Methylen-bis(acrylamid) [29:1] [ml] 5 3.33 
10% APS [µl] 100 100 
TEMED [µl] 25 25 
H2O [ml] 12.5 14.2 
Total [ml] 24 24 
 
Separation gels: 
 8% 10% 12% 15%
4x Lower Buffer [ml] 15 15 15 15
30% Acrylamid/N,N’-Methylen-bis(acrylamid) [29:1] [ml] 16 20 24 30
10% APS [µl] 500 500 500 500
TEMED [µl] 50 50 50 50
H2O [ml] 28 24 20 14
Total [ml] 60 60 60 60
 
For non-reducing SDS-PAGE, protein samples were mixed with SDS sample buffer 
and boiled for 5 min at 95°C. For reducing SDS-PAGE, 20 mM DTT was added 
before boiling. After cooling to RT, samples were mixed with 40 mM NEM and 
incubated for 5 min at RT before loading on the gel. Precision Plus ProteinTM Dual 
Color Standard (Bio-Rad) was used as a standard protein marker. Large gels were 
run for 16 h at 80 V, small gels were run for 1-2 h at 100 V. 
3.3.5 2D diagonal SDS-PAGE (non-reducing/reducing) 
For the identification of Trx1 target proteins, conjugates from 1.5 x 109 J16-145 cells 
were loaded onto a 5-12% gradient SDS-PAGE under non-reducing conditions. The 
lane was excised and incubated with SDS sample buffer supplemented with 250 mM 
DTT for 20 min at 56°C. DTT was removed by washing with DTT-free SDS sample 
buffer and NEM was added to a final concentration of 100 mM. After incubation for 
20 min at 21°C, the lane was washed again and transferred to a 5-12% SDS-PAGE 
gradient gel. Proteins were visualized with colloidal Coomassie and analyzed by 
mass spectrometry. Pre-cast 4-12% NuPAGE Bis-Tris gradient gels (Invitrogen) were 
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used for non-preparative N/NR gel using the same protocol as for preparative gels. 
Protein complexes from these gels were visualized by silver-staining. 
3.3.6 Colloidal Coomassie staining 
For staining with colloidal Coomassie, gels were washed two times for 5 min in 
ddH2O and stained in colloidal Coomassie staining solution (12.5% (w/v) (NH4)2SO4, 
1.45% (v/v) H3PO4, 0.125% (w/v) Coomassie Blue G-250, 20% methanol) over night 
at RT. The staining solution was exchanged and gels were incubated again for 2 h at 
RT. Gels were destained in ddH2O. For staining with Coomassie Brilliant Blue, gels 
were treated as described above but stained in Coomassie staining solution and 
destained in the same solution without dye. 
3.3.7 Silver staining 
Gels were incubated in fixing solution (10% acetic acid, 30% ethanol, 60% H2O) over 
night or for 1 h at RT. Gels were washed three times 15 min with 30% ethanol, 
sensitized for 30 min at RT in sensitization solution (0.02% (w/v) Na2S2O3 x 5 H2O) 
washed in ddH2O twice for 1 min and incubated in impregnation solution (0.2% (w/v) 
AgNO3, 0.075% (v/v) formaldehyde) for 1 h. After briefly rinsing twice with ddH2O, 
gels were developed in developer solution (6% (w/v) Na2CO3, 2% (v/v) sensitization 
solution, 0.05% (v/v) formaldehyde) until bands were clearly visible and the reaction 
was stopped with stop solution (4% (w/v) Tris, 2% acetic acid). 
3.3.8 Immunoblotting 
Proteins separated by SDS-PAGE were transferred to polyvinylidene fluoride (PVDF) 
membranes (Immobilon-P, Millipore) by semi-dry blotting. PVDF membranes were 
activated with methanol for 15 sec, washed twice with ddH2O and equilibrated with 
Towbin buffer for 15 min. Semi-dry blotting was performed using a Trans-Blot SD 
Semi-Dry Transfer Cell (Bio-Rad) according to the manufacturer’s protocol for 1 h at 
15 V. Membranes were blocked with TBS / 5% non-fat milk for 1 h at RT or ON at 
4°C, before the primary antibody was added for 1 h at RT or ON at 4°C. Working 
dilutions for primary antibodies are listed in section 2.4. After washing three times 
with PBS-T, horseradish peroxidase (HRP)-coupled secondary antibodies were 
added for 45 min at RT, followed by additional five washing steps for at least 5 min 
each. Peroxide-luminol solution (Supersignal West, Pierce) was added and chemo 
luminescence was detected with x-ray films. 
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3.3.9 Stripping of immunoblots 
Bound antibodies were removed from PVDF membranes by so-called “stripping”. 
Freshly prepared stripping buffer (62.5 mM Tris/HCl, 2% (v/v) SDS, 0.7% (v/v) β-
mercaptoethanol, pH 6.8) was added to membranes and incubated for 20 min at 
65°C. Before the membrane was blocked again with PBS-T / 5% non-fat milk, it was 
briefly washed 10 times with ddH2O, shaked in ddH2O for 5 min and again briefly 
washed 10 times in ddH2O. 
3.3.10 Mass spectrometry 
Individual spots were excised, reduced with DTT, alkylated with iodoacetamide and 
digested with trypsin (Catrein et al, 2005) using a Digest pro MS liquid handling 
system (Intavis AG). Following digestion, tryptic peptides were extracted from the gel 
pieces with 50 % acetonitrile/0.1 % TFA and concentrated. For MALDI-TOF mass 
spectrometry (Ultraflex, Bruker), the sample was desalted using ZipTip and spotted 
onto a steel target using a-cyano-4-hydroxy cinnamic acid as matrix, and the peptide 
mass fingerprint (PMF) was acquired after external calibration (peptide calibration 
standard II, Bruker). For protein identification by PMF, peptide masses were labeled 
manually without smoothing and background subtraction using a sample from an 
empty area of the same gel as background control. The PMF was searched against 
the NCBInr database (download 04.01.2007) using Mascot 2.1 (Matrix Science). The 
algorithm was set to use homo sapiens as taxonomy (189945 entries), trypsin as 
enzyme, allowing at maximum for one missed cleavage site and assuming 
carbamidomethyl as a fixed modification of cysteine and oxidized methionine as a 
variable modification. Mass tolerance was set to 100 ppm. Protein hits were taken as 
identified if the mascot score exceeded the significance level (p<0.05). 
3.3.11 Caspase-2 activity assay 
For the detection of caspase-2 activity 1 x 106 SWK 6.4 cells were left untreated or 
stimulated in 1 ml RPMI / 10% FCS with 10 µg/ml anti-APO for 1 h. Cells were lysed 
in 300 µl caspase assay buffer without DTT (50 mM HEPES, 100 mM NaCl, 0.1% 
(w/v) CHAPS, 10% (w/v) sucrose, pH 7.4) (Lavrik et al, 2006). Trx1 was pre-reduced 
with 30 mM DTT and eluted 2 mM biotin to a final concentration of 100 µM. 5 µl 
reduced Trx1 was mixed with 45 µl lysate. The caspase-2 substrate N-Acetyl-Val-
Asp-Val-Ala-Asp-7-amido-4-trifluoromethylcoumarin (Ac-VDVAD-AFC) was obtained 
from Sigma (#A-5345) and a 20 mM stock solution was prepared in DMSO. A 
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100 µM working dilution was prepared in caspase-2 assay buffer. 50 µl 100 µM Ac-
VDVAD-AFC was mixed with 50 µl Trx1-containing lysate in a 96 well microtiter plate. 
Fluorescence at 505 nm was measured after excitation at 400 nm every 5 min for 
2 h. 
For the in vitro caspase-2 assay, 0.25 units of recombinant caspase-2 (Alexis # ALX-
201-057-U025) were incubated with 10 µM pre-reduced Trx1, 2.5 µM TrxR and 1 mM 
NAPDH in 50 µl caspase-2 assay buffer. After addition of 50 µl 100 µM Ac-VDVAD-
AFC fluorescence was recorded as described above. 
3.3.12 In vitro kinase assay 
Activity of cdk6 was measured by its ability to phosphorylate a recombinant 
retinoblastoma (Rb) peptide in vitro. 5 x 106 HEK 293T cells were co-transfected with 
SBP-tagged cdk6 and its regulatory subunit cyclin D3 and lysed on ice in cdk6 lysis 
buffer (40 mM Tris/HCl, 0.4% (v/v) NP-40, 150 mM NaCl, 2 mM EDTA, 0.5 mM 
EGTA, 5 mM NaF, 10 mM glycerol-2-phosphate, Complete protease inhibitors 
(Roche), pH 7.5). Pre-clear of the lysate was done twice for 30 min at 4°C with 100 µl 
(50% slurry) CL-4B sepharose (GE Healthcare) equilibrated in lysis buffer. Cyclin D3 
– cdk6 complexes were isolated by addition of 60 µl streptavidin (SA) sepharose 
(50 % slurry, GE Healthcare) for 1 h at 4°C. After washing three times with 3 ml lysis 
buffer, cdk6-loaded SA beads were equilibrated in 1 ml kinase assay buffer (KAB) 
(50 mM Tris/HCl, 10 mM MgCl2, 1 mM DTT, pH 7.5), and a 50% slurry was prepared. 
From this slurry, 10 µl beads were mixed with 7.5 µl KAB, 2.5 µl recombinant Rb 
peptide (2 µg/µl, amino acids 773-928, Upstate #12-439) and 1 µl 32P γ-ATP (Perkin 
Elmer #NEG502A250UC, 10 mCi/ml, 3000 Ci (111 TBq)/mmol). The reaction was 
incubated at 30°C for 10 min while shaking with 650 rpm and stopped by addition of 
4 µl 5x reducing SDS sample buffer and heating for 5 min at 90°C. Free 32P γ-ATP 
was separated from phosphorylated Rb by SDS-PAGE (10%, 45 mA), the gel was 
washed twice with ddH2O and dried on a whatman paper with a gel vacuum dryer for 
2 h at 80°C. Finally, audioradiography was performed by exposing an x-ray film to the 
dried gel for 6 to 24 h, depending on signal intensity. 
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4 Results 
4.1 Kinetic trapping of cytosolic Trx1 target proteins  
4.1.1 Cloning and purification of Trx1(C35S) 
To generate a Trx1 trapping mutant, the second cysteine of the 32CxxC35 active site 
motif was mutated to serine, thereby preventing the escape reaction to occur. A 
double affinity tag was introduced to meet the different requirements of bacterial 
purification and target protein isolation. High-yield purification of the recombinant 
trapping mutant from E.coli lysates requires an affinity tag with high capacity. For this 
purpose, Trx1(C35S) was C-terminally fused to a hexahistidine (His6) tag that binds 
to HisTrap nickel columns with a capacity of approximately 40 mg protein/ml matrix. 
However, due to its moderate affinity the His6 tag is not suitable for purification of 
Trx1 target proteins from cytosolic preparations. Therefore, Trx1(C35S) was 
additionally tagged with the high-affinity streptavidin-binding peptide (SBP) that binds 
to the biotin-binding pocket of streptavidin with nanomolar affinity (Keefe et al, 2001) 
and allows for specific, highly efficient and quantitative purification (Call et al, 2002). 
Figure 11: Purification of hTrx1(C35S)-SBP-His 
(A) Chromatogram of a typical nickel chelate purification on an ÄKTA purifier. (B) Visualization of 
collected fractions by Coomassie staining. FT = flow through (C) Chromatogram of Trx1 desalting with 
HiTrap columns. (D) Coomassie staining of Trx1 fractions after desalting. M = molecular weight 
marker 
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The Trx1 trapping mutant C35S was generated by site-directed mutagenesis using 
the bacterial expression vector pQE60-hTrx1-SBP-His as a template (Schwertassek 
et al, 2007). Trx1(C35S) was expressed in the E.coli strain M15 and purified via the 
His6 tag using nickel chelate chromatography on an ÄKTA purifier HPLC system (GE 
Healthcare). The chromatogram shows that high amounts of His-tagged Trx1 can be 
eluted (Figure 11A). Coomassie staining of the eluted fractions revealed that even 
though several other proteins were co-purified as bacterial contaminants, Trx1 was 
highly enriched in fractions four to six (Figure 11B). Up to 10 mg trapping mutant 
could be purified from 1 l of E.coli culture. For buffer exchange and removal of 
imidazol, gel filtration chromatography was performed. Protein-containing fractions 
could be efficiently separated from the imidazol-containing fraction as measured by 
conductivity and the optical density at 280 nm (Figure 11C). Trx1 was recovered and 
slightly diluted after desalting as shown by Coomassie staining (Figure 11D). 
4.1.2 Kinetic trapping stabilizes Trx1-target protein conjugates 
Trx1(C35S) was bound to streptavidin sepharose via its SBP tag before it was 
incubated with cytosol for kinetic trapping of target proteins. Even though Trx1 
preparations are stored with 20 mM DTT it cannot be excluded that the protein is 
oxidized over time. Catalytically inactive disulfide-linked Trx1 dimers have been 
described to form in vitro after purification (Holmgren, 1977). Trx1 can also form a 
second intramolecular disulfide bond between Cys62 and Cys69 suggested to 
decrease Trx1 activity (Watson et al, 2003). Moreover, the active site can be oxidized 
by oxygen during storage. To fully reduce Trx1 and thereby ensure maximal activity, 
the protein was bound to streptavidin sepharose in the presence of DTT. After 
removal of unbound protein and DTT, Trx1(C35S) coupled beads were incubated 
with cytosol preparations of Jurkat T cells. Conjugates formed by trapping after 
60 min were protected by addition of the alkylating agent N-ethylmaleimide (NEM). 
NEM prevents any further thiol oxidation or reduction during the subsequent washing 
steps. Due to the high affinity of the SBP tag, harsh washing conditions involving high 
salt and urea could be used to decrease the amount of non-covalently bound 
proteins. Thereafter, Trx1(C35S) conjugates were eluted with biotin and visualized by 
silver staining and immunoblotting. 
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Streptavidin beads alone did not show any non-specific binding of proteins as judged 
by silver staining. Beads coupled to wild type (WT) Trx1 showed binding of two 
proteins in addition to recombinant Trx1 (17 kDa) used as bait (Figure 12A). Under 
non-reducing conditions a prominent band of 34 kDa was observed which has been 
identified as a disulfide-linked Trx1 dimer by mass spectrometry. Consistent with that, 
this band is no longer detectable under reducing conditions. Interestingly, the Trx1 
dimer is hardly detectable for Trx1(C35S) which suggests that in this case formation 
of mixed-disulfide conjugates with target proteins is favored over homodimer 
formation. The other protein is bound to WT Trx1 under both reducing and non-
reducing conditions and was identified as one of the isoforms of thioredoxin 
reductase. In contrast to WT Trx1 numerous proteins were bound to Trx1(C35S) 
demonstrating that Trx1 target proteins can be efficiently trapped in the cytosol of 
mammalian cells. The most prominent Trx1 target protein has a molecular weight of 
approximately 21 kDa and forms a 1:1 complex with Trx1 (38 kDa). As expected, 
most of the trapped proteins undergo a shift of 17 kDa upon reduction, indicating that 
Figure 12: Specific purification of Trx1 target proteins 
(A) Trx1(C35S) was added to Jurkat cytosol and after washing, eluted protein complexes were 
visualized by silver staining. (B) Immunoblotting of Trx1 trapping conjugates with an anti-SBP 
antibody. Input lysate was blotted against actin as loading control. 
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they have been disulfide-linked to the Trx1 trapping mutant (Figure 12A). 
 
In order to verify that the protein bands purified with Trx1(C35S) indeed represent 
complexes containing Trx1 as a covalent binding partner, they were analyzed by 
immunoblotting against the SBP tag (Figure 12B). Under non-reducing conditions 
Trx1(C35S)-SBP-His containing complexes were clearly identified. As expected, 
these complexes were destroyed by reduction which separates Trx1(C35S)-SBP-His 
from its targets (Figure 12B+13B). 
4.1.3 Trx1 target proteins are not covalently captured by a Grx1 trapping 
mutant 
To further confirm that trapping by Trx1 is specific, Trx1(C35S) was directly 
compared to the corresponding trapping mutant of another member of the Trx 
superfamily, glutaredoxin-1 (Grx1). Like Trx1, Grx1 is a cytosolic disulfide reductase 
Figure 13: A Grx1 trapping mutant does not form mixed-disulfide intermediates with cytosolic 
target proteins 
(A) Trx1(C35S) or Grx(C25S) were incubated with Jurkat cytosol and after washing, eluted protein 
complexes were visualized by silver staining. (B) Immunoblotting of Trx1 trapping conjugates with an 
anti-SBP antibody. Input lysate was blotted against actin as loading control. 
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also using the CxxC active site motive for substrate reduction. However, in contrast 
to Trx1, Grx1 reduces protein-glutathione mixed-disulfide bonds and forms mixed-
disulfides with glutathione rather than with target proteins (Yang et al, 1998; 
Peltoniemi et al, 2006). In agreement with this reaction mechanism Grx1 did not form 
mixed-disulfide conjugates with other proteins and thus no protein trapping could be 
detected for WT Grx1 or the Grx1 trapping mutant by silver staining or 
immunoblotting (Figure 13A+B). These results demonstrate that the mere availability 
of an active site thiol is not sufficient for the generation of the trapping profile 
observed with Trx1. In fact it suggests that target protein reduction by Trx1 requires 
specific protein-protein interactions. 
4.1.4 The pattern of Trx1 target proteins differs in different T cell lines 
The expression level of Trx1 varies between different cell types (Sahaf et al, 1997) 
and this could influence the oxidation state of Trx1 target proteins. In order to analyze 
whether differences in target protein expression and/or redox state influence the Trx1 
trapping pattern, kinetic trapping was performed on cytosol preparations of six 
different T cell lines. Three lymphoblastic T cell lines (Jurkat, CEM, Molt-4) were 
compared with three cutaneous T cell lymphoma lines (Hut78, MyLa, HH), either un-
stimulated or stimulated with PMA/ionomycin. Although no differences in the Trx1 
Figure 14: Comparisons and modulation of the Trx1 trapping profile 
(A) Trx1(C35S) was added to cytosol prepared from different T cell lines either left untreated or treated 
with 10 ng/ml PMA and 1 µM ionomycin for 30 min. After washing, eluted protein complexes were 
reduced before separation and visualized by silver staining. (B) Jurkat T cells were treated with the 
indicated compounds for 30 min. Trx1 trapping conjugates were reduced before separation and 
visualized by silver staining. P/I = PMA/Ionomycin 
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trapping profile were observed 30 minutes after T cell stimulation, both qualitative 
and quantitative differences were detected among the cell lines tested (Figure 14A). 
Interestingly, the lymphoblastic T cell lines among each other showed a very similar 
profile, except for some quantitative differences. Trapping of two proteins with a 
molecular weight of approximately 40 and 42 kDa as well as a 50 kDa target was 
enhanced in Jurkat T cells, whereas trapping of a 110 kDa target was increased in 
Molt-4 cells. In contrast, the trapping profile of cutaneous T cell lines Hut78, MyLa 
and HH was much less comparable to the pattern of the lymphoblastic lines tested. 
Target protein trapping was decreased in Hut78 and MyLa, while the overall amount 
of trapped cytosolic target proteins was the highest in HH T cells. Interestingly, the 
ratio of trapped Prx to other Trx1 target proteins is very different in the cell lines 
tested. Whereas Prx represents the predominant Trx1 target in Jurkat and CEM T 
cells, the amount of trapped Prx in Molt-4 and HH T cells is comparable to the 
amounts of other Trx1 target proteins. As the protein content of the cytosol 
preparations and the amount of trapping mutant were matched, these data suggest 
that differences in the oxidation of Trx1 target proteins exist and can be visualized by 
kinetic trapping. However, some differences observed might also be due to unequal 
expression levels of Trx1 target proteins. 
4.1.5 Inhibition of TrxR leads to an increase in Trx1 trapping 
Because T cell stimulation with PMA/ionomycin did not alter the Trx1 trapping profile 
after 30 minutes (Figure 14A) redox-active compounds were applied to Jurkat T cells 
in order to test their influence on the oxidation state of Trx1 target proteins. No effect 
was seen after treatment of cells for 30 minutes with different concentrations of H2O2, 
the GSH reductase inhibitor BCNU (also known as Carmustine) (Frischer & Ahmad, 
1977; Karplus et al, 1988) or the anti-oxidant N-acetyl cysteine (NAc) (Figure 14B). 
However, treatment of Jurkat T cells with the TrxR inhibitor DNCB (Arner et al, 1995) 
resulted in an overall increase in the formation of Trx1(C35S) conjugates, in 
agreement with the assumption that inhibition of TrxR leads to increased oxidation of 
Trx1 target proteins. In subsequent experiments increased trapping of Trx1 target 
proteins was observed shortly (5 minutes) after treatment with 100 µM H2O2, thus 
indicating that 30 minutes after oxidant treatment proteins have already returned to 
their reduced ground state (data not shown). In agreement with this observation, 
treatment of cells with redox-active compounds did not induce major long-term 
changes in protein oxidation, most likely due to the efficient action of the intracellular 
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scavenging and reducing systems. 
4.1.6 Trx1 target proteins have different susceptibilities to oxidation 
Some redox-sensitive proteins undergo rapid oxidation when exposed to increased 
levels of oxygen, as is observed for members of the peroxiredoxins family (C. 
Winterbourn, personal communication). In order to test whether pre-lysis thiol 
alkylation influences the quantity or quality of proteins targeted by Trx1(C35S), Jurkat 
T cells were pre-treated with increasing concentrations of NEM prior to lysis. Less 
trapping by Trx1(C35S) was observed for some proteins when cells were pre-treated 
with 200 µM or higher concentrations of NEM, indicating that some proteins may 
undergo post-lysis oxidation during lysis or incubation with the Trx trapping mutant 
(Figure 15). Interestingly, Trx1 target proteins are affected by alkylation in different 
ways, indicating individual susceptibilities for oxidation. It should be considered that 
unreacted NEM could inactive the active site of the Trx1 trapping mutant which may 
account for some of the observed effects. Removal of NEM by gel filtration before 
application of the trapping mutant could circumvent this problem in the future. 
4.1.7 Separation of covalent from non-covalent Trx1 interaction partners 
Even though immunoblotting against the SBP tag confirmed that Trx1(C35S) forms 
Figure 15: Trx1 target proteins are differently affected by thiol alkylation 
Jurkat T cells were either not treated or treated with 10 ng/ml PMA and 1 µM ionomycin for 30 min. 
After stimulation cells were treated with the indicated concentrations of NEM for 5 min. Trx1(C35S) 
was added to cytosol preparations of these cells and after washing, eluted protein complexes were 
visualized by silver staining. 
Results 
 
54 
disulfide-linked conjugates with target proteins (Figure 12) it is likely that, despite 
intensive washing, some proteins remain non-covalently attached to the trapping 
mutant. On one-dimensional gels these proteins cannot be easily differentiated from 
covalently linked Trx1 target proteins due to the complexity of the trapping profile. 
 
In order to separate disulfide-linked Trx1 targets from non-covalently interacting 
proteins, eluted Trx1 conjugates were analyzed by non-reducing/reducing (NR/R) 
2D-SDS-PAGE. In contrast to conventional 2D electrophoresis separating proteins by 
Figure 16: Visualization of Trx1 trapping complexes by NR/R 2D SDS-PAGE 
(A) Schematic overview of NR/R 2D SDS-PAGE. See text for details. (B) Trx1(C35S) was applied to 
Jurkat cytosol. After washing, eluted trapping conjugates were separated by NR/R 2D electrophoresis 
and visualized by silver staining. (C) Trapping was performed as in (B), conjugates bound to SA beads 
were denatured by boiling for 5 min in TBS / 1% SDS / 1 mM iodoacetamide. The supernatant was 
diluted to a final concentration of 0.02% SDS and trapping conjugates were re-captured on fresh SA 
beads. After washing, eluted trapping conjugates were separated by NR/R 2D electrophoresis and 
visualized by silver staining. 
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isoelectric point and molecular mass, both dimensions of NR/R 2D electrophoresis 
separate proteins by molecular weight. In the first dimension disulfide-linked 
conjugates are preserved in the absence of reducing agents. A gel slice containing 
the separated non-reduced proteins is then treated with DTT and the reduced 
proteins are separated again on a second gel. Proteins that were not disulfide-linked 
to other proteins show very similar mobility in both dimensions and will therefore 
come to lie on a diagonal, whereas Trx1-linked proteins will appear on a diagonal 
below the main diagonal as a result of separation under reducing conditions 
(Figure 16A). Most of the proteins captured by the Trx1 trapping mutant appeared 
below the main diagonal on a NR/R 2D gel, showing that they have in fact formed a 
disulfide-linked conjugate with Trx1(C35S). As expected, the mobility difference 
between the main diagonal and the lower diagonal corresponds to 17 kDa, the size of 
recombinant Trx1(C35S)-SBP-His (Figure 16B). It should be noted that proteins 
running on the main diagonal may include some disulfide-linked Trx1 complexes in 
case of inefficient reduction. Interestingly, in addition to the lower diagonal shifted by 
17 kDa additional minor diagonals could be detected, likely explained by disulfide-
linked oligomers (Figure 16+17). 
 
To confirm that proteins appearing on the main diagonal are non-covalent interaction 
partners, Trx1 complexes were depleted of non-covalent interactions by boiling in 
1% SDS. Disulfide-linked Trx1 conjugates were then re-captured via the SBP tag on 
streptavidin sepharose and analyzed by NR/R 2D electrophoresis. Following the 
stripping and Re-IP procedure hardly any proteins were detectable on the main 
diagonal, whereas covalently bound Trx1 target proteins still appeared on the lower 
diagonal (Figure 16C). These results clearly demonstrate that Trx1(C35S) forms 
mixed-disulfide conjugates with its target proteins, which can be separated by NR/R 
2D electrophoresis. 
4.1.8 Depletion of endogenous Trx1 influences the Trx1 trapping profile 
Treatment with pro- or antioxidants did not permanently alter the Trx1 trapping profile 
in Jurkat T cells, most likely because of efficient counter-regulation by the 
endogenous thioredoxin system. However, the TrxR inhibitor DNCB changed the 
Trx1 trapping pattern when tested after 30 minutes (Figure 14B). In order to exclude 
non-specific effects of this inhibitor and to test whether the expression level of 
endogenous Trx1 also influences the Trx1(C35S) trapping profile, endogenous Trx1 
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was down-regulated in HeLa cells by shRNA. To avoid cellular adaptation to reduced 
levels of Trx1, shRNA-mediated Trx1 knockdown was induced by the addition of 
doxycycline (see section 4.5.2 for details). A comparison of trapping profiles of HeLa 
cells transfected with non-silencing and silencing shRNA constructs (Figure 17A) 
showed that overall trapping of target proteins was only weakly affected by the Trx1 
knockdown (Figure 17B+C). Possibly, differences in protein oxidation may be lost 
during or after cell lysis which could account for the weak effect of the Trx1 
knockdown on the profile of trapped target proteins. Alkylation could protect proteins 
from artificial oxidation or reduction, thereby preserving the altered redox status of 
Trx1 target proteins. Nevertheless, peroxiredoxins were clearly trapped more 
extensively in knockdown cells, most likely due to impaired reduction by endogenous 
Trx1. 
 
Figure 17: Depletion of endogenous Trx1 influences the Trx1 trapping profile 
(A) Endogenous Trx1 was down-regulated by shRNA in HeLa T-REx cells after addition of 1 µg/ml 
doxycycline. NS = non-silencing shRNA construct. Total cell lysate was analyzed by immunoblotting 
against Trx1 and actin. After trapping, Trx1(C35S) conjugates were reduced with DTT and the 
amounts of trapping mutant were visualized by immunoblotting against the SBP tag. (B) NR/R 2D 
electrophoresis and silver staining of trapping conjugates from HeLa T-REx cells expressing a non-
silencing shRNA construct. (C) NR/R 2D electrophoresis and silver staining of trapping conjugates 
from HeLa T-REx cells with reduced Trx1 expression. 
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4.2 Preparative purification and identification of cytosolic Trx1 target proteins 
After having confirmed the specificity of kinetic trapping, large-scale preparation of 
Trx1 conjugates was performed. WT Trx1 was used as control to ensure that 
complex formation was based on the catalytic mechanism of thioredoxin (Figure 18). 
4.2.1 Identification of cytosolic Trx1(C35S) interaction partners 
For the identification of proteins interacting with Trx1 in the cytosol of mammalian 
cells, proteins captured by the Trx1 trapping mutant were separated under reducing 
conditions (Figure 18, lane 4), excised, digested with trypsin and subjected to liquid 
chromatography coupled electrospray ionization mass spectrometry (LC-MS/MS). In 
total 73 proteins were identified by mass spectrometry. These were classified into 
different functional categories based on Swiss-Prot entries and published data 
(Table 1). As many proteins act in several functional contexts and others are poorly 
characterized this functional categorization can only be considered a simplification. 
However, it does provide a broad overview. 
 
 
Figure 18: Purification of Trx1 targets for mass spectrometry 
Cytosol from 3 x 109 Jurkat T cells was incubated with 0.75 ml streptavidin sepharose coupled with 
500 µg pre-reduced Trx1(C35S)-SBP-His. NEM was added to preserve the disulfide-linked Trx1 
complexes and prevent their reduction during washing. Eluted Trx1 complexes were separated by 
SDS-PAGE under non-reducing and reducing conditions and visualized by colloidal Coomassie 
staining. Band labels for lane 4 are shown on the right. M = molecular weight marker 
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Category UniProt  Protein name Band(s) Score Mass Pep Cover
Cytoskeleton Q549M8 CLE7 2 131 28 3 15 
 CNN2 Calponin 2 4, 5 122 34 3 12 
 ACTB Actin beta 7 534 42 13 44 
 TBB5 Tubulin beta-5 chain 9, 10 781 50 18 43 
 TBA3C Tubulin alpha-2 chain 9 412 50 11 31 
 TBB2C Tubulin beta-2 chain 10 574 50 14 40 
 PLSL L-plastin 11, 12 640 70 12 27 
 KIF2C Mitotic centromere-associated kinesin 14 109 81 3 15 
 FLII Flightless-1 homolog 16 219 145 6 5 
 DREB Drebrin 16, 17 131 71 2 5 
 DIAP1 Diaphanous homolog 1 16 118 141 3 3 
 CKAP5 Cytoskeleton-associated protein 5 18 328 218 9 6 
 MAP4 Microtubule-associated protein 4 18 310 121 8 10 
Metabolism RPIA Ribose-5-phosphate isomerase 2, 3 112 26 3 18 
 G3P Glyceraldehyde-3-phosphate dehydrogenase 5 68 36 2 8 
 RIR1 Ribonucleoside-diphosphate reductase M1 chain 14 595 90 16 18 
 K6PP Phosphofructokinase 1 14 520 86 12 19 
 GFPT1 Glutamine:fructose 6 phosphate amidotransferase 1 14 382 77 9 16 
 PYR1 CAD protein 18 82 240 2 2 
 FAS Fatty acid synthase 18 80 272 1 2 
Redox PRDX2 Peroxiredoxin-2 1 430 22 10 41 
 PRDX4 Peroxiredoxin-4 2, 3 367 31 9 40 
 TRXR1 Thioredoxin Reductase 10, 11 1005 54 19 41 
Signaling RAC2 Ras-related C3 botulinum toxin substrate 2 1 59 21 2 13 
 MTMRE Myotubularin-related protein 14 12 80 72 1 4 
 DPYL2 Dihydropyrimidinase-related protein 2 11, 12, 13 737 62 17 43 
 KHDR1 P21 Ras GTPase-activating protein-associated p62 13 122 68 3 10 
 TBK1 TANK-binding kinase 1 14 175 83 5 11 
 PSD4 PH and SEC7 domain-containing protein 4 17 58 116 1 1 
 FNBP2 SLIT-ROBO Rho GTPase-activating protein 2 17 137 124 3 3 
 SLK STE20-like serine/threonine-protein kinase 18 381 142 9 11 
 PPP6 Serine/threonine-protein phosphatase 6 4 127 36 3 11 
 TTK Dual specificity protein kinase TTK 15 430 97 11 20 
 MCM5 DNA replication licensing factor MCM5 15 116 82 2 3 
 AKP8L Helicase A-binding protein 95 15 90 73 2 4 
 RB Retinoblastoma-associated protein 16, 17 491 106 12 15 
 PDS5A Sister chromatid cohesion protein 112 17 141 146 3 3 
Transcription SFRS7 Splicing factor, arginine/serine-rich 7 1 47 19 1 8 
 HNRPF Heterogeneous nuclear ribonucleoprotein F 8 184 46 5 18 
 HNRPK Heterogeneous nuclear ribonucleoprotein K 11, 12 506 51 13 38 
 IKZF1 Ikaros family zinc finger protein 1 11 78 58 1 3 
 DDX59 DEAD box protein 59 13 147 68 5 11 
 LRRF1 Leucine-rich repeat flightless-interacting protein 1 16, 17 257 86 6 10 
 NCOR1 Nuclear receptor corepressor 1 19 117 270 4 10 
 DCPS Scavenger mRNA-decapping enzyme DcpS 5 55 39 1 5 
Translation EF1D Elongation factor 1 delta  6 115 71 2 8 
 EF1A1 Elongation factor 1 alpha 1 4, 5, 8 510 50 13 32 
 SYFA Phenylalanyl-tRNA synthetase alpha chain 10 200 57 4 9 
 SYCC Cysteinyl-tRNA synthetase 13 772 85 19 30 
 HBS1L HBS1-like protein 14 152 75 5 12 
 EF2 Elongation factor 2 15 1151 95 32 38 
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 JHD2A JmjC domain-containing histone demethylation protein 2A 17 136 147 3 3 
Folding HSP7C Heat shock 70kDa protein 8 12 856 71 16 36 
 HSP76 Heat shock 70kDa protein 6 12 142 71 3 5 
 HS105 Heat shock protein 105 kDa 16 967 106 22 30 
Transport RANB3 Ran-binding protein 3 12 100 60 2 5 
 SC23B Sec23B 13 102 86 3 5 
 SC16A Sec16A 19 638 234 16 11 
 NADAP Solute carrier family 4 (anion exchanger), member 1 17 135 89 3 4 
Degradation CUL5 Cullin-5 14 160 91 5 7 
 TRI33 E3 ubiquitin-protein ligase TRIM33 16 160 122 3 3 
 UBAP2 Ubiquitin-associated protein 2 17 133 117 3 4 
 ATG7 Autophagy-related protein 7 12 100 78 2 3 
Others IAN-1 Immune associated nucleotide 4 110 35 2 10 
 CHRD1 Cysteine and histidine-rich domain-containing protein 1 5 456 37 11 42 
 CCD22 Coiled-coil domain-containing protein 22 12 64 71 1 2 
 CB044 WD repeat-containing protein C2orf44 13 194 79 6 10 
 CG027 HEAT repeat-containing protein C7orf27  13 133 88 3 7 
 K1967 Deleted in breast cancer gene 1 protein 17 329 103 10 16 
 DOCK7 Dedicator of cytokinesis protein 7 18 487 174 13 7 
 FNBP4 Formin-binding protein 4 18 443 114 10 10 
 ANXA2 Annexin A2 4, 5 871 39 18 53 
 ZFY16 Zinc finger FYVE domain-containing protein 16 18 294 168 7 7 
 
 
A majority of proteins was found to be associated with the cytoskeleton, including 
structural components actin and tubulin as well as regulatory proteins like L-plastin 
(Janji et al, 2006), flightless-1 homolog (Claudianos & Campbell, 1995), 
dihydropyrimidinase-related protein 2 (Fukata et al, 2002) or Map4 (MacRae, 1992). 
Even though actin and tubulin are highly abundant and frequently found in proteomic 
screens as false positives, there are reports describing redox-regulation of both actin 
(Tang et al, 1999; Fiaschi et al, 2006) and tubulin (Landino et al, 2004; Britto et al, 
2005). Thus, both proteins can be considered candidate Trx1 target proteins despite 
their abundance. Most previously known Trx1 target proteins could be identified in 
this screen, including peroxiredoxins (Björnstedt et al, 1994), annexin-2 (Kwon et al, 
2005b), GAPDH (Baalmann et al, 1995; Kumar et al, 2004) and ribonucleoside-
diphosphate reductase (RIR1) (Laurent et al, 1964), thus demonstrating the 
capability of kinetic trapping to identify well established Trx1 target proteins. Besides 
RIR1 and GAPDH five other metabolic enzymes were trapped by Trx1. These are 
Table 1: Candidate Trx1 target proteins in Jurkat T cells identified from 1D SDS-PAGE 
Proteins identified from lane 4 (Figure 18) by ESI LC MS/MS. UniProt: protein entry name in the 
UniProtKB/Swiss-Prot database, Band(s): band on gel from which protein was identified, Score: 
Protana significance score, Mass: molecular weight of the identified protein [kDa], Pep: number of 
unique peptides sequenced, Cover: coverage of total protein sequence by identified peptides [%]. 
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involved in glycolysis (phosphofructokinase 1), nucleotide sugar biosynthesis 
(glutamine:fructose 6 phosphate amidotransferase 1) and fatty acid synthesis (fatty 
acid synthase). In addition, the trifunctional enzyme CAD which is required for 
pyrimidine synthesis as well as ribose-5-phosphate isomerase, a key enzyme of the 
pentose phosphate cycle, were found to be targeted by Trx1. Interestingly, besides 
these metabolic enzymes, several target proteins are involved in signal transduction. 
G protein-mediated signal transduction is regulated by candidate Trx1 target proteins 
Rac2 (Didsbury et al, 1989), p62 (Wong et al, 1992), PSD4 (Derrien et al, 2002) and 
SrGAP2 (Wong et al, 2001). Surprisingly, most of the identified regulatory proteins 
are regulators of the cell cycle. Retinoblastoma-associated protein (Rb) is a tumor 
suppressor and key regulator of cell cycle entry by acting as transcriptional repressor 
of E2F1 target genes (Chau & Wang, 2003). Protein phosphatase PP6 restricts G1 to 
S phase progression in human cancer cells (Stefansson & Brautigan, 2007). Msp1 is 
a regulator of the spindle-assembly checkpoint (Musacchio & Salmon, 2007) and 
mediates correct attachment of the chromosomes to the mitotic spindle (Jelluma et 
al, 2008). During early G1 phase of the cell cycle, the MCM5 is recruited as a subunit 
of the prereplication complex that assembles at replication origins (Tye, 1999) and 
also facilitates STAT1-mediated transcription (Snyder et al, 2005). Thus, Trx1 may 
not only have a regulatory function in various signaling pathways but might 
furthermore regulate cell cycle progression at different stages. Two members of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) family which belong to a 
multiprotein complex involved in pre-mRNA processing were identified (Krecic & 
Swanson, 1999). Among the proteins involved in translation, EF1A1 and EF2 have 
already been described to be targeted by Trx1 in Dictyostelium (Brodegger et al, 
2004) and Arabidopsis (Yamazaki et al, 2004), respectively. Finally, a number of 
proteins with unknown functions were trapped, including C2orf44, C7orf27 and 
CCD22. 
4.2.2 Separation of Trx1 trapping conjugates by NR/R 2D SDS-PAGE 
The first trapping screen identified proteins which remained bound to Trx1(C35S) 
after intensive washing with high salt und urea-containing buffers, suggesting that 
most of them were disulfide-linked to the trapping mutant. As already discussed, it 
could not be excluded that some of the potential Trx1 targets listed in table 1 were 
purified due to non-covalent association. Therefore, Trx1 trapping conjugates were 
again purified and re-analyzed on a NR/R 2D gel, which allows for discrimination 
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between disulfide-linked and non-covalently bound proteins (see also Figure 16). For 
improved resolution, a 4−12% gradient gel was used to separate target proteins. 
Only proteins from below the main diagonal were selected for further analysis 
(Figure 19). 
4.2.3 Identification of disulfide-linked Trx1 target proteins 
Because many spots contained more than one protein, 62 candidate Trx1 targets 
were identified from 44 spots by tandem mass spectrometry (Table 2). Of those, 23 
proteins were also found in the first trapping screen. Compared to the first screen, 
the number of cytoskeleton-associated proteins was reduced, suggesting that some 
of these proteins may have interacted non-covalently. The number of metabolic 
enzymes was increased whereas the number of candidate target proteins involved in 
signal transduction was equally high (Figure 20). 
 
Figure 19: Preparative separation of proteins covalently trapped by Trx1(C35S) by diagonal 
NR/R 2D SDS-PAGE 
Cytosol from 3 x 109 Jurkat T cells was incubated with 500 µg Trx1(C35S)-SBP-His bound to 
streptavidin sepharose beads. NEM was added to preserve the disulfide-linked Trx1 complexes and 
prevent further thiol interactions during washing. Trapping conjugates were separated by NR/R 2D 
electrophoresis and visualized by colloidal Coomassie staining. 
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The metabolic enzymes identified from the 2D gel have diverse functions ranging 
from acyl-CoA hydrolysis (cytosolic acyl coenzyme A thioester hydrolase) and 
nucleotide synthesis (guanine monophosphate synthetase) to epoxide detoxification 
(cytosolic epoxide hydrolase). In addition to ribose-5-phosphate isomerase, found in 
the first screen, glucose-6-phosphate 1-dehydrogenase (G6PD) was identified as a 
second enzyme involved in the pentose phosphate pathway. Besides elongation 
factors-1 alpha and -2, hnRNPs could be confirmed as targets for Trx1. 
 
Additionally, p120 RasGAP was identified as a candidate Trx1 target protein. This 
enzyme stimulates the weak intrinsic GTP-hydrolysis activity of the Ras oncogene, 
thereby inactivating it (Bernards & Settleman, 2004). PKN1, also known as protein 
kinase C-related kinase 1 (PRK1), is a serine/threonine protein kinase, which has a 
catalytic domain highly homologous to that of protein kinase C (PKC). NimA-related 
kinase 9 (NEK9) plays a central role for cdc2-mediated initiation of mitosis in the G2 
phase of the cell cycle. Interestingly, the third kinase found is also involved in cell 
cycle regulation. Cyclin-dependent kinase 6 (cdk6) cooperates with cdk4 in G1/S 
phase transition. As already suggested from the first Trx1 interaction screen, the 
identification of further cell cycle regulators as candidate Trx1 target proteins 
strengthens the possibility that Trx1 plays an important role in redox-regulation of cell 
cycle progression. 
Figure 20: Comparison of candidate Trx1 target proteins identified from 1D and NR/R 2D gels 
(A) Venn diagram showing the total number of Trx1 target proteins identified in each trapping 
experiment and the number of target proteins indentified in both screens. (B) Classification of identified 
Trx1 target proteins in functional groups according to published data and database entries. 
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Category UniProt  Protein name Spot(s) 1D Score Mass Pep Cover
Cytoskeleton ACTB Actin beta 37 ? 338 42 7 24 
 TBB2A Tubulin beta-2A chain 15, 17 ? 778 50 15 28 
 CNN2 Calponin 2  5 ? 60 35 1 4 
 FLII Flightless-I homolog 41 ? 1789 144 48 31 
 PLSL L-plastin  21, 23 ? 1884 71 35 49 
 DIAP1 Diaphanous homolog 1 39 ? 88 139 5 3 
  PLST T-plastin 21  526 65 9 15 
Metabolism BACH Cytosolic acyl coenzyme A thioester hydrolase 10  199 42 3 11 
 HYES Cytosolic epoxide hydrolase  18  578 64 15 26 
 DLDH Dihydrolipoyl dehydrogenase 18  49 57 3 5 
 G6PD Glucose-6-phosphate 1-dehydrogenase 16  80 60 3 5 
 G3P Glyceraldehyde-3-phosphate dehydrogenase 37 ? 59 36 2 5 
 GUAA Guanine monophosphate synthetase  24  300 78 11 13 
 HCD2 Hydroxysteroid (17-beta) dehydrogenase 10  1  113 27 3 12 
 KPRB Phosphoribosyl pyrophosphate synthetase-associated protein 2 8  98 42 2 7 
 RIR1 Ribonucleoside-diphosphate reductase M1 chain 28, 29 ? 712 90 20 20 
 SPTC2 Serine palmitoyltransferase, subunit 2  19  275 64 7 13 
 GLU2B Glucosidase II subunit beta 29  329 59 7 13 
Redox PRDX1 Peroxiredoxin 1  1-3, 6-8  560 22 12 55 
 PRDX2 Peroxiredoxin 2 1, 6-8 ? 361 16 7 27 
 PRDX3 Peroxiredoxin 3  1, 2, 6-8  616 28 12 36 
 PRDX4 Peroxiredoxin 4  1, 2, 7 ? 570 31 14 45 
 SQRD Sulfide:quinone oxidoreductase 13  148 51 3 6 
  TRXR1 Thioredoxin reductase 19 ? 214 56 6 10 
Signaling CDK6 Cyclin-dependent kinase 6  6  272 37 7 24 
 DPYL2 Dihydropyrimidinase-related protein 2 21, 24-26 ? 1420 68 27 44 
 MTMRE Myotubularin related protein 14 23 ? 142 74 3 5 
 NEK9 Never in mitosis A-related kinase 9 33, 34  327 107 9 9 
 PKN 1 Protein kinase N1  34  468 105 13 11 
 RASA1 Ras GTPase-activating protein 1 (p120 ) 32  116 102 4 4 
 S10A9 S100 calcium-binding protein A9 37  51 13 1 13 
 ARL15 ADP-ribosylation factor-like 15  1  67 23 2 8 
 APIP APAF1 interacting protein 3, 4  335 28 13 44 
  CASP2 Caspase 2 12  87 52 4 11 
Transcription HNRPF Heterogeneous nuclear ribonucleoprotein F 12 ? 269 46 8 23 
 HNRPH1 Heterogeneous nuclear ribonucleoprotein H1 14  480 50 12 27 
 HNRPH2 Heterogeneous nuclear ribonucleoprotein H2 14  370 50 10 20 
 PTBP1 Heterogeneous nuclear ribonucleoprotein I 16  162 58 5 9 
 HNRPK Heterogeneous nuclear ribonucleoprotein K  22 ? 152 41 2 7 
 * Histone 2B 6  68 14 3 24 
 LRRF1 Leucine-rich repeat flightless-interacting protein 1 36-43 ? 1563 89 36 47 
  THOC3 THO complex 3 8  575 39 12 27 
Translation BZW1 Basic leucine zipper and W2 domains 1 9  700 48 15 27 
 SYCC Cysteinyl-tRNA synthetase 26 ? 597 84 16 22 
 EF1A1 Elongation factor 1 alpha 1  13, 37 ? 268 44 4 13 
 EF2 Elongation factor 2 30 ? 1153 95 30 30 
  HBS1L HBS1-like 27, 29 ? 699 77 17 28 
Folding HS90B Heat shock 90kDa protein 1, beta  28  51 40 3 9 
  HSPB1 Heat shock protein 27  37  130 23 2 13 
Transport SC24A Sec24A 34  261 120 10 8 
  NADAP Solute carrier family 4 (anion exchanger), member 1 32-35 ? 1993 90 41 41 
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Degradation EDEM3 ER degradation enhancer, mannosidase alpha-like 3 31  508 100 15 17 
  UBR1 Ubiquitin protein ligase E3 component n-recognin 1 43  155 200 5 2 
Others ANXA2 Annexin A2 5, 37 ? 700 39 16 41 
 ATD3A ATPase family, AAA domain containing 3A 20  609 66 11 24 
 CCDC88 Coiled-coil domain containing 88 42  48 165 2 1 
 DOCK7 Dedicator of cytokinesis 7 44 ? 65 239 5 1 
 EFHD2 EF hand domain family, member D2 (swiprosin 1) 4  60 27 1 3 
 LAP2B Lamina-associated polypeptide 2, isoforms beta/gamma 8, 16  344 42 7 23 
 LMBRL Lipocalin-1-interacting membrane receptor 21  51 46 1 2 
 TBC15 TBC1 domain family, member 15  24, 25  973 79 23 26 
  TB22B TBC1 domain family, member 22B 17  210 59 6 13 
 
 
Finally, also regulators of cell death were trapped by Trx1. Apaf-1 interacting protein 
(APIP) competes with caspase-9 for binding to Apaf-1 thereby inhibiting apoptosis 
whereas caspase-2 is can initiate programmed cell death after stimulation with TNF-
α, CD95 or etoposide (Troy & Shelanski, 2003). 
Overall, the collective data from both trapping screens suggest the Trx1 does not 
only function as antioxidant but may play important additional roles in regulating 
metabolic processes, cell cycle progression or induction of apoptosis. 
Table 2: Cytosolic Trx1 target proteins from Jurkat T cells identified from below the diagonal in 
NR/R 2D gel electrophoresis 
UniProt: protein entry name in the UniProtKB/Swiss-Prot database, Spot(s): on gel from which protein 
was identified, 1D: checked if protein was also found in first screen (see Table 1), Score: MASCOT 
score, Mass: molecular weight of the identified protein [kDa], Pep: number of unique peptides 
sequenced, Cover: coverage of total protein sequence by identified peptides [%]. * Histone 2B sutype 
could not be identified. 
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4.3 Characterization of Trx1-linked conjugates by immunoblotting 
4.3.1 Identification of multimeric Trx1 trapping conjugates 
In order to validate the data obtained from mass spectrometry, selected proteins 
trapped by Trx1(C35S) were analyzed by immunoblotting. WT Trx1 was included as 
a negative control to ensure that proteins were in fact captured by the trapping 
mechanism. Interestingly, among the candidate targets tested only annexin-2 and 
RasGAP formed a single 1:1 disulfide-linked complex with Trx1, whereas other 
proteins showed a more complex trapping pattern consisting of multiple forms 
(Figure 21). Prx1 represents the major cytosolic target protein of Trx1. It forms a 1:1 
complex of 39 kDa and, in addition, a second complex of around 55 kDa. The subunit 
composition of the larger complex remained unclear. Judged by its size it may be a 
Trx1-(Prx1)2 or (Trx1)2-Prx1 complex, expected to give rise to 61 kDa and 56 kDa 
bands, respectively. Furthermore, it cannot be excluded that the 55 kDa complex 
Figure 21: Analysis of Trx1-containing disulfide conjugates by specific immunoblotting 
Trx1 trapping conjugates were separated by SDS-PAGE under reducing and non-reducing conditions. 
Conjugate formation was analyzed by immunoblotting against indicated proteins. 
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represents a hetero-trimer of Trx1, Prx1 and a third (unknown) component with a 
molecular weight of approximately 15−20 kDa. Besides the two main Prx1-Trx1 
complexes several additional conjugates of higher molecular weight could be 
detected after prolonged exposure of the immunoblot, all of which resolved upon 
addition of DTT. 
 
Similar to Prx1, cdk6 forms two major complexes with Trx1, a putative heterodimer of 
54 kDa and a second complex of higher molecular weight. The cdk6 complex of 
around 140 kDa is too large to represent a hetero-trimer of Trx1 and cdk6 alone. 
Caspase-2 and Trx1 form an expected 1:1 complex of 69 kDa. However, caspase-2 
forms various additional complexes, comparable to the trapping patterns of cdk6 and 
Prx1. Thus, it seems that Trx1 target proteins show a divergent redox behavior 
ranging from only one oxidized redox form (e.g. annexin-2) to various different 
oxidized forms (e.g. caspase-2) targeted by Trx1. 
 
These differences in redox behavior are also reflected by the distribution of cysteines 
in annexin-2 and caspase-2. Annexin-2 contains only four cysteines, of which 
Cys133 and Cys262 are in close enough proximity to allow for formation of an 
intramolecular disulfide bond which would then be targeted by Trx1 to form the 
observed 1:1 disulfide-linked complex (Figure 22A). In contrast, the unprocessed 
form of caspase-2 contains a total of 18 cysteines of which 11 belong to the active 
Figure 22: Cysteines in annexin-2 and caspase-2 
(A) Crystal structure of annexin-2 (aa 29-339) generated from PDB file 1W7B, Cys9 is not depicted. 
(B) Crystal structure of the active p12/p18 caspase-2 heterodimer generated from PDB file 1PYO. 
Cysteine residues are highlighted in yellow. Images generated with Swiss-PdbViewer 4.0 
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p12/p18 heterodimer (Figure 22B). The high number of cysteines could lead to the 
formation of several (alternative) intra- and intermolecular disulfide bonds, thus 
generating a complex trapping pattern. 
4.3.2 Redox interactions between Trx1 and its target proteins are highly 
selective 
Specific formation of disulfide-linked Trx1 target conjugates was demonstrated using 
a Grx1 trapping mutant as negative control (Figure 13) and NR/R 2D gel 
electrophoresis (Figure 16). To test in addition the selectivity of Trx1 reactivity with 
regard to closely related proteins, members of the annexin, caspase and cdk families 
were tested by immunoblotting for their propensity to form Trx1 target complexes. 
Out of five annexins tested only annexin-2 was targeted by Trx1(C35S) (Figure 23A). 
Concerning caspases, in addition to caspase-2 also caspase-8 was found to be 
trapped by Trx1. Caspase-8 had not been identified by mass spectrometry, most 
likely due to insufficient sensitivity or incomplete sampling. In contrast, caspase-3 
and -9 were not trapped by Trx1(C35S) (Figure 23B). Interestingly, although cdk6 is 
a target for Trx1, neither cdk1 (cdc2), cdk2 nor cdk4 (Figure 23C) showed any 
reactivity, despite the fact that cdk6 and cdk4 are closely related and share two 
conserved cysteines (Cys83 and Cys207). These results clearly demonstrate that 
although Trx1 interactions are pleiotropic with regard to target protein function, they 
are nevertheless highly selective. 
Figure 23: Trx1 selectively targets only certain members of protein families 
Input and Trx1 trapping conjugates from Jurkat T cell cytosol were separated by SDS-PAGE under 
reducing conditions. Trapping of proteins by Trx1(C35S) was analyzed by immunoblotting against 
indicated proteins. 
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4.4 Functional analysis of Trx1 target proteins 
4.4.1 Caspase-2 activity is regulated by the Trx1 system 
Following the identification of numerous novel Trx1 target proteins, the influence of 
Trx1 on the activity of a selected target protein, Caspase-2, was analyzed. Caspase-
2 activity was measured in lysates of SKW 6.4 T cells stimulated with an anti-CD95 
antibody which was shown to efficiently activate caspase-2 (Lavrik et al, 2006) as 
measured with the fluorogenic substrate Ac-VDVAD-AFC. Addition of 10 mM DTT to 
the lysate increased caspase-2 activity over time (Figure 24A) which was strictly 
dependent on CD95 stimulation since untreated control cells did not shown any 
caspase-2 activity (data not shown). Interestingly, the Trx1 system can efficiently 
replace DTT in promoting caspase-2 activation. By comparison, caspase-2 activity 
was not significantly enhanced by the inactive Trx1 mutants C35S and C32S/C35S 
or TrxR alone (Figure 24A), showing that the enzymatic activity of Trx1 was 
responsible for the activation of caspase-2. In conclusion, caspase-2 appears to be 
inactivated by oxidation which is counteracted by Trx1. Even though the peptide 
substrate VDVAD is thought to be specific for caspase-2, Douglas Green and 
colleagues could recently show that this substrate is cleaved by caspase-3 even 
more efficiently (McStay et al, 2008). In order to exclude side-effects of caspase-3 or 
any other caspase, the influence of Trx1 on caspase-2 activity was also measured in 
a cell-free system using recombinant proteins. Because of auto-catalytic processing, 
recombinant caspase-2 is already pre-activated, but further reduction is required to 
Figure 24: Regulation of caspase-2 activity by Trx1 
(A) SKW 6.4 cells were stimulated for 1h with 10 µg/ml anti-CD95 antibody (anti-APO, kindly provided 
by Peter Krammer), lysed and caspase-2 activity was measured in the presence or absence of DTT  
or pre-reduced Trx1. CS: Trx1(C35S), SS: Trx1(C32S/C35S). (B) Activity of recombinant caspase-2 
was measured in the presence of DTT or the Trx1 system. RFU = relative fluorescence units 
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completely activate the enzyme. Again, Trx1 could substitute for DTT in reducing 
caspase-2, although the recovered activity was lower compared to lysate 
preparations (Figure 24B). This could either result from cleavage of VDVAD by 
caspase-3 in the lysate or lower concentrations of caspase-2 in the cell-free system. 
An involvement of caspase-3 seems unlikely as it is not a target of Trx1 redox activity 
(Figure 23). From these experiments it was concluded that Trx1 is likely to play a role 
in the reduction of caspase-2 after oxidative inactivation. 
4.4.2 Identification of the Trx1 target cysteine in cdk6 
The interaction between the Trx1 trapping mutant and its target proteins depends on 
thiol-disulfide exchange, it should therefore be disrupted by mutation of the cysteines 
involved. Mutation of the N-terminal active site cysteine in the Trx1 trapping mutant to 
serine (C32S/C35S) completely abolishes target protein trapping (Schwertassek et 
al, 2007) and data not shown). Accordingly, the replacement of cysteines forming the 
target disulfide bond in the target protein should also abolish trapping. This notion 
was further tested for candidate Trx1 target protein cdk6. As amino acids with 
important regulatory functions are conserved during evolution, a multiple sequence 
alignment of cdk6 orthologs was performed (Figure 25). Six cysteines are present in 
human cdk6 of which Cys7 is unique among the species analyzed, Cys306 is weakly 
conserved, whereas Cys280 is conserved between four out of the seven orthologs. 
Cys83 and Cys207 appear to be absolutely conserved amongst the animal kingdom, 
suggesting the possibility that these cysteine residues form the disulfide bond which 
is targeted by Trx1. 
Figure 25: Conservation of cdk6 cysteine residues of during evolution 
Multiple sequence alignment of cdk6 protein sequences. Orthologs of human cdk6 from the indicated 
species were aligned using the ClustalW algorithm. Numbers indicate cysteine positions in human 
cdk6. 
 
                                       |7      |15           |83        |207 
Homo sapiens                     MEKDGLCRADQQYECVAEI … VRLFDVCTV … LWSVGCIFAEMF … 
Mus musculus                     MEKDSLSRADQQYECVAEI … VRLFDVCTV … LWSVGCIFAEMF … 
Rattus norvegicus                MEKDSLSRADQQYECVAEI … VRLFDVCTV … LWSVGCIFAELF … 
Gallus gallus                    MDKDGTNLADQQYECVAEI … VRLFDVCTV … LWSVGCIFAEMF … 
Danio rerio                      MDKE---SSTQQYEPVAEI … VRLFDVCTV … LWSVGCIFAEMF … 
Xenopus laevis                   MSKE----MKGQYEPVAEI … VKLMDVCAS … LWSVGCIFAEMF … 
Drosophila melanogaster        … QAKKFGDGDPFNYQELNII … VKLYEVCQF … IWSAACIIFEMF … 
 
                                        |280             |306 
Homo sapiens                   … GKDLLLKCLTFNPA … YFQDLERCKENLDSHLPP … 
Mus musculus                   … GKDLLLKCLTFNPA … YFQDLERYKDNLNSHLPS … 
Rattus norvegicus              … GKDLLLKCLTFNPA … YFQDLERYKDNLHSHLSS … 
Gallus gallus                  … GKDLLLKCLAFNPA … YFHDLEKCKENLDSHMSS … 
Danio rerio                    … GKSLLLSLDSTS-- … ---------------FPS … 
Xenopus laevis                 … GADLLLAMLTFSPQ … FFADDPQACSKQEHFTHI  
Drosophila melanogaster        … ADDLLNKMLSYDLH … YFQQEPL----------- … 
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According to the crystal structure of cdk6 four of six cysteines are exposed at the 
protein surface (Figure 26A-E). Interestingly, the highly conserved Cys207 residue is 
buried inside the protein whereas Cys7 and Cys83 are in close proximity on the 
surface. As Cys7 is located on a flexible N-terminal loop, it is conceivable that upon 
oxidation the protein undergoes a conformational change which would allow these 
two cysteines to form a disulfide bond (Figure 26F). Moreover, Cys7 is located N-
terminally of the so-called activation loop which buries the phosphate binding pocket 
in the inactive state of cdk6. Thus, the redox state of Cys7 and Cys83 may have a 
direct effect on cdk6 activity. 
 
For the identification of the Trx1 target cysteines in cdk6, site directed mutagenesis 
was performed to generate six single-cysteine cdk6 mutants which were tagged with 
a 3xFlag tag to discriminate them from endogenous cdk6. After co-expression of 
these mutants with SBP-tagged Trx1(C35S) in HEK 293T cells, Trx1 complexes were 
purified with streptavidin sepharose and the ability of the cdk6 cysteine mutants to 
serve as a target protein for Trx1 was determined by immunoblotting against the Flag 
tag. Surprisingly, all cdk6 mutants except C7S were trapped by Trx1(C35S) 
(Figure 27A). 
Figure 26: Cysteine localization in the crystal structure of human cdk6 
(A)-(E) Space-filling model of human cdk6 with highlighted cysteines. The sulphur atom of cysteine 
residues is depicted in yellow. (F) Ribbon model of the human cdk6 activation loop. Structure 
generated from PDB entry 1JOW using Swiss-Pdb Viewer 4.0 
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Figure 27: Identification of the Trx1 target cysteine in cdk6 
(A) HEK 293T cells were transiently transfected with cyclin D3 and the indicated cdk6 mutants, C-
terminally tagged with a 3xFlag tag. GFP was used as control. Lysate from these cells was incubated 
with Trx1(C35S) and trapping of the cdk6 mutants was determined by immunoblotting against Flag. 
Immunoblotting of input material against cdk6 detects both endogenous and Flag-tagged cdk6. (B) 
Cells from (A) were lysed and cdk6 mutants were immunoprecipitated with anti-3xFlag antibodies. 
Immunoprecipitates were analyzed for co-precipitation of cyclin D3. (C) Jurkat T cells were treated 
with increasing concentrations of H2O2 and lysed in the presence of NEM. Total cell lysate (TCL) was 
loaded under non-reducing conditions and the redox state of cdk6 was determined by immunoblotting. 
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If an intramolecular disulfide bond was targeted by Trx1, two of the cdk6 cysteine 
mutants should resist trapping by Trx1(C35S). Instead, it seems that Cys7 is forming 
an intermolecular disulfide bond potentially with another cdk6 molecule (Cys7-Cys7 
homodimer), an unknown protein or small thiol compound. To exclude the possibility, 
that mutagenesis of Cys7 interfered with correct folding of cdk6, the interaction with 
cyclin D3 was tested. Cyclin D3 could be co-immunoprecipitated with all mutants to 
the same extent as with WT cdk6 (Figure 27B). Furthermore, all mutants showed that 
same activity in phosphorylating recombinant Rb in vitro (data not shown) which 
demonstrates that cysteine mutagenesis of cdk6 does not interfere with protein 
folding or activity. 
 
Independently of target cysteine mapping, the redox status of endogenous cdk6 was 
determined after treatment with H2O2. At a concentration of 100 µM H2O2 cdk6 
showed increased mobility on a non-reducing SDS-PAGE (Figure 27C), a strong 
indication for the formation of an intramolecular disulfide bond. This finding is in 
contrast to the observation that only Cys7 is required for trapping by Trx1(C35S), 
suggesting that cdk6 forms two alternative disulfide bonds upon oxidation. Most likely 
an intermolecular disulfide bond is formed by Cys7 (Figure 27A) in addition to an 
alternative intramolecular disulfide bond that could be formed between Cys7 and 
Cys83 (Figure 23E). In order to identify the cysteines involved in the formation of the 
intramolecular disulfide bond, cdk6 cysteine mutants need to be tested for their redox 
status after H2O2 treatment. 
Formation of the intramolecular disulfide could be favored because no disulfide-
linked complex of cdk6 could be detected by immunoblotting. Alternatively, the 
intermolecular disulfide could be rapidly reduced by Trx1 thereby impeding the 
identification of the interaction partner. In case that a small thiol compound is 
covalently linked to cdk6 Cys7, the detection could be limited by its low molecular 
weight. 
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4.5 Development of novel tools for the analysis of Trx1-mediated redox-
regulation 
4.5.1 Inducible expression of tagged Trx1mutants in Jurkat cells 
Oxidation by O2 after or during cell lysis may lead to artificial alterations of protein 
redox states, a common problem in the redox field. Reagents like N-ethylmaleimide 
(NEM), iodoacetamide (IAM) or methylmethanethiosulfonate (MMTS) can be used to 
alkylate cysteine residues and thereby conserve their redox state, but if these agents 
are applied to cells they impede further analysis by trapping as recombinant 
Trx1(C35S) is easily inactivated in the continued presence of alkylating agents. 
Transient transfection of a Trx1 trapping mutant would circumvent this problem 
because Trx1 trapping conjugates can form before the addition of alkylation agents, 
yet this approach has quantitative limitations which make it less applicable for large 
scale proteomic screens. Alternatively, cells could be stably transduced with retroviral 
expression vectors coding for the Trx1 trapping mutant, which would allow for their 
expansion on a scale suitable for redox proteomics. However, constitutive over-
expression of Trx1(C35S) likely disturbs intracellular redox homeostasis and leads to 
cellular crisis and subsequent adaptive changes. To attenuate the problems of 
constitutive expression, an inducible expression system for Trx1 was established. 
 
The Tet-system is an inducible expression system based on the essential regulatory 
components of the E coli Tn10 tetracycline-resistance operon. The repressor (TetR) 
of this operon binds specifically to its operator (tetO). This is prevented in the 
presence of tetracycline, particularly by doxycycline (Dox). By fusing TetR with 
transcription activation domains, tetracycline-controlled transactivators (tTAs) were 
generated which have been shown to activate minimal promoters fused downstream 
of tetO sequences (Ptet) in the absence of Dox (Gossen & Bujard, 1992; Baron et al, 
1997). In this Tet-Off system addition of Dox inhibits ptet activation. A tTA containing 
mutations in the tetracycline-binding site requires Dox for activation of Ptet. This so-
called reverse tTA (rtTA) has been shown to activate transcription in mammalian 
cells in a tetracycline-dependent way and established the basis for the Tet-On 
system (Gossen et al, 1995). 
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Figure 28: Doxycycline-dependent expression of Trx1-SBP-His 
(A) Overview of the Tet-On system for Dox-regulated Trx1 expression. (B) HeLa cells were transiently 
transfected with pMXs-IN-Puro rtTA-M2 and pRev-Tight Trx1-SBP-His. CS: C35S, CCAAA: 
C62A/C69A/C73A, CSAAA: C35S/C62A/C69A/C73A. (C) Jurkat cells stably transfected rtTA-M2 and 
pRev-Tight Trx1-SBP-His CSAAA were treated with increasing concentrations of Dox for 48h. 
* unspecific band served as loading control (D) The same cells as in (C) were treated with 1 µg/ml Dox 
for various time points. Expression of endogenous and SBP-tagged Trx1 was analyzed by 
immunoblotting against Trx1. 
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For the regulated expression of SBP-tagged Trx1, a Tet-On system was developed in 
Jurkat T cells using the improved transactivator rtTA-M2 (kindly provided by 
Hermann Bujard, ZMBH) which functions at lower Dox concentrations and causes no 
background expression in the absence of Dox (Urlinger et al, 2000). Jurkat T cells 
were transduced with a vector coding for rtTA-M2 and the truncated human low-
affinity nerve growth factor receptor (LNGFR) separated by an internal ribosome 
entry site (IRES). LNGFR-positive cells were transduced with a response-plasmid for 
Trx1-SBP-His under the control of the Dox-responsive promoter consisting of seven 
tetO sites just upstream of the minimal CMV promoter (pRev-Tight) and expression 
of SBP-tagged Trx1 was induced by the addition of Dox (Figure 28A). 
In addition to WT Trx1, the Trx1 trapping mutant C35S was introduced into pRev-
Tight to analyze trapping conjugate formation in intact cells. To test the influence of 
non-catalytic cysteines on Trx1 function and/or trapping behaviour, the two Trx1 
mutants C62A/C69A/C73A (CCAAA) and C35S/C62A/C69A/C73A (CSAAA) were 
also cloned into pRev-Tight. 
The functional capability of the newly generated expression vectors was tested by 
expression in HeLa cells in the presence of Dox for 48 h. Only if the transactivator 
rtTA-M2 was present, Trx1-SBP-His was expressed from the response-plasmid in the 
presence of Dox, even though to a lesser extent as endogenous Trx1 (Figure 28B). 
Trx1-SBP-His expression was dependent on Dox, as tested in an independent 
experiment (data not shown), demonstrating that both transactivator and response-
plasmid were working properly. 
After the functional validation of the system Jurkat T cells stably expressing the Tet-
On Trx1 system were generated. First, Jurkat cells were transduced with rtTA-M2 
and selected with puromycin followed by magnetic-activated cell sorting (MACS) of 
LNGFR-positive cells. Single Jurkat clones were tested for a functional rtTA-M2 with 
a pRev-Tight-EGFP reporter by flow cytometry. The clone with the highest EGFP 
expression after Dox treatment was chosen for transduction with pRev-Tight-Trx1-
SBP-His followed by double selection with puromycin and hygromycin. Trx1-SBP-His 
expression could be tightly regulated and correlated with the applied concentration of 
Dox (Figure 28C). Maximal expression was reached after 48 to 96 h with 1 µg/ml 
Dox, however the expression level was very low compared to endogenous Trx1 
(Figure 28D). 
Because of the low expression of SBP-tagged Trx1 this system is not suitable for 
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large-scale proteomic screens but it can be used for the analysis of Trx1 trapping 
conjugates in intact cells. Low inducibility is a common problem of Tet-On systems 
(Gopalkrishnan et al, 1999; Munoz et al, 2004) which may result form epigenetic 
silencing of the CMV promoter that drives expression of rtTA-M2 (Pikaart et al, 1998; 
Berens & Hillen, 2003). The Trx1 Tet-On system could be further improved by 
replacement of the CMV promoter with the chicken β-actin promoter, which has been 
described to be less prone to epigenetic silencing and thus facilitates stable 
expression of rtTA-M2 (Welman et al, 2005). 
4.5.2 Inducible shRNA-mediated Trx1 knockdown 
For the analysis of Trx1-regulated pathways, inhibition of endogenous Trx1 or TrxR is 
often required. Unfortunately, substances which have been reported to specifically 
inhibit the Trx system have been shown to induce unspecific off-target effects. PX-12 
is claimed to be a specific inhibitor of Trx1 and TrxR (Kirkpatrick et al, 1998) and has 
already completed phase I clinical trails in cancer patients (Ramanathan et al, 2007). 
Very recently it was reported, that PX-12 not only inhibits the Trx system but also 
other thiol-containing proteins like tubulin and cysteine-dependent proteases (Huber 
et al, 2008). Auronofin is also referred to as specific TrxR inhibitor, even though it has 
been shown to inhibit glutathione reductase, glutathione peroxidase (Gromer et al, 
1998) as well as PKC (Wong et al, 1990). DCNB is also used in the clinic and has 
been shown to inhibit TrxR, it strongly increases the NADPH-oxidase-like function of 
this enzyme leading to the formation of superoxide (Arner et al, 1995). To avoid the 
problems associated with pharmacologic inhibitors, Trx1 expression can be 
specifically depleted using shRNA. Similar to over-expression, constitutive down-
regulation of Trx1 will lead to adaptation of the cell. Therefore, an inducible shRNA-
based knockdown system was established in HeLa cells which allows for the analysis 
of Trx1-dependent signaling pathways. 
 
To develop an inducible Trx1 knockdown system, again the Tet system was utilized. 
In contrast to transactivator-based Tet-On or Tet-Off systems the original TetR from 
E.coli was used to suppress expression of Trx1 shRNA. HeLa cells stably expressing 
the TetR were obtained from Invitrogen (HeLa T-REx). For the expression of Trx1-
specific shRNA pSUPER-Retro-NeoGFP (OligoEngine) was used, a retroviral vector 
based on pSUPER (Brummelkamp et al, 2002) in which a neomycin resistance gene 
and a GFP marker were introduced. With this vector shRNA is constitutively 
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transcribed from an unmodified H1 promoter by RNA polymerase I. In order to create 
an inducible expression vector for shRNA, the H1 promoter of pSUPER-Retro-
NeoGFP was replaced with the modified H1 promoter of pTER (van de Wetering et 
al, 2003) kindly provided by Hans Clevers, Utrecht. The modified H1 promoter 
contains a tetO sequence directly upstream of the transcription start site which can 
bind TetR and thereby inhibit shRNA transcription. Trx1-specific shRNA were cloned 
into this newly generated vector (pSUPER-Retro-TRE-NG) downstream of the H1 
promoter. Targeting sequences specific for human Trx1 were generated using the 
SiSearch algorithm (Chalk et al, 2004) which is primarily based on thermodynamic 
properties but also incorporates previously published criteria for shRNA design 
(Reynolds et al, 2004; Jagla et al, 2005). Using this algorithm, four different Trx1 
targeting sequences were selected (Table 3). 
HeLa T-REx cells were transduced with a retrovirus carrying the pSUPER-Retro-
TRE-NG expression vector, selected with neomycin and sorted for GFP expression 
by flow cytometry. In these cells expression of Trx1 specific shRNA is inhibited by the 
TetR which blocks access to the H1 promoter for RNA polymerase I. In the presence 
of Dox the TetR dissociates from the H1 promoter and Trx1 specific shRNA is 
transcribed (Figure 29A) which targets Trx1 mRNA for degradation by the RISC 
complex. HeLa T-REx cells stably transduced with Trx1 shRNA constructs were 
cultivated in the presence or absence of Dox for one week and the expression level 
of Trx1 was analyzed by immunoblotting. Construct 281 had no effect on Trx1 
expression, whereas construct 212 reduced Trx1 expression by 60%. Two of the four 
shRNA constructs (252 and NCR) showed a strong down-regulation above 90% in 
the presence of Dox (Figure 29B-D). Possible off-target effects of RNAi-mediated 
gene knockdowns (Boutros & Ahringer, 2008) can be reduced by using these two 
independent shRNA constructs which both induce down-regulation of Trx1 
Table 3: shRNA targeting sequences generated with SiSearch 
Region: CDS (coding sequence), NCR (non-coding region), Score: Stockholm rules score (0-7) (Chalk 
et al, 2004), dG Diff: energy difference between sense and antisense ends (Schwarz et al, 2003) 
Region Start End GC human Trx1 mRNA target sequence Score unique dG Diff 
CDS 212 230 42.11% CCAACGUGAUAUUCCUUGA 6 True -1.0 
CDS 252 270 47.37% GGAUGUUGCUUCAGAGUGU 6 True -1.5 
CDS 281 299 47.37% GCAUGCCAACAUUCCAGUU 6 True -2.6 
3’NCR 91 109 57.89% CCAGUUGCCAUCUGCGUGA 3 True -0.6 
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expression. Moreover, as one silencing construct targets Trx1 mRNA in the non-
coding region, Trx1 expression can be restored by transfection of Trx1 cDNA lacking 
this sequence. Thus, specificity of this targeting sequence can be easily 
demonstrated by reconstitution of Trx1. 
 
This inducible Trx1 knockdown system provides a powerful tool for the analysis of 
Trx1-mediated redox-regulation because it is very specific compared to the use of 
thioredoxin inhibitors. Furthermore it circumvents the problem of cellular long-term 
adaption to low Trx1 expression levels. 
 
 
Figure 29: Inducible shRNA-mediated knockdown of Trx1 
(A) Overview of the Dox-dependent shRNA-mediated down-regulation of Trx1 expression. For details 
see text. (B) HeLa T-REx cells expressing the Trx1 shRNA constructs listed in table 3 were cultivated 
for one week in the absence or presence of 1 mg/ml Dox. Cells were lysed and Trx1 expression was 
analyzed by immunoblotting. Actin was used as loading control. (C) Actin and Trx1 expression was 
quantified with a Lumi-Imager F1 (Roche Diagnostics) and relative expression levels were calculated. 
(D) Relative Trx1 expression after Dox treatment normalized to actin expression. 
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5 Discussion 
5.1 Trapping of cytosolic Trx1 target proteins in mammalian cells 
A number of redox-sensitive proteins is known to be regulated by Trx1, including 
NFκB (Hayashi et al, 1993), Ref-1 (Hirota et al, 1997) and PTP1B (Lee et al, 1998). 
However, no comprehensive analysis of Trx1 target proteins in the cytosol of 
mammalian cells has been performed so far. The characterization of proteins 
interacting with Trx1 was limited to yeast two-hybrid screens leading to the 
identification of p40phox (Nishiyama et al, 1999b), VDUP1 (Yamanaka et al, 2000) 
and pro-α 1 type 1 collagen (Matsumoto et al, 2002) as Trx1 interaction partners. 
Notably, these screens were done with WT Trx1 and therefore the proteins identified 
do not necessarily interact with Trx1 by thiol-disulfide exchange. Characterization of 
Trx1 substrate proteins is difficult due to the short half-life of the mixed-disulfide 
intermediates which are generated during disulfide bond reduction by Trx1 (Figure 7). 
Mutation of the second active site cysteine of thioredoxin has been shown to stabilize 
this otherwise transient reaction intermediate (Wynn et al, 1995). A yeast two-hybrid 
screen using a human brain cDNA library and the Trx(C35S) trapping mutant as a 
bait led to the identification of Jun activation domain-binding protein 1 (Jab1). 
However, Jab1 also co-immunoprecipitated with WT Trx1, thus indicating that the 
interaction does not depend on Trx1 catalytic activity (Hwang et al, 2004). On a 
cautionary note, the redox status of gene products ectopically expressed in yeast 
may not be representative of the mammalian cellular environment. Moreover, the 
high number of false positives and the inability to differentiate between non-covalent 
interactions and true enzyme-substrate (i.e. disulfide exchange) relationships are 
major drawbacks of the two-hybrid approach. 
 
For the specific large-scale identification of novel mammalian cytosolic Trx1 target 
proteins recombinant Trx1 trapping mutant was incubated with cytosolic preparations 
of human Jurkat T cells. Several controls were implemented in order to minimize the 
number of false positives and to assure specificity of the kinetic trapping technique. 
Firstly, recombinant WT Trx1 was used as a negative control in all experiments. After 
stringent washing the only protein found to interact with WT Trx1 was TrxR, whereas 
a substantial number of proteins were reproducibly trapped by Trx1(C35S) 
(Figure 12), thus demonstrating the specificity of kinetic trapping for the identification 
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of disulfide exchange interactions. These and other experiments confirmed that 
mixed disulfide conjugates which form between Trx1 and target proteins are 
stabilized in the absence of the resolving cysteine in the active site. Furthermore, 
disulfide-linked Trx1 targets (Figure 30A) could be efficiently separated from non-
covalent interaction partners (Figure 30B) by non-reducing/reducing 2D gel 
electrophoresis (Figure 16A). Denaturating re-precipitation (so-called ‘Strip-Re-IP’) of 
conjugates almost completely removed non-covalently attached proteins 
(Figure 16B). However, even though these measures can dramatically decrease the 
number of non-covalent Trx-binding proteins, it could not be excluded that a few 
proteins were captured indirectly, because they form a disulfide bond with a Trx1 
target protein, rather than with Trx1 itself (Figure 30C). 
No proteins were captured by the corresponding Grx1 trapping mutant, showing that 
substrate trapping is based on protein-protein-interactions and not simply due to the 
exposure of a reactive thiol, which is a common feature of both Grx and Trx 
(Figure 13). Moreover, these data not only confirm target specificity of Trx1-based 
trapping but also provide important insights in the reaction mechanism of Grx1. It is 
widely accepted that Grx1 catalyzes de-glutathionylation by a mono-thiol mechanism 
(Figure 4A). In addition, Holmgren and colleagues introduced the concept that Grx1, 
precisely like Trx1, can act by a di-thiol mechanism to reduce protein disulfide bonds 
(Figure 4B). However, this notion is based on a single experiment, namely the 
observation that E.coli glutaredoxin lacking the second active site cysteine does not 
reduce ribonucleotide reductase (Bushweller et al, 1992). However, protein disulfide 
bond reduction by Grx has not been described in eukaryotes and experiments 
demonstrate that mammalian Grx1 is a reductase specific for protein-glutathionyl 
mixed disulfide bonds (Gravina & Mieyal, 1993). Nevertheless, the possibility of a 
Figure 30: Possible protein-protein interactions of Trx1(C35S) 
Schematic overview of possible covalent and non-covalent protein-protein interactions of Trx1(C35S). 
(A) direct trapping of a protein target. (B) non-covalent interaction. (C) indirect trapping of a protein 
which is disulfide-linked to a Trx1 target protein. 
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dithiol reaction mechanism has not been generally disproven. If Grx1 could catalyze 
protein disulfide reduction via the proposed dithiol mechanism, mutation of the 
second active site cysteine should stabilize the transient reaction intermediate 
analogous to Trx1 substrate trapping. As no protein substrates could be trapped with 
the human Grx1(C25S) mutant (Figure 13), Grx1 does not seem to exhibit any 
protein disulfide reductase activity under the conditions of our experiments. In 
agreement with this finding, other studies concluded that Grx1 only reduces protein-
glutathione mixed-disulfide bonds (Yang et al, 1998; Peltoniemi et al, 2006) and that 
Grx1(C25S) only forms mixed-disulfide intermediates with glutathione. Moreover, the 
lack of protein trapping clearly demonstrates that Grx1 specifically attacks the sulfur 
atom of the glutathionyl residue but not that of the protein cysteine residue, thus 
reflecting the structurally precise recognition of protein-SSG conjugates by Grx1. This 
conclusion is also supported by a structural comparison of the thioredoxin and 
glutaredoxin active sites. The thioredoxin surface exhibits a hydrophobic and 
elongated groove to interact with a continuous peptide chain of a target protein. In 
contrast, Grx exhibits a conformation that seems inappropriate for the recognition of 
substrate proteins (Maeda et al, 2006). Instead, reduction of glutathionylated proteins 
proceeds via binding of the glutathionyl moiety, but not of the glutathionylated protein 
itself (Fernandes & Holmgren, 2004). 
 
Even though our experiments strongly suggest that Grx1 does not reduce any protein 
disulfides, the opposite situation should be considered as a possibility: Does Trx 
reduce glutathione-protein mixed disulfide bonds? If so, the Trx1 trapping mutant 
may not only trap substrates with an intra- or intermolecular protein-protein disulfide 
bond but also glutathionylated proteins. Structural restrictions argue against a direct 
reduction of glutathionylated proteins by Trx. It has been suggested that the 
hydrophobic surface of the Trx active site lacks groups that complement the charged 
and polar groups of glutathione (Nordstrand et al, 1999). 
To clarify a possible role for Trx1 in de-glutathionylation radiolabeled 35S-GSSG 
could be used in future experiments. Treatment of a cytosolic preparation with 35S-
GSSG and recombinant Grx1 should lead to radiolabeled glutathionylated proteins. 
Following removal of unbound GSSG, recombinant Trx1 can be tested for its ability 
to de-glutathionylate proteins which would show as a decrease in protein-associated 
radioactivity. 
Discussion 
 
82 
Recently it has been shown that Trx1 can catalyze denitrosylation of caspase-3 
(Benhar et al, 2008). However, it remains to be confirmed that this is a general 
phenomenon affecting many proteins. To address this issue on a proteomics scale, 
cells could be treated with nitrosylating compounds like S-nitrosoglutathione (GSNO), 
blocked with NEM, incubated with recombinant Trx1 and analyzed for a reduction in 
nitrosylation using the biotin-switch method (Jaffrey et al, 2001). 
 
To perform Trx1 target trapping on cytosolic preparations, proteins were released 
from their physiological environment. Upon release, cytosolic proteins become 
exposed to increased oxygen levels and, potentially, to redox enzymes released from 
non-cytosolic compartments. Accordingly, the redox status of the trapped proteins 
may be altered during lysis. In order to prevent leakage of oxidoreductases and 
GSSG from the endoplasmic reticulum, cytosolic proteins can be released by plasma 
membrane permeabilization rather than general membrane solubilization. However, 
even though some disulfide bonds targeted by Trx1(C35S) in lysates may have 
formed by artificial oxidation during or after lysis, trapped proteins nevertheless are 
likely to represent proteins specifically recognized by Trx1. In order to verify that the 
same proteins which were identified by lysate trapping are also targeted by Trx1 in 
intact cells under more physiological conditions, expression of the trapping mutant 
was induced in intact cells expressing the reverse Tet-transactivator rtTA-M2 and 
Trx1(C35S) under control of a doxycycline-dependent promoter (Figure 28D). Before 
lysis and pulldown of Trx1-linked conjugates the cells were treated with NEM to 
preserve the redox states of intracellular thiol groups. The resulting trapping pattern 
was comparable to the one obtained using recombinant trapping mutant albeit the 
total amount of Trx1 conjugates was less due to the lower expression level of the 
trapping mutant (data not shown). These data indicate that most Trx1 target proteins 
identifiable in cytosolic preparations also act as Trx1 substrates in intact cells. 
Accordingly, similar results were obtained by transient expression of Trx1(C35S) in 
HEK 293T cells which have been treated with NEM prior to lysis and isolation of 
Trx1-linked conjugates. 
 
Notably, it appears that only a minor fraction of each Trx1 target protein’s total 
amount was trapped in our experiments. No absolute quantification was performed, 
which would require the use of recombinant calibrators and normalizers (Schilling et 
Discussion 
 
83 
al, 2005). This observation is in accordance with the concept that proteins in the 
cytosol are normally reduced and that local generation of ROS leads to transient and 
spatially limited oxidation of redox-sensitive proteins. 
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5.2 The influence of T cell stimulation on the Trx1 trapping profile 
Treatment of Jurkat T cells with PMA/ionomycin for 30 minutes was reported to 
induce ROS production as measured by H2DCFDA-staining (Gülow et al, 2005). 
However, 30 minutes after stimulation we could not detect any significant difference 
in the Trx trapping pattern. The lack of a Trx1 trapping response upon T cell 
stimulation might have several reasons. Firstly, the kinetics of ROS generation and 
decomposition may limit detection of protein oxidation in the Trx1 trapping assay. 
Inside the cell H2DCFDA is hydrolyzed to H2DCF which is in turn oxidized by 
peroxides to fluorescent DCF. As DCF is stable, its fluorescence will accumulate and 
persist over time even if the initial ROS signal has already vanished. Thus, the 
oxidative state induced by T cell stimulation could be gone after 30 minutes, even 
though the oxidative signal is detectable by DCF fluorescence. In fact, subsequent 
experiments have shown that treatment of cells with a single bolus of H2O2 
substantially increased Trx1 trapping, but only for up to 5 minutes. The notion that 
pro-oxidative states can be extremely short-lived is also supported by independent 
measurements with biosensors in live imaging experiments (Gutscher et al, 2008). In 
conclusion, the issue of Trx1 trapping after T cell stimulation needs to be re-
addressed in future experiments at earlier time points.  
 
Secondly, differences in protein oxidation may be lost during or after cell lysis. 
Following disruption of the cell oxidant-sensitive proteins may become oxidized 
independently of their initial redox state inside the intact cell. However, this 
explanation seems unlikely as inhibition of TrxR by DCNB (Figure 14B) and 
knockdown of endogenous Trx1 (Figure 17B) changed the Trx1 substrate trapping 
pattern. In order to diminish the danger of post-lysis oxidation free thiol groups need 
to be rendered inert to oxidation prior to cellular disruption. However, treatment of 
cells with the membrane-permeable alkylating agent NEM just before lysis would 
interfere with subsequent Trx1 substrate trapping as unreacted NEM in the lysate 
would also alkylate the active site cysteine of the Trx1 trapping mutant. A possibility 
to circumvent this problem is to remove unreacted NEM by gel filtration before 
application of the trapping mutant. The conservation of protein redox states by 
trichloroacetic acid (TCA) precipitation (Leichert & Jakob, 2004) is not compatible 
with the trapping procedure, which requires the target proteins to maintain their 
native structure. 
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Thirdly, even though it has been shown that ROS are generated by T cell stimulation, 
it not clear if and to which extent protein disulfide bonds are formed and 
subsequently reduced by the thioredoxin system. It is possible that the glutathione/ 
glutaredoxin system plays a more important role under the specific conditions of T 
cell activation. Stimulation of primary T cells leads to oxidation of the cytosolic 
glutathione pool (Gutscher et al, 2008) and it is therefore possible that redox-
sensitive proteins are mainly subject to glutathionylation rather than intramolecular 
disulfide bond formation (Figure 2). In this scenario, changes in the Trx1 trapping 
pattern are not expected to follow as a consequence of T cell activation. A detailed 
characterization of the protein subsets targeted by Trx1 and Grx1 would provide a 
better understanding of the oxidative events induced by T cell stimulation. 
 
Finally, sensitivity could limit detection of stimulation-dependent changes in Trx1 
substrate trapping. As only a small subpopulation of Trx1 targets may become 
oxidized and thus trapped by Trx1(C35S), minor changes in protein oxidation could 
be too marginal to be detected by silver staining or immunoblotting. Since oxidation 
of at least some Trx1 target proteins is nevertheless likely to occur after stimulation of 
ROS-generating signaling pathways, optimized experimental conditions should 
eventually facilitate identification of stimulation-dependent changes in Trx1 target 
trapping. A promising approach is rapid analysis at early time points in combination 
with NEM alkylation and gel filtration. Titrations of stimuli need to be tested at various 
time points in order to find to optimal parameters for the analysis of these oxidative 
changes. 
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5.3 Identification of novel Trx1 substrates 
Two independent large-scale trapping experiments were performed to identify 
cytosolic Trx1 target proteins. First, conjugates were separated under reducing and 
non-reducing conditions on conventional 1D SDS-PAGE (Figure 18). From this 
experiment 73 candidate Trx1 target proteins were identified by mass spectrometry 
(Table 1). In order to differentiate between disulfide-linked Trx1 targets and proteins 
non-covalently interacting with Trx1, complexes from a second experiment were 
separated by NR/R 2D SDS-PAGE (Figure 19). Only proteins from below the main 
diagonal - representing disulfide-linked Trx1 target proteins - were sequenced by 
tandem mass spectrometry (Table 2). Among the 62 Trx1 targets isolated from the 
2D gel, 23 were also found in the first experiment (Figure 20A), thus confirming 
approximately one third of the target proteins in an independent experiment. The 
seemingly low proportion of overlap is, however, not unexpected as different mass 
spectrometry setups and machines were used in the two experiments. Even slight 
differences in instrument settings are known to influence the collection of tandem 
mass spectra (Berg et al, 2006). It is furthermore likely, that additional Trx1 targets 
could be identified by increasing the number of cells used for the experiment or by 
oxidative treatment of cells to increase target protein oxidation and subsequent Trx1 
substrate trapping. 
 
The limitation of current approaches to global redox proteomics is sensitivity. Often 
the identified proteins are those with relatively high copy numbers, and important 
target proteins may well be in too low abundance to be detected. This problem 
should be solvable with techniques actively enriching specific subsets of redox-
regulated proteins (Winterbourn & Hampton, 2008). Kinetic trapping provides such a 
selective method as only Trx1 target proteins are captured, enriched and efficiently 
separated from highly abundant contaminants. Indeed, high abundance proteins 
typically contaminating results from proteomics (e.g. ribosomal or proteasomal 
proteins) were not observed in our experiments. Instead, it appears that mostly 
proteins of low abundance were identified. 
 
The family of peroxiredoxins represents the major cytosolic target for Trx1 in the 
Jurkat T cell line as large quantities of these proteins were trapped by Trx1(C35S). 
Most interestingly, we obtained indications that Prx1 may form disulfide-linked 
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conjugates not only with Trx1, but also with numerous other proteins (Figure 21). 
This possibility is also supported by the finding that peroxiredoxins are broadly 
distributed on the NR/R 2D gel (Figure 10) thus implicating that they are disulfide-
linked to a wide variety of Trx1 target proteins. The reasons for this surprising finding 
are not yet understood, but it seems possible that Prx1 is critically involved in the 
oxidation of Trx1 target proteins. Peroxiredoxins, representing the primary target of 
H2O2, have been suggested to act as peroxide sensors and protein oxidases for 
redox-sensitive proteins (Winterbourn, 2008). Thus, the presence of peroxiredoxins 
as components in a vast number of Trx1 target protein conjugates could result from 
their role as oxidases for those proteins which are subsequently reduced by Trx1. 
 
Because of the high number of newly identified Trx1 targets, this discussion will focus 
on selected examples and their physiological function. In addition to peroxiredoxins, 
flightless-1 homolog (FLII) is a very prominent Trx1 target of which over 40 peptide 
fragments were detected by mass spectrometry corresponding to a protein coverage 
over 30% (Table 2). FLII was first identified in Drosophila melanogaster (Campbell et 
al, 1993) and is required for actin distribution during cellularization of the fly embryo 
(Straub et al, 1996). It contains a C-terminal gelsolin-like domain (GLD) and belongs 
to the gelsolin superfamily of actin-remodeling proteins (Silacci et al, 2004). Because 
the GLD of FLII is more divergent from that in other gelsolin family members, it has 
been suggested that it may have other unique regulatory functions. In addition to the 
GLD, FLII contains an N-terminal leucine-rich repeat (LRR) domain which has been 
shown to interact with leucine-rich repeat flightless-interacting protein 1 (LRRFIP1), a 
protein also found in the Trx1 kinetic trapping screen. Whether LRRFIP1 was directly 
trapped or bound to FLII by disulfide-linkage still remains to be tested. FLII serves as 
coactivator for nuclear receptor-mediated transcription (Lee et al, 2004) but 
suppresses β-catenin dependent gene expression (Lee & Stallcup, 2006). Recently, 
new functions of FLII have been characterized. FLII interacts with the pro-
inflammatory protein caspase-1 and inhibits its activity (Li et al, 2008), activates 
Ca2+/calmodulin dependent protein kinase type II (CaMK-II) (Seward et al, 2008) and 
negatively regulates the TLR4-MyD88 pathway (Wang et al, 2006). Thus, this 
prominent target of Trx1 is involved in actin-remodeling and signal transduction, and 
provides a novel link to redox-regulation of these processes. 
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The hematopoietic-specific GTPase Rac2 belongs to the family of Rho GTPases that 
facilitates cell adhesion and chemotaxis response in macrophages and neutrophils 
(Van Hennik & Hordijk, 2005). In addition, formation and activation of the phagocyte 
NADPH oxidase (phox) can be promoted by Rac2 in vitro (Knaus et al, 1991). 
Accordingly, O2• – production in phagocytes from Rac2 knockout mice is markedly 
diminished (Roberts et al, 1999; Glogauer et al, 2003) demonstrating a major in vivo 
relevance of Rac2 in phox activation. Upon phagocytosis p67phox and active GTP-
bound Rac2 translocate to the cell membrane to activate the cytochrome-b558 subunit 
of phox to produce O2• – which contributes to the killing of microbes internalized into 
the phagosome. Furthermore, Rac2 does not only regulate phox activation in 
phagocytes but also has pivotal roles in lymphocytes. T cell activation is 
compromised in Rac2 deficient mice due to decreased activation of ERK1/2 and p38 
MAPK as well as defective cytoskeletal changes (Yu et al, 2001). As also T cells 
express a phagocyte-type NADPH oxidase (Jackson et al, 2004), Rac2 may also 
contribute to ROS formation after T cell receptor stimulation. In B cells Rac2 has 
recently been shown to be required for immunological synapse formation (Arana et 
al, 2008). Trx1-mediated regulation of Rac2 may provide a novel mechanism of how 
NADPH oxidase activity is feedback-regulated by redox state. Interestingly, the Rac2 
active site contains a conversed cysteine which may facilitate redox-regulation by 
Trx1. 
 
Finally, it should be highlighted that several of the newly identified Trx1 target 
proteins have important functions in sugar metabolism. These include Ribose-5-
phosphate isomerase, glutamine:fructose 6 phosphate amidotransferase 1 (GFPT1), 
phospho-fructokinase-1 (PFK-1) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Most interestingly, glucose-6-phosphate dehydrogenase (G6PD) was also 
identified as a candidate Trx1 target protein. G6PD is a key enzyme of the pentose 
phosphate pathway, the main source of NADPH in the cytosol. As NADPH serves as 
the electron donor for the reduction of GSSG by glutathione reductase, and for the 
regeneration of Trx1 by TrxR, it is tempting to speculate that the interaction between 
Trx1 and G6PD provides feedback regulation of NADPH production. For example, 
under oxidative conditions G6PD may be activated through thiol oxidation to promote 
generation of NADPH. Thioredoxin in the reduced state may act as a negative 
feedback regulator by reducing a putative disulfide bond in G6PD to downregulate its 
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activity and NADPH output. However, it is also conceivable that the interaction 
constitutes a positive feedback loop to enhance reducing conditions. 
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5.4 Redox regulation of the cell cycle 
Proliferation and cell division is regulated by an ordered sequence of events. In the S 
phase of the cell cycle the cellular DNA is duplicated, in the following G2 phase the 
cell prepares for mitosis and in M phase the DNA gets segregated and the cell 
divides into two. In the following G1 phase the cell decides whether to stop 
proliferation or continue with another round of the cell cycle. This decision is made at 
the so-called restriction point after which the cell enters S phase and becomes 
independent on mitogenic signaling. Already in 1969 the finding that the cellular 
protein disulfide content fluctuates during cell cycle and reaches a minimum at the 
G1/S transition suggested a redox-dependent control of the cell cycle (Mauro et al, 
1969). A requirement for oxidants in cell cycle progression was indicated by the 
observation that overexpression of catalase inhibits proliferation (Brown et al, 1999) 
and that treatment with the antioxidant NAc induces cell cycle arrest in the G1 phase 
(Sekharam et al, 1998; Kim et al, 2001). This arrest has been shown to be 
accompanied with decreased cyclin D1 levels (Menon et al, 2003). The three D 
cyclins (cyclin D1, D2 and D3) are major regulators of the G1 phase and represent 
the regulatory subunit of the G1 cyclin-dependent kinases cdk4 and cdk6. These 
cyclin-cdk complexes phosphorylate Rb which induces its dissociation from E2F, 
allowing E2F-dependent transcription and entry into S phase (Ekholm & Reed, 2000; 
Massague, 2004). Cyclin D expression levels are regulated by de novo synthesis 
after growth factor stimulation and degradation by the ubiquitin-proteasome pathway. 
Both mechanisms have been described to be regulated by ROS. Incubation of 
fibroblasts with H2O2 leads to accumulation of cyclin D1 even in the presence of 
protein synthesis inhibitors and MAPK inhibitors, suggesting inhibition of proteasome-
dependent cyclin D1 degradation (Martinez Munoz et al, 2001). In addition, 
stimulation of growth factor and cytokine receptors induce ROS which lead to 
activation of the MAPK pathway and induction of cyclin D expression (Cakir & 
Ballinger, 2005). 
 
In yeast, thioredoxin deficiency prolongs S phase and shortens the G1 interval of the 
cell cycle (Muller, 1991) which was later attributed to its function as electron donor for 
ribonucleotide reductase during DNA precursor synthesis (Koc et al, 2006). 
Considering the newly identified as well as established cytosolic Trx1 substrates, 
Trx1 seems to regulate cell cycle progression at various additional stages besides 
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DNA synthesis. Interestingly, most Trx1 substrate proteins identified by kinetic 
trapping and involved in cell cycle regulation play an important role in G1/S transition 
(Figure 31). Cyclin D1 expression is up-regulated after growth factor receptor 
stimulation via the Ras-MAPK pathway. Redox-regulation of the Ras inhibitor 
RasGAP by Trx1 could influence cell cycle progression by altering cyclin D1 levels. 
At the transcriptional level cyclin D is regulated by different transcription factors, 
including AP-1 and NFκB (Burch & Heintz, 2005), both of which have been shown to 
be substrates of Trx1 (Hirota et al, 1997; Hirota et al, 1999). 
 
Overexpression of protein phosphatase 6 (PP6) induces cell cycle arrest in G1 by 
suppression of cyclin D1 expression and Rb phosphorylation (Stefansson & 
Brautigan, 2007). Thus, PP6 reduction by Trx1 could directly influence cyclin D1 
levels and transition from G1 to S phase of the cell cycle. This function of Trx1 has 
already been described for cdc25, a phosphatase that counteracts the kinase wee1 
which phosphorylates and thereby inhibits cdks. It has been proposed that the 
growth-promoting effect of Trx1 could be partially exerted by keeping cdc25 in a 
reduced and active state (Sohn & Rudolph, 2003). In addition to phosphorylation-
based cdk regulation, Trx1 could directly regulate cdk6 by thiol disulfide exchange. 
Figure 31: Redox regulation of the G1/S transition by Trx1 
Overview of Trx1 target proteins involved in the G1/S transition of the cell cycle. See text for details. 
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Among the family of cdks, only cdk6 but not cdk1, cdk2 or cdk4 were targeted by the 
trapping mutant Trx1(C35S) (Figure 23C). Cysteine mutagenesis revealed that Cys7 
is required for trapping of cdk6 (Figure 27A) suggesting the formation of a mixed 
disulfide with another protein. As no such disulfide-linked homo- or heterodimer was 
detected by immunoblotting the half-life of this conjugate, if it does exist, may be very 
short, possibly as a consequence of rapid reduction by the endogenous thioredoxin 
system. When the disulfide bond between cdk6 and the unknown disulfide-linked 
partner protein is attacked by Trx1(C35S) only one of the two proteins becomes 
covalently linked to the Trx1 trapping mutant. The alkylating agent MMTS was used 
to block thiol redox states after H2O2 treatment but even under these conditions no 
disulfide-linked cdk6 conjugates could be detected (data not shown). Depletion of 
Trx1 by shRNA may serve as a strategy in future experiments to inhibit rapid 
reduction of cdk6 disulfide-linked conjugates. No difference in kinase activity was 
measured for the different cdk6 mutants, speaking against a regulatory role of Cys7. 
For the in vitro kinase assay Flag-tagged cdk6 mutants were purified from HEK 293T 
cells over-expressing cyclin D. However, the status of other cdk6 regulators like p21, 
CAK, wee1 and cdc25 is poorly defined. A more appropriate strategy to prove the 
functional relevance of particular cdk6 cysteines would be the depletion of 
endogenous cdk6 and reconstitution with cdk6 cysteine mutants at a physiological 
expression level. However, this approach requires that depletion of cdk6 results in a 
distinct phenotype different from WT cells which can be rescued by re-transfection of 
cdk6. Unfortunately, cdk6 knockout mice have a very mild phenotype. These mice 
are viable, have thymic and splenic hypoplasia, and mild defects in hematopoiesis. 
Only T lymphocytes show a delayed S-phase entry (Malumbres et al, 2004). 
Apparently, the loss of cdk6 can be largely compensated by cdk4. Cdk4-null mice are 
viable but sterile and develop diabetes due to abnormal β-islet cell development 
(Rane et al, 1999). In contrast, cdk4/cdk6 double knockout mice show progressive 
embryonic lethality from E14.5 onwards and the few surviving animals die soon after 
birth (Malumbres et al, 2004), clearly demonstrating the redundancy between the two 
cdks. MEFs deficient in both cdks were only partially able to respond to mitogenic 
stimulation and to exit quiescence. Thus, the activity of cdk6 cysteine mutants may 
only be properly analyzed in the absence of cdk4. Recently, mice lacking all 
interphase cdks (cdk2, cdk3, cdk4 and cdk6) have been shown to undergo 
organogenesis and MEFs from these cells proliferate in vitro (Santamaria et al, 
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2007). These results indicate that cdk1 is the only essential cell cycle cdk which can 
execute all events that are required for cell division in the absence of interphase 
cdks. Thus, the effect of cdk6 on cell cycle progression is difficult to analyze, which 
becomes even more complicated by the finding that active cdk6 complexes are 
predominantly nuclear and represent only a minority of the total cdk6 pool (Mahony 
et al, 1998). 
Alternatively, recently identified functions specific to cdk6 may be assayed to assess 
the relevance of certain cysteine residues for its activity. Ectopic expression of cdk6 
circumvents TGF-β mediated growth inhibition in mink epithelial cells (Zhang et al, 
2001) and recent findings demonstrate an unexpected role for cdk6 in differentiation 
of a variety of cell types, a function that is not shared with cdk4. Expression of cdk6 
but not cdk4 in mouse astrocytes was associated with de-differentiation to glial 
progenitor-like cells (Ericson et al, 2003). Accordingly, over-expression of cdk6 
blocked osteoblast differentiation without altering cell cycle progression (Ogasawara 
et al, 2004). Even though the exact mechanism of how cdk6 blocks differentiation is 
not understood, it may be asked if this cdk4-independent function depends on 
particular cdk6 cysteine residues and redox-regulation. 
 
As Rb was identified as a Trx1 target protein, cell cycle progression may be 
influenced by redox-regulation of this tumor suppressor. Moreover, inhibition of Rb by 
Trx1 could provide an additional explanation for the observation that tumor growth 
benefits from increased levels of Trx1, adding to the picture that Trx1 can play an 
important role in tumor development (Figure 9). 
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5.5 Redox regulation of apoptosis 
Programmed cell death or apoptosis was first described in 1972 (Kerr et al, 1972). It 
is characterized by a tightly regulated cascade of proteolytic events eventually 
leading to controlled disposal of the cell without induction of inflammation or tissue 
damage. Apoptosis can be executed by two distinct pathways. The extrinsic pathway 
is initiated by activation of death receptors including CD95 (APO-1/Fas), TNF-R or 
TRAIL-R (Bhardwaj & Aggarwal, 2003; Krammer et al, 2007) which induces 
formation of the so-called death-inducing signaling complex (DISC) and activation of 
caspase-8. Caspase-3 is a key enzyme at the end of a caspase activation cascade 
which eventually leads to degradation of cellular caspase substrates and execution of 
apoptosis. 
The intrinsic pathway is activated by cellular stress including cytokine deprivation, 
mutagenic irradiation or oxidative stress and induces aggregation of the pro-apoptotic 
Bcl-2 family members Bak and Bax. These BH3-only proteins induce mitochondrial 
outer membrane permeabilization (MOMP) which leads to release of cytochrome c. 
Cytoplasmic cytochrome c interacts with caspase-9, apoptotic peptidase activating 
factor 1 (APAF1) and ATP to form an oligomeric complex, called the apoptosome 
(Green & Kroemer, 2004). Apoptosome formation eventually leads to activation of 
caspase-3 and execution of apoptosis. Death receptor mediated apoptosis can be 
amplified by cleavage of Bid and subsequent cytochrome c release which integrates 
the extrinsic and intrinsic pathway. 
Oxidative stress activates JNK and p38 MAPK via ASK1 (Ichijo et al, 1997). 
Constitutively active mutants of ASK1 induce cytochrome c release and activation of 
caspase-3 and -9, but not of caspase-8, indicating that ASK1 activates mainly the 
intrinsic apoptotic pathway (Hatai et al, 2000). The mechanism of ASK1 regulation by 
Trx1 has been already been described in chapter 1.2.2. Additionally, Trx1 regulates 
p53 function which is a direct transcriptional activator of the Bax gene (Miyashita & 
Reed, 1995).  
ROS do not only promote oxidative stress and apoptosis via ASK1 but are also 
produced after death receptor stimulation (Gulbins et al, 1996; Sato et al, 2004; 
Medan et al, 2005). Antioxidants like NAc can block CD95-mediated cell death 
indicating that both the extrinsic and the intrinsic pathway are redox regulated. 
Kinetic trapping identified so far unknown Trx1 substrates involved in both pathways 
(Figure 32). Among the four heat-shock proteins found in the trapping screen, Hsp27, 
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Hsp70 and Hsp90 have been shown to inhibit apoptosis (Garrido et al, 2003; Beere, 
2005). Hsp70 inhibits TNF-induced caspase-8 activation, Bid cleavage and 
cytochrome c release independently of its chaperone activity (Gabai et al, 2002). 
Moreover, Hsp70 and Hsp90 prevent recruitment of caspase-9 to the apoptosome 
(Beere et al, 2000; Pandey et al, 2000) and Hsp27 negatively regulates cell death by 
interacting with cytochrome c (Bruey et al, 2000). Interestingly, Hsp70 also inhibits 
Trx1-mediated activation of ASK1 (Park et al, 2002). Thus, the heat-shock proteins 
targeted by Trx1 not only facilitate protein folding but furthermore play a regulatory 
role in apoptosis. 
 
APAF1-interacting protein (APIP) inhibits cytochrome-c induced activation of 
caspase-3 and caspase-9 which would otherwise lead to induction of apoptosis (Cho 
et al, 2004). Recently, it has been shown that APIP also leads to sustained activation 
of Akt (PKB) and extracellular signal-regulated kinase (Erk) which can suppress 
hypoxia-induced cell death (Cho et al, 2007). 
Figure 32: Redox regulation of apoptosis by Trx1 
Trx1 target proteins involved in apoptosis. See text for details. 
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Regulation of caspase-3 by Trx1 has been described earlier. Recombinant caspase-
3 was suggested to be activated by Trx1 (Baker et al, 2000) and inactivated by H2O2 
(Hampton et al, 2002). It was demonstrated that Trx1 can catalyze the S-nitrosylation 
of the caspase-3 active site, leading to inhibition of caspase-3 activity (Mitchell & 
Marletta, 2005). Recently, caspase-3 and GST-tagged Trx1(C35S) were co-
expressed in HEK 293T cells and caspase-3 could be co-precipitated with the 
trapping mutant after treatment with S-nitrosocysteine (CysNO). No interaction was 
observed in untreated cells or cells transfected with GST-tagged WT Trx1, 
suggesting that Trx1 specifically reduces nitrosylated caspase-3 which can be 
trapped with Trx1(C35S). Moreover, it was proposed that Trx2 denitrosylates 
mitochondria-associated caspase-3 to promote CD95-induced apoptosis (Benhar et 
al, 2008). The observation that the interaction beween Trx1 and caspase-3 strictly 
depends on nitrosylation is in line with our finding that Trx1 does not form a disulfide-
linked conjugate with caspase-3 which is not likely to be nitrosylated in our 
experimental setup (Figure 23B). 
 
In this study, caspase-2 was found to be targeted by Trx1(C35S). Caspase-2 is 
classified as initiator caspase due to its long pro-domain and the requirement of 
dimerization rather than cleavage for activation (Baliga et al, 2004). The mode of 
caspase-2 activation is very controversial ranging from cytoskeletal disruption (Ho et 
al, 2008), genotoxic stress (Tinel & Tschopp, 2004), DNA damage (Sidi et al, 2008), 
ER stress (Upton et al, 2008) and death receptor stimulation (Shin et al, 2005; Lavrik 
et al, 2006). The role of caspase-2 in heat-shock induced apoptosis was confirmed 
by the demonstration that caspase-2 deficient cells remain viable after heat-shock 
(Tu et al, 2006). Heat-shock induces caspase-2 mediated Bid cleavage which results 
in MOMP and apoptosome formation (Bonzon et al, 2006). It has been proposed that 
oxidative stress activates caspase-2 (Prasad et al, 2006; Tamm et al, 2008) but this 
conclusion was drawn from data obtained with the peptide inhibitor z-VDVAD-fmk or 
the fluorogenic substrate VDVAD-AMC. Recently it has been demonstrated the 
peptide sequence VDVAD is also targeted by caspase-3 (McStay et al, 2008) which 
undermines the results from experiments in which this peptide was used in the 
presence of caspase-3. To address this complication, the effect of Trx1 on caspase-2 
activity was reproduced with recombinant caspase-2 (Figure 23B). WT Trx1, but not 
the active site mutant, could activate recombinant as well as endogenous caspase-2 
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after stimulation of CD95. 
The analysis of Trx1-mediated caspase regulation in intact cells is complicated by the 
lack of specific caspase substrates, but also by our finding that caspase-8 is another 
substrate of Trx1. TRAIL-induced caspase-8 activation can be blocked by catalase 
and vitamin C (Perez-Cruz et al, 2007), indicating that caspase-8 itself could be 
redox-regulated. Moreover, overexpression of Trx1 enhances interferon and retinoid-
induced caspase-8 activation (Ma et al, 2001). However, no mixed-disulfide between 
Trx1 and caspase-8 has been described prior this study. 
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5.6 Conclusion and future directions 
In this study, activity-based kinetic trapping of Trx1 target proteins was applied for the 
first time to the cytoplasmic compartment of a mammalian cell line. This work 
demonstrates that this technique is particularly suitable to selectively capture and 
identify mammalian cytosolic Trx1 target proteins. While the current work is focused 
on the identification of Trx1-interactions under steady-state conditions, in the future it 
will be most interesting to apply this method to comparative studies, i.e. to detect 
changes in protein redox states specifically associated with changes in cellular 
behavior, e.g. upon activation, entry into the cell cycle or differentiation. For this 
purpose the preservation of intracellular protein redox states prior to trapping is a 
major concern. However, the protection of thiols and disulfides with cell-permeable 
alkylating agents and the endogenous expression of the Trx1 trapping mutant should 
allow for comparative studies of Trx1 target protein oxidation in different physiological 
as well as pathophysiological conditions.  
 
The next step, and another major challenge for the future is to address in detail the 
physiological relevance of Trx1-mediated redox regulation. Having identified 
individual Trx1-interacting redox-sensitive proteins, specific questions about the 
functional changes associated with oxidation and reduction can be asked. In this 
study, the regulation of caspase-2 activity by oxidation and Trx1-mediated reduction 
could be demonstrated in vitro. However, the functional consequences of caspase-2 
redox regulation in intact cells and in vivo still need to be investigated. In many 
cases, the analysis of Trx1-dependent regulation in intact cells is complicated by 
redundancy. For example, the activity and function of cdk6 is difficult to study in cells 
which also express cdk4. Moreover, the relevance of Trx1 for certain cellular 
processes is not easy to analyze due to the lack of specific Trx1 inhibitors. However, 
the inducible Trx1-knockdown system established in this thesis is likely to provide a 
valuable tool for future analysis of Trx1-regulated pathways. 
 
Cysteine mutagenesis of cdk6 led to the somewhat unexpected finding that only one 
cysteine is required for the interaction with Trx1. Even though formation of disulfide-
linked homodimers is a likely explanation for this observation, other possibilities may 
be considered. This raises the more general question which cysteine modifications 
can actually be targeted by Trx1. In this regard, the long-held assumption that Trx1 
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only reduces protein disulfide bonds should be reviewed. Recent observations from 
other groups suggest that Trx1 can target nitrosylated thiols (-SNO). The possibility 
that Trx1 directly attacks sulfenic acid residues (-SOH) should also be considered. As 
outlined before, the kinetic trapping procedure can be used to address and answer 
these important questions. 
 
From two independent proteomic trapping experiments over 100 novel Trx1 
candidate target proteins were identified. These are involved in a wide variety of 
cellular processes including regulation of the cytoskeleton, sugar metabolism, cell 
cycle and apoptosis. Despite this functional variety, Trx1 target interactions were 
found to be highly specific. Among the large number of newly identified proteins, 
flightless-1 homolog stood out as a predominant Trx1 target protein. This makes the 
gelsolin-like actin-binding protein a prime candidate for further study, as it suggests a 
major role for the cytoskeleton in the response to oxidants. In addition, it will be 
especially interesting to address the Trx1-Rac2 redox interaction which potentially 
regulates the activity of NADPH oxidases, thus providing a mechanism of how ROS 
production can be feedback-regulated by oxidants.  
 
Another conclusion of this work is that kinetic trapping should be applicable to other 
members of the thioredoxin family using the same CXXC based reaction mechanism. 
Other Trx isoforms or Trx-like proteins from different cellular compartments, 
especially mitochondrial Trx2 may be studied the same way. Such experiments will 
provide important information on how the different thioredoxin family members differ 
in their substrate specificity and associated cellular functions. 
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6 Abbreviations 
AP-1 activator protein-1 
APIP Apaf-1 interacting protein 
APS ammonium peroxodisulfate 
ASK1 apoptosis signal-regulating kinase 1 
BCNU 1,3-bis(2-chloroethyl)-1-nitrosourea 
BSA bovine serum albumin 
CaMK-II Ca2+/calmodulin dependent protein kinase type II 
Cdk cyclin-dependent kinase 
CDS Coding sequence 
Csk C-terminal Src kinase 
ddH2O Double distilled water 
DISC death-inducing signaling complex 
DMEM Dulbecco's modified Eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNCB 1-chloro-2,4-dinitrobenzene 
dNTP deoxynucleoside 
Dox Doxycycline 
DTT dithiothreitol 
E.coli Escherichia coli 
EBV Epstein-Bar virus 
EDTA ethylenediaminetetraacetic acid 
EF Elongation factor 
EGF Epidermal growth factor 
Erk extracellular signal-regulated kinase 
ESI  electrospray ionization mass  
ETC electron-transport chain 
FAD flavin adenine dinucleotide 
FCS fetal calf serum 
FLII flightless-1 homolog 
FRT ferredoxin-thioredoxin reductase 
G6PD glucose-6-phosphate 1-dehydrogenase 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GFP green fluorescent protein 
GFPT1 glutamine:fructose 6 phosphate amidotransferase 1 
GLD gelsolin-like domain 
GPx Glutathione peroxidase 
Grx1 glutaredoxin-1 
GSH Reduced glutathione 
Abbreviations 
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GSSG Oxidized glutathione 
GST glutathione S-transferase 
H2DCFDA 2',7'-dichlorohydrofluorescein diacetate 
HBS HEPES buffered saline 
HDAC histone deacetylase 
HEPES N-(2-hydroxyethyl)piperazine-N’-2-ethanesulfonic acid 
HIF-1α hypoxia-inducible factor-1 alpha 
HIV-1 human immunodeficiency virus 1 
hnRNP heterogeneous nuclear ribonucleoprotein 
HRP horseradish peroxidase 
Hsp Heat-shock protein 
HTLV-I human T-cell leukemia virus type-I 
IAM Iodoacetamide 
IB Immunoblot 
IL Interleukin 
IMDM Iscove's modified Dulbecco's medium 
INF-γ Interferon-γ 
IP Immunoprecipitation 
IPTG isopropyl-β-D-thiogalactopyranosid 
IRES Internal ribosome entry site 
JAK2 Janus kinase-2 
JNK c-Jun N-terminal kinase 
kDa kilodalton 
LB lysogeny broth 
LC-MS/MS liquid chromatography-tandem mass spectrometry 
LMW-PTP low molecular weight protein tyrosine phosphatase 
LNGFR low affinity nerve growth factor receptor 
LPS Lipopolysaccharide 
LRR leucine-rich repeat 
LRRFIP1 leucine-rich repeat flightless-interacting protein 1 
MACS magnetic-activated cell sorting 
MALDI-TOF matrix assisted laser desorption/ionisation-time of flight 
MAPK Mitogen-acitvated protein kinase 
MEF mouse embryonic fibroblast 
MES Morpholinoethanesulfonic acid 
MMTS Methylmethanethiosulfonate 
MMULV moloney murine leukemia virus 
MOMP mitochondrial outer membrane permeabilization 
NAc N-acetyl cysteine 
NADPH nicotinamide adenine dinucleotide phosphate 
NCR Non-coding sequence 
Abbreviations 
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NEK9 NimA-related kinase 9 
NEM N-ethylmaleimide 
NFκB nuclear factor-κB 
NO nitric oxide 
Nox NAPDH oxidase 
NR Non-reducing 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDB Protein data base 
PDGF Platelet-derived growth factor 
PDI protein disulfide-isomerase 
PKA cyclic AMP-dependent protein kinase 
PKC protein kinase C 
PKN1 Protein kinase N1 
PMA phorbol 12-myristate 13-acetate 
PMF peptide mass fingerprint 
PP6 Protein phosphatase 6 
Prx Peroxiredoxin 
PTEN phosphatase and tensin homolog 
PTK protein tyrosine kinase 
PTP protein tyrosine phosphatase 
PVDF polyvinylidene fluoride 
R Reducing 
Rb retinoblastoma 
Ref-1 redox-factor 1 
RIR1 ribonucleoside-diphosphate reductase 
RNA ribonucleic acid 
ROS Reactive oxygen species 
Rpm rounds per minute 
RT room temperature 
rtTA Reverse tetracycline controlled transactivator 
SA streptavidin 
SBP streptavidin binding peptide 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
SeCys Selenocysteine 
SH2 Src homology 2 
SHP2 SH2 domain-containing protein tyrosine phosphatase-2 
shRNA short-hairpin RNA 
siRNA small-interfering RNA 
SOD Superoxide dismutase 
Srx Sulfiredoxin 
Abbreviations 
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STAT-1 signal transducer and activator of transcription-1 
TBS Tris buffered saline 
TCA trichloroacetic acid 
TEMED N,N,N’,N’-Tetramethylethylenediamine 
tetO Tet operator 
TetR Tet repressor 
TFA trifluoroacetic acid 
TGF-β transforming growth factor-beta 
TLR4 Toll-like receptor 4 
TNF-α tumor necrosis factor-α 
Tris tris (hydroxymethyl) aminomethane 
Trx1 thioredoxin-1 
TrxR thioredoxin reductase 
tTA tetracycline controlled transactivator 
T-X100 Triton X-100 
U Units 
VDUP1 vitamin D3 up-regulated protein 1 
VEGF vascular endothelial growth factor 
WT wild type 
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